{"5f52ac4738312fdb215ad06e5a2e886a6fb63efd": [["Biallelic mutations using CRI SPR-Cas9 in RAW cells.", [["RAW cells", "ANATOMY", 42, 51], ["CRI SPR-Cas9", "GENE_OR_GENE_PRODUCT", 26, 38], ["RAW cells", "CELL", 42, 51], ["CRI SPR-Cas9", "DNA", 26, 38], ["RAW cells", "CELL_LINE", 42, 51], ["Biallelic mutations", "PROBLEM", 0, 19], ["CRI SPR", "TREATMENT", 26, 33], ["Cas9 in RAW cells", "TREATMENT", 34, 51]]], ["Electropherograms of WT versus biallelic mutants in RAW cells for genes (A) Cpb1, (B) C3aR, and (C) C3.", [["RAW cells", "ANATOMY", 52, 61], ["RAW cells", "CELL", 52, 61], ["Cpb1", "GENE_OR_GENE_PRODUCT", 76, 80], ["(B) C3aR", "GENE_OR_GENE_PRODUCT", 82, 90], ["(C) C3", "GENE_OR_GENE_PRODUCT", 96, 102], ["RAW cells", "CELL_LINE", 52, 61], ["Cpb1", "DNA", 76, 80], ["C3aR", "DNA", 86, 90], ["C3", "DNA", 100, 102], ["Electropherograms", "TEST", 0, 17], ["WT", "TEST", 21, 23], ["biallelic mutants in RAW cells", "PROBLEM", 31, 61], ["genes (A) Cpb1, (B) C3aR, and (C) C3", "PROBLEM", 66, 102], ["RAW cells", "OBSERVATION", 52, 61], ["C3aR", "ANATOMY", 86, 90]]], ["C3aR \u2212/\u2212 and C3 \u2212/\u2212 BMDMs harbor a WT copy of caspase-11.", [["C3 \u2212/\u2212 BMDMs", "ANATOMY", 13, 25], ["C3aR", "GENE_OR_GENE_PRODUCT", 0, 4], ["C3", "GENE_OR_GENE_PRODUCT", 13, 15], ["caspase-11", "GENE_OR_GENE_PRODUCT", 46, 56], ["C3aR \u2212/\u2212 and C3 \u2212/\u2212 BMDMs", "CELL_LINE", 0, 25], ["caspase-11", "PROTEIN", 46, 56], ["C3aR", "TEST", 0, 4], ["caspase", "TEST", 46, 53]]], ["Caspase-11 from WT, C3aR-deficient (C3aR \u2212/\u2212 ), and C3-deficient (C3 \u2212/\u2212 ) BMDMs was sequenced and analyzed for the presence or absence of a 5-bp deletion found in Sv129 mice (sequence underlined).", [["BMDMs", "ANATOMY", 75, 80], ["Caspase-11", "GENE_OR_GENE_PRODUCT", 0, 10], ["C3aR", "GENE_OR_GENE_PRODUCT", 20, 24], ["C3aR", "GENE_OR_GENE_PRODUCT", 36, 40], ["C3", "GENE_OR_GENE_PRODUCT", 52, 54], ["Sv129 mice", "ORGANISM", 164, 174], ["Caspase-11", "PROTEIN", 0, 10], ["WT, C3aR-deficient (C3aR \u2212/\u2212 ), and C3-deficient (C3 \u2212/\u2212 ) BMDMs", "CELL_LINE", 16, 80], ["5-bp deletion", "DNA", 141, 154], ["mice", "SPECIES", 170, 174], ["mice", "SPECIES", 170, 174], ["Caspase", "TEST", 0, 7], ["WT", "TEST", 16, 18], ["C3aR", "TEST", 20, 24], ["C3aR", "TEST", 36, 40], ["C3", "TEST", 52, 54], ["BMDMs", "PROBLEM", 75, 80], ["a 5-bp deletion", "PROBLEM", 139, 154]]], ["Table S2 . gRNAs for each CRI SPR-Cas9 KO cell linePrimer name SequenceCasp11", [["S2", "ANATOMY", 6, 8]]]], "PMC7212215": [["IntroductionMysterious pneumonia has been reported during December 2019.", [["pneumonia", "DISEASE", 23, 32], ["IntroductionMysterious pneumonia", "PROBLEM", 0, 32], ["pneumonia", "OBSERVATION", 23, 32]]], ["The causative agent for this pneumonia was identified to be a novel coronavirus (nCoV) named earlier as 2019-nCoV and now termed coronavirs 2).", [["pneumonia", "DISEASE", 29, 38], ["coronavirus", "ORGANISM", 68, 79], ["this pneumonia", "PROBLEM", 24, 38], ["a novel coronavirus", "PROBLEM", 60, 79], ["pneumonia", "OBSERVATION", 29, 38]]], ["The disease caused by SARS-CoV-2 was named as coronavirus disease 2019 (COVID-19).", [["SARS", "DISEASE", 22, 26], ["coronavirus disease", "DISEASE", 46, 65], ["SARS-CoV-2", "ORGANISM", 22, 32], ["coronavirus", "ORGANISM", 46, 57], ["SARS-CoV", "SPECIES", 22, 30], ["The disease", "PROBLEM", 0, 11], ["SARS", "PROBLEM", 22, 26], ["coronavirus disease", "PROBLEM", 46, 65], ["COVID", "TEST", 72, 77], ["disease", "OBSERVATION", 4, 11]]], ["This virus belongs to the subfamily Coronavirinae; this group of viruses is known to cause respiratory and gastrointestinal infections [1].", [["respiratory", "ANATOMY", 91, 102], ["gastrointestinal", "ANATOMY", 107, 123], ["respiratory and gastrointestinal infections", "DISEASE", 91, 134], ["Coronavirinae", "GENE_OR_GENE_PRODUCT", 36, 49], ["gastrointestinal", "ORGANISM_SUBDIVISION", 107, 123], ["This virus", "PROBLEM", 0, 10], ["viruses", "PROBLEM", 65, 72], ["respiratory and gastrointestinal infections", "PROBLEM", 91, 134], ["viruses", "OBSERVATION", 65, 72], ["gastrointestinal", "ANATOMY", 107, 123], ["infections", "OBSERVATION", 124, 134]]], ["The first coronavirus was reported in the 1960s because it caused mild respiratory symptoms; these viruses were given the names (i) human CoV 229E (HCoV-229E) and (ii) HCoV-OC43 [2].", [["respiratory", "ANATOMY", 71, 82], ["respiratory symptoms", "DISEASE", 71, 91], ["coronavirus", "ORGANISM", 10, 21], ["human", "ORGANISM", 132, 137], ["CoV 229E", "ORGANISM", 138, 146], ["HCoV-229E", "GENE_OR_GENE_PRODUCT", 148, 157], ["human", "SPECIES", 132, 137], ["human CoV 229E (HCoV-229E", "SPECIES", 132, 157], ["The first coronavirus", "PROBLEM", 0, 21], ["mild respiratory symptoms", "PROBLEM", 66, 91], ["these viruses", "PROBLEM", 93, 106], ["human CoV", "TEST", 132, 141], ["HCoV", "TEST", 148, 152], ["HCoV", "TEST", 168, 172], ["coronavirus", "OBSERVATION", 10, 21], ["mild", "OBSERVATION_MODIFIER", 66, 70], ["respiratory symptoms", "OBSERVATION", 71, 91]]], ["In 2003, sever acute respiratory syndrome-Cov (SARS-CoV) was identified as the agent that caused a global pandemic [3].", [["acute respiratory syndrome-Cov (SARS-CoV)", "DISEASE", 15, 56], ["SARS-CoV", "ORGANISM", 47, 55], ["SARS-CoV", "SPECIES", 47, 55], ["sever acute respiratory syndrome", "PROBLEM", 9, 41], ["a global pandemic", "PROBLEM", 97, 114], ["sever", "OBSERVATION_MODIFIER", 9, 14], ["acute", "OBSERVATION_MODIFIER", 15, 20], ["respiratory syndrome", "OBSERVATION", 21, 41]]], ["As of 03:00 GMT+3, 9 April 2020, more than 200 countries have been affected around the world, with a total of 1,436,198 diagnosed cases and 85,522 deaths [4].", [["deaths", "DISEASE", 147, 153], ["GMT", "TEST", 12, 15]]], ["Compared to the coronavirus reported to cause an outbreak in the Middle East, so-called MERS-CoV, the mortality rate for SARS-CoV-2 is relatively low; however, the number of affected cases is extremely high [2, 4, 5].", [["coronavirus", "DISEASE", 16, 27], ["SARS", "DISEASE", 121, 125], ["coronavirus", "ORGANISM", 16, 27], ["MERS-CoV", "ORGANISM", 88, 96], ["SARS-CoV-2", "ORGANISM", 121, 131], ["MERS-CoV", "SPECIES", 88, 96], ["SARS-CoV", "SPECIES", 121, 129], ["the coronavirus", "PROBLEM", 12, 27], ["the mortality rate", "TEST", 98, 116], ["SARS", "TEST", 121, 125], ["CoV", "TEST", 126, 129], ["outbreak", "OBSERVATION", 49, 57], ["Middle", "ANATOMY_MODIFIER", 65, 71], ["low", "OBSERVATION_MODIFIER", 146, 149], ["high", "OBSERVATION_MODIFIER", 202, 206]]], ["The latest SARS-CoV-2 was isolated by Chinese scientists, and the genetic sequence of the virus is now available [6].", [["SARS-CoV-2", "ORGANISM", 11, 21], ["SARS-CoV", "SPECIES", 11, 19], ["The latest SARS", "TEST", 0, 15], ["the virus", "PROBLEM", 86, 95]]], ["The new outbreak is believed to be related to meat that derived from wild or captive sources at a seafood market [7].", [["meat", "ANATOMY", 46, 50], ["meat", "ORGANISM_SUBDIVISION", 46, 50], ["new", "OBSERVATION_MODIFIER", 4, 7], ["outbreak", "OBSERVATION", 8, 16], ["believed to be", "UNCERTAINTY", 20, 34]]], ["All of the human CoV are known to have an animal source: SARS-CoV, MERS-CoV, HCoV-NL63, and HCoV-229E are considered to have originated from bats; HCoV-OC43 and HKU1 probably originated from rodents [8] The recurrent corona outbreaks pose a global health threat as a new outbreak could not be avoided due to the interaction between human and animals, as well as human to human contact [1].", [["human", "ORGANISM", 11, 16], ["CoV", "ORGANISM", 17, 20], ["SARS-CoV", "ORGANISM", 57, 65], ["MERS-CoV", "ORGANISM", 67, 75], ["HCoV-NL63", "ORGANISM", 77, 86], ["HCoV-229E", "ORGANISM", 92, 101], ["bats", "ORGANISM", 141, 145], ["HCoV-OC43", "ORGANISM", 147, 156], ["HKU1", "GENE_OR_GENE_PRODUCT", 161, 165], ["human", "ORGANISM", 332, 337], ["human", "ORGANISM", 362, 367], ["human", "ORGANISM", 371, 376], ["HKU1", "DNA", 161, 165], ["human", "SPECIES", 11, 16], ["human", "SPECIES", 332, 337], ["human", "SPECIES", 362, 367], ["human", "SPECIES", 371, 376], ["human CoV", "SPECIES", 11, 20], ["SARS-CoV", "SPECIES", 57, 65], ["MERS-CoV", "SPECIES", 67, 75], ["HCoV-229E", "SPECIES", 92, 101], ["human", "SPECIES", 332, 337], ["human", "SPECIES", 362, 367], ["human", "SPECIES", 371, 376], ["SARS", "PROBLEM", 57, 61], ["CoV", "TEST", 62, 65], ["MERS", "TEST", 67, 71], ["CoV", "TEST", 72, 75], ["HCoV", "TEST", 77, 81], ["HCoV", "TEST", 92, 96], ["HCoV", "TEST", 147, 151], ["The recurrent corona outbreaks", "PROBLEM", 203, 233], ["corona", "OBSERVATION_MODIFIER", 217, 223]]], ["This urges the need to develop new curative treatment strategies and possible vaccines.IntroductionHelicase is a viral replication enzyme in coronavirus, which has the characteristics of unwinding DNA and RNA and separating them into two single-stranded nucleic acids [9, 10].", [["nucleic acids", "CHEMICAL", 254, 267], ["Helicase", "GENE_OR_GENE_PRODUCT", 99, 107], ["coronavirus", "ORGANISM", 141, 152], ["DNA", "CELLULAR_COMPONENT", 197, 200], ["nucleic acids", "SIMPLE_CHEMICAL", 254, 267], ["Helicase", "PROTEIN", 99, 107], ["viral replication enzyme", "PROTEIN", 113, 137], ["new curative treatment strategies", "TREATMENT", 31, 64], ["vaccines", "TREATMENT", 78, 86], ["a viral replication enzyme in coronavirus", "PROBLEM", 111, 152], ["unwinding DNA and RNA", "PROBLEM", 187, 208], ["stranded nucleic acids", "TEST", 245, 267], ["unwinding DNA", "OBSERVATION", 187, 200]]], ["These vital characteristics of coronavirus helicase describe the importance of helicase as a druggable target [9\u201311].", [["coronavirus", "ORGANISM", 31, 42], ["coronavirus helicase", "PROTEIN", 31, 51], ["helicase", "PROTEIN", 79, 87], ["coronavirus helicase", "PROBLEM", 31, 51]]], ["In the present study, SARS-CoV-2 helicase was selected to identify helicase inhibitors by using computational state-of-the-art tools to identify drug targets among clinically approved drugs.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 22, 32], ["SARS-CoV-2 helicase", "PROTEIN", 22, 41], ["SARS-CoV", "SPECIES", 22, 30], ["the present study", "TEST", 3, 20], ["SARS", "PROBLEM", 22, 26], ["helicase inhibitors", "TREATMENT", 67, 86]]], ["The study suggests the best active clinically approved drugs against SARS-CoV-2 helicase through molecular docking analysis.Amino acid sequence retrieval and prediction of secondary structure ::: Material and methodsThe ORF1ab polyprotein sequence of SARS-CoV-2 isolate 2019-nCoV/USA-WA1-F6/2020 (GenBank: QHU79203.1) was retrieved from NCBI database on 12 Feb 2020 (Figure 1).", [["SARS", "DISEASE", 69, 73], ["Amino acid", "CHEMICAL", 124, 134], ["Amino acid", "CHEMICAL", 124, 134], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 69, 79], ["Amino acid", "AMINO_ACID", 124, 134], ["ORF1ab", "GENE_OR_GENE_PRODUCT", 220, 226], ["SARS-CoV-2", "ORGANISM", 251, 261], ["SARS-CoV-2 helicase", "PROTEIN", 69, 88], ["ORF1ab polyprotein sequence", "DNA", 220, 247], ["SARS-CoV-2 isolate 2019-nCoV/USA-WA1-F6/2020", "DNA", 251, 295], ["SARS-CoV", "SPECIES", 69, 77], ["SARS-CoV-2 isolate 2019-nCoV/USA-WA1-F6/2020", "SPECIES", 251, 295], ["The study", "TEST", 0, 9], ["SARS", "PROBLEM", 69, 73], ["CoV", "TEST", 74, 77], ["molecular docking analysis", "TEST", 97, 123], ["Amino acid sequence retrieval", "TREATMENT", 124, 153], ["The ORF1ab polyprotein sequence", "TEST", 216, 247], ["SARS", "TEST", 251, 255], ["CoV", "TEST", 256, 259], ["isolate", "TEST", 262, 269], ["secondary structure", "OBSERVATION", 172, 191]]], ["The helicase region was selected based on the amino acid sequence alignment using MAFFT [12] and MEGA7 [13] with Bat SARS, SARS-CoV, MERS-CoV, and other sequences.", [["amino acid", "CHEMICAL", 46, 56], ["amino acid", "CHEMICAL", 46, 56], ["amino acid", "AMINO_ACID", 46, 56], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 123, 131], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 133, 141], ["helicase region", "PROTEIN", 4, 19], ["Bat SARS, SARS-CoV, MERS-CoV, and other sequences", "DNA", 113, 162], ["SARS-CoV", "SPECIES", 123, 131], ["MERS-CoV", "SPECIES", 133, 141], ["the amino acid sequence alignment", "TEST", 42, 75], ["MAFFT", "TEST", 82, 87], ["MEGA7", "TEST", 97, 102], ["Bat SARS", "TEST", 113, 121], ["SARS", "TEST", 123, 127], ["MERS-CoV, and other sequences", "TEST", 133, 162]]], ["For the homology modelling, the sequences of helicase were searched against the protein database using BLAST-P [14].", [["helicase", "PROTEIN", 45, 53]]], ["The proteins having PDB Id: 6jyt.2.A [15] and 5wwp.1.A [16] were selected for use as templates for 3D modelling of helicase protein of SARS-CoV-2.Prediction and validation of 3D structure ::: Material and methodsAn automated SWISS MODEL server was used to predict the structure by homology modelling [8].", [["PDB Id: 6jyt.2", "GENE_OR_GENE_PRODUCT", 20, 34], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 135, 145], ["PDB Id: 6jyt.2", "PROTEIN", 20, 34], ["helicase protein", "PROTEIN", 115, 131], ["SWISS MODEL server", "DNA", 225, 243], ["SARS-CoV", "SPECIES", 135, 143], ["helicase protein", "TEST", 115, 131], ["SARS", "TEST", 135, 139], ["CoV", "TEST", 140, 143]]], ["The modelled PDB was visualised using PYMOL [17] and validated using PROCHECK [18].", [["The modelled PDB", "TREATMENT", 0, 16]]], ["Ramachandran plot statistics using the PDBsum structural analysis server was used to validate the 3D models [18].", [["PDBsum", "DNA", 39, 45]]], ["The best model among the generated models was selected based on the criteria of having the minimum number of residues in the disallowed region and the highest number of residues in the allowed region, which was considered as a suitable model for helicase protein of SARS-CoV-2, and the same was used for further analysis.", [["helicase protein", "PROTEIN", 246, 262], ["SARS-CoV", "SPECIES", 266, 274], ["residues in the disallowed region", "PROBLEM", 109, 142], ["SARS", "TEST", 266, 270], ["CoV", "TEST", 271, 274], ["further analysis", "TEST", 304, 320], ["highest", "OBSERVATION_MODIFIER", 151, 158], ["number", "OBSERVATION_MODIFIER", 159, 165]]], ["In the validated model, 3D atomic coordinates of the receptor were used to verify potential sites for binding of clinically approved drugs and docking.Clinically approved drugs and molecular docking ::: Material and methodsStructure data of all the clinically approved drugs (such as protease inhibitors, nucleoside reverse transcriptase inhibitors, and non-nucleoside reverse transcriptase inhibitors) used to treat HIV (human immunodeficiency virus) infection were taken from the DrugBank and PubChem databases (Table I) [19, 20].", [["nucleoside reverse transcriptase inhibitors, and non-nucleoside reverse transcriptase inhibitors", "CHEMICAL", 305, 401], ["HIV (human immunodeficiency virus) infection", "DISEASE", 417, 461], ["nucleoside", "CHEMICAL", 305, 315], ["nucleoside reverse transcriptase", "GENE_OR_GENE_PRODUCT", 305, 337], ["non-nucleoside reverse transcriptase", "GENE_OR_GENE_PRODUCT", 354, 390], ["HIV", "ORGANISM", 417, 420], ["human immunodeficiency virus", "ORGANISM", 422, 450], ["nucleoside reverse transcriptase", "PROTEIN", 305, 337], ["non-nucleoside reverse transcriptase", "PROTEIN", 354, 390], ["HIV", "SPECIES", 417, 420], ["human", "SPECIES", 422, 427], ["immunodeficiency virus", "SPECIES", 428, 450], ["HIV", "SPECIES", 417, 420], ["human immunodeficiency virus", "SPECIES", 422, 450], ["the receptor", "TREATMENT", 49, 61], ["clinically approved drugs", "TREATMENT", 113, 138], ["drugs", "TREATMENT", 269, 274], ["protease inhibitors", "TREATMENT", 284, 303], ["nucleoside reverse transcriptase inhibitors", "TREATMENT", 305, 348], ["non-nucleoside reverse transcriptase inhibitors", "TREATMENT", 354, 401], ["HIV (human immunodeficiency virus) infection", "PROBLEM", 417, 461]]], ["All the clinically approved drugs screened in the study are listed in Table I with the mechanism of action based on DrugBank and others [19\u201321http://www.myhealth.gov.my/en/hiv-theraphy/].", [["drugs", "TREATMENT", 28, 33]]], ["The clinically approved drugs were obtained from the PubChem database as structure-data file (SDF) format, which were used in MOE software.", [["the PubChem database", "TEST", 49, 69]]], ["Energy minimisation was completed through MOE tools followed by protonation the structure with default parameters [21, 22].", [["default parameters", "TEST", 95, 113]]], ["The selected approved drug molecules were subjected to a Lipinski filter and used for further analysis.", [["The selected approved drug molecules", "TREATMENT", 0, 36], ["a Lipinski filter", "TREATMENT", 55, 72], ["further analysis", "TEST", 86, 102]]], ["Helicase-approved drug interaction analysis was done through flexible molecular docking by 3D protonation followed by energy minimisation in MOE software [23].Molecular docking ::: ResultsThe modelled helicase protein of SARS-CoV-2 was analysed by MOE software for the helicase-approved drug interaction, initially by 3D protonation, energy minimisation and prediction of active site and properties for the 21 clinically approved drugs using default parameters.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 221, 231], ["helicase protein", "PROTEIN", 201, 217], ["helicase", "PROTEIN", 269, 277], ["SARS-CoV", "SPECIES", 221, 229], ["Helicase", "TREATMENT", 0, 8], ["drug interaction analysis", "TEST", 18, 43], ["3D protonation", "TREATMENT", 91, 105], ["SARS", "TEST", 221, 225], ["CoV", "TEST", 226, 229], ["energy minimisation", "TREATMENT", 334, 353], ["active site", "TREATMENT", 372, 383], ["the 21 clinically approved drugs", "TREATMENT", 403, 435], ["default parameters", "TEST", 442, 460], ["active site", "OBSERVATION", 372, 383]]], ["The SARS-CoV-2 helicase protein docked with the 21 anti-HIV clinically approved drugs.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 4, 14], ["SARS-CoV-2 helicase protein", "PROTEIN", 4, 31], ["HIV", "SPECIES", 56, 59], ["The SARS", "TEST", 0, 8]]], ["Furthermore, the recently approved anti-influenza drug (favipiravir) and widely used hydroxychloroquine were docked separately in MOE (Figure 5, Table I).Molecular docking ::: ResultsThe 23 input clinically approved drugs were screened based on binding affinity, London dG scoring function and MOE score or GBVI/WSA binding free energy (S, kcal/mol).", [["favipiravir", "CHEMICAL", 56, 67], ["hydroxychloroquine", "CHEMICAL", 85, 103], ["favipiravir", "CHEMICAL", 56, 67], ["hydroxychloroquine", "CHEMICAL", 85, 103], ["favipiravir", "SIMPLE_CHEMICAL", 56, 67], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 85, 103], ["WSA", "PROTEIN", 312, 315], ["anti-influenza drug (favipiravir)", "TREATMENT", 35, 68], ["hydroxychloroquine", "TREATMENT", 85, 103], ["drugs", "TREATMENT", 216, 221], ["MOE score", "TEST", 294, 303], ["GBVI", "TEST", 307, 311]]], ["The helicase-approved drug interaction through molecular docking predicted that vapreotide (affinity: \u201312.88; S score: \u20139.84 kcal/mol) and atazanavir (affinity: \u201311.28; S score: \u20139.32 kcal/mol) are the most potent inhibitors of helicase of SARS-CoV-2 amongst clinically approved drugs (Table I).", [["vapreotide", "CHEMICAL", 80, 90], ["atazanavir", "CHEMICAL", 139, 149], ["vapreotide", "CHEMICAL", 80, 90], ["atazanavir", "CHEMICAL", 139, 149], ["vapreotide", "SIMPLE_CHEMICAL", 80, 90], ["atazanavir", "SIMPLE_CHEMICAL", 139, 149], ["SARS-CoV-2", "ORGANISM", 240, 250], ["helicase", "PROTEIN", 228, 236], ["SARS-CoV", "SPECIES", 240, 248], ["The helicase", "TREATMENT", 0, 12], ["S score", "TEST", 110, 117], ["atazanavir", "TREATMENT", 139, 149], ["S score", "TEST", 169, 176], ["SARS", "PROBLEM", 240, 244]]], ["Furthermore, we visualised the interaction between vapreotide and atazanavir and SARS-CoV-2 helicase, as shown in Figure 5.", [["vapreotide", "CHEMICAL", 51, 61], ["atazanavir", "CHEMICAL", 66, 76], ["vapreotide", "CHEMICAL", 51, 61], ["atazanavir", "CHEMICAL", 66, 76], ["vapreotide", "SIMPLE_CHEMICAL", 51, 61], ["atazanavir", "SIMPLE_CHEMICAL", 66, 76], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 81, 91], ["SARS-CoV-2 helicase", "PROTEIN", 81, 100], ["vapreotide", "TREATMENT", 51, 61], ["atazanavir", "TREATMENT", 66, 76], ["SARS", "TREATMENT", 81, 85], ["CoV-2 helicase", "TREATMENT", 86, 100]]], ["The residue position of GLY79 and GLN331 of SARS-CoV-2 helicase protein showed the hydrogen bond with vapreotide and atazanavir, respectively (Figures 5 A, C) and it shows a strong affinity (Table 1).", [["vapreotide", "CHEMICAL", 102, 112], ["atazanavir", "CHEMICAL", 117, 127], ["hydrogen", "CHEMICAL", 83, 91], ["vapreotide", "CHEMICAL", 102, 112], ["atazanavir", "CHEMICAL", 117, 127], ["GLY79", "AMINO_ACID", 24, 29], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 44, 54], ["vapreotide", "SIMPLE_CHEMICAL", 102, 112], ["atazanavir", "SIMPLE_CHEMICAL", 117, 127], ["GLY79", "PROTEIN", 24, 29], ["GLN331", "PROTEIN", 34, 40], ["SARS-CoV-2 helicase protein", "PROTEIN", 44, 71], ["The residue position of GLY79", "TEST", 0, 29], ["SARS", "TEST", 44, 48], ["CoV", "TEST", 49, 52], ["helicase protein", "TEST", 55, 71], ["vapreotide", "TREATMENT", 102, 112], ["atazanavir", "TREATMENT", 117, 127], ["position", "OBSERVATION_MODIFIER", 12, 20]]], ["The active residue of helicase, GLY79, and GLN331 were satisfactory at a distance of 2.44\u00c5 and 2.43 \u00c5 from bound vapreotide and atazanavir, respectively (Table I).", [["vapreotide", "CHEMICAL", 113, 123], ["atazanavir", "CHEMICAL", 128, 138], ["vapreotide", "CHEMICAL", 113, 123], ["atazanavir", "CHEMICAL", 128, 138], ["GLY79", "GENE_OR_GENE_PRODUCT", 32, 37], ["GLN331", "GENE_OR_GENE_PRODUCT", 43, 49], ["vapreotide", "SIMPLE_CHEMICAL", 113, 123], ["atazanavir", "SIMPLE_CHEMICAL", 128, 138], ["helicase", "PROTEIN", 22, 30], ["GLY79", "PROTEIN", 32, 37], ["GLN331", "PROTEIN", 43, 49], ["helicase", "TEST", 22, 30], ["atazanavir", "TREATMENT", 128, 138], ["active", "OBSERVATION_MODIFIER", 4, 10], ["residue", "OBSERVATION", 11, 18]]], ["Furthermore, both predicted drugs satisfy the condition of the Lipinski rule of five, such as partition coefficient (logP), hydrogen bond acceptor, and donor (Table I).DiscussionCoronavirus disease 2019 (COVID-19) cased by SARS-CoV-2 (previously 2019-nCoV) is a global pandemic health threat [4, 7, 8, 24\u201326].", [["DiscussionCoronavirus disease", "DISEASE", 168, 197], ["COVID-19", "CHEMICAL", 204, 212], ["SARS", "DISEASE", 223, 227], ["hydrogen", "CHEMICAL", 124, 132], ["SARS-CoV-2", "ORGANISM", 223, 233], ["SARS-CoV", "SPECIES", 223, 231], ["the Lipinski rule", "TEST", 59, 76], ["hydrogen bond acceptor", "TREATMENT", 124, 146], ["DiscussionCoronavirus disease", "PROBLEM", 168, 197], ["COVID", "TEST", 204, 209]]], ["The present rapid molecular docking study was carried out considering the extreme health and economic problems arising due to COVID-19 and the consequent high mortality all over the world, to screen anti-SARS-CoV-2 drugs among approved drugs for treating HIV infection.", [["HIV infection", "DISEASE", 255, 268], ["HIV", "ORGANISM", 255, 258], ["HIV", "SPECIES", 255, 258], ["HIV", "SPECIES", 255, 258], ["The present rapid molecular docking study", "TEST", 0, 41], ["economic problems", "PROBLEM", 93, 110], ["COVID", "TEST", 126, 131], ["anti-SARS", "TEST", 199, 208], ["CoV-2 drugs", "TREATMENT", 209, 220], ["drugs", "TREATMENT", 236, 241], ["HIV infection", "PROBLEM", 255, 268], ["rapid", "OBSERVATION_MODIFIER", 12, 17], ["infection", "OBSERVATION", 259, 268]]], ["Characterisation and biochemical properties of helicase in severe acute respiratory syndrome CoV showed that it unwound DNA and RNA [9, 11].", [["acute respiratory syndrome", "DISEASE", 66, 92], ["DNA", "CELLULAR_COMPONENT", 120, 123], ["helicase", "PROTEIN", 47, 55], ["severe acute respiratory syndrome CoV", "SPECIES", 59, 96], ["helicase in severe acute respiratory syndrome CoV", "PROBLEM", 47, 96], ["severe", "OBSERVATION_MODIFIER", 59, 65], ["acute", "OBSERVATION_MODIFIER", 66, 71], ["respiratory syndrome", "OBSERVATION", 72, 92]]], ["Helicase enzyme in coronavirus is a prominent viral replication enzyme.", [["Helicase enzyme", "GENE_OR_GENE_PRODUCT", 0, 15], ["coronavirus", "ORGANISM", 19, 30], ["Helicase enzyme", "PROTEIN", 0, 15], ["viral replication enzyme", "PROTEIN", 46, 70], ["Helicase enzyme", "TEST", 0, 15], ["coronavirus", "PROBLEM", 19, 30], ["a prominent viral replication enzyme", "PROBLEM", 34, 70], ["coronavirus", "OBSERVATION", 19, 30], ["prominent", "OBSERVATION_MODIFIER", 36, 45], ["viral replication", "OBSERVATION", 46, 63]]], ["Helicases are evolutionarily conserved proteins in coronaviruses and Nidovirales [27].", [["Helicases", "GENE_OR_GENE_PRODUCT", 0, 9], ["coronaviruses", "ORGANISM", 51, 64], ["Helicases", "PROTEIN", 0, 9], ["evolutionarily conserved proteins", "PROTEIN", 14, 47]]], ["Furthermore, double-stranded nucleic acids are separated into two single-stranded nucleic acids by helicases, which catalyse the separation [10].", [["nucleic acids", "CHEMICAL", 29, 42], ["nucleic acids", "CHEMICAL", 82, 95], ["nucleic acids", "SIMPLE_CHEMICAL", 82, 95], ["helicases", "PROTEIN", 99, 108], ["double-stranded nucleic acids", "TREATMENT", 13, 42]]], ["Earlier studies have described the importance of coronavirus helicase on the therapeutic target [10].", [["coronavirus", "ORGANISM", 49, 60], ["coronavirus helicase", "PROTEIN", 49, 69], ["Earlier studies", "TEST", 0, 15], ["coronavirus helicase", "TREATMENT", 49, 69]]], ["Helicase can hydrolyse all ribonucleotide triphosphates and deoxyribonucleotide triphosphates in the SARS coronavirus [9, 11].", [["ribonucleotide triphosphates", "CHEMICAL", 27, 55], ["deoxyribonucleotide triphosphates", "CHEMICAL", 60, 93], ["SARS coronavirus", "DISEASE", 101, 117], ["ribonucleotide triphosphates", "CHEMICAL", 27, 55], ["deoxyribonucleotide triphosphates", "CHEMICAL", 60, 93], ["Helicase", "SIMPLE_CHEMICAL", 0, 8], ["ribonucleotide triphosphates", "SIMPLE_CHEMICAL", 27, 55], ["deoxyribonucleotide triphosphates", "SIMPLE_CHEMICAL", 60, 93], ["SARS coronavirus", "ORGANISM", 101, 117], ["SARS coronavirus", "SPECIES", 101, 117], ["Helicase can hydrolyse all ribonucleotide triphosphates", "TREATMENT", 0, 55], ["deoxyribonucleotide triphosphates", "TREATMENT", 60, 93], ["the SARS coronavirus", "PROBLEM", 97, 117]]], ["Helicase enzyme in coronavirus increases the unwinding of nucleic acid by twofold [10].", [["nucleic acid", "CHEMICAL", 58, 70], ["Helicase enzyme", "GENE_OR_GENE_PRODUCT", 0, 15], ["coronavirus", "ORGANISM", 19, 30], ["nucleic acid", "SIMPLE_CHEMICAL", 58, 70], ["Helicase enzyme", "PROTEIN", 0, 15], ["Helicase enzyme", "TEST", 0, 15], ["coronavirus", "PROBLEM", 19, 30], ["nucleic acid", "TEST", 58, 70], ["coronavirus", "OBSERVATION", 19, 30]]], ["Hence, SARS-CoV-2 helicase was selected to identify helicase inhibitors through state-of-the-art tool-based screening to reveal the anti-SARS-CoV-2 drug targets.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 7, 17], ["anti-SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 132, 147], ["SARS-CoV-2 helicase", "PROTEIN", 7, 26], ["anti-SARS-CoV-2 drug targets", "DNA", 132, 160], ["SARS", "PROBLEM", 7, 11], ["based screening", "TEST", 102, 117], ["the anti-SARS", "TEST", 128, 141]]], ["We used 23 clinically approved drugs previously listed for the treatment of HIV infection [19, 21].", [["HIV infection", "DISEASE", 76, 89], ["HIV", "ORGANISM", 76, 79], ["HIV", "SPECIES", 76, 79], ["drugs", "TREATMENT", 31, 36], ["HIV infection", "PROBLEM", 76, 89]]], ["The phylogenetic analysis of SARS-CoV-2 helicase amino acid (420 amino acid) sequence against various sequence data retrieved through RefSeq protein BLAST and PSI-BLAST revealed > 90% similarity with SARS CoV in molecular phylogenetic analysis by maximum likelihood method with 500 replications in bootstrap [13].", [["amino acid", "CHEMICAL", 49, 59], ["amino acid", "CHEMICAL", 65, 75], ["amino acid", "CHEMICAL", 49, 59], ["amino acid", "CHEMICAL", 65, 75], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 29, 39], ["amino acid", "AMINO_ACID", 49, 59], ["amino acid", "AMINO_ACID", 65, 75], ["SARS-CoV-2 helicase amino acid (420 amino acid) sequence", "DNA", 29, 85], ["SARS-CoV", "SPECIES", 29, 37], ["SARS CoV", "SPECIES", 200, 208], ["The phylogenetic analysis", "TEST", 0, 25], ["SARS", "TEST", 29, 33], ["CoV", "TEST", 34, 37], ["helicase amino acid", "TREATMENT", 40, 59], ["amino acid)", "TREATMENT", 65, 76], ["various sequence data", "TEST", 94, 115], ["RefSeq protein BLAST", "TEST", 134, 154], ["PSI", "TEST", 159, 162], ["BLAST", "TEST", 163, 168], ["SARS CoV", "TEST", 200, 208], ["molecular phylogenetic analysis", "TEST", 212, 243], ["bootstrap", "TEST", 298, 307]]], ["Furthermore, the selected (PDB Id: 6jyt.2.A) template from severe acute respiratory syndrome coronavirus [15] showed 99.78% sequence identity with the SARS-CoV-2 helicase.DiscussionCurrently used drugs [28], favipiravir-SARS-CoV-2 helicase interaction, and hydroxychloroquine-SARS-CoV-2 helicase interaction have less binding affinity compared to most of the drugs screened in the study.", [["acute respiratory syndrome coronavirus", "DISEASE", 66, 104], ["favipiravir", "CHEMICAL", 208, 219], ["hydroxychloroquine", "CHEMICAL", 257, 275], ["favipiravir", "CHEMICAL", 208, 219], ["hydroxychloroquine", "CHEMICAL", 257, 275], ["severe acute respiratory syndrome coronavirus", "ORGANISM", 59, 104], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 151, 161], ["favipiravir", "SIMPLE_CHEMICAL", 208, 219], ["CoV-2", "GENE_OR_GENE_PRODUCT", 225, 230], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 257, 275], ["CoV-2", "GENE_OR_GENE_PRODUCT", 281, 286], ["PDB Id: 6jyt", "PROTEIN", 27, 39], ["SARS-CoV-2 helicase", "PROTEIN", 151, 170], ["severe acute respiratory syndrome coronavirus", "SPECIES", 59, 104], ["SARS-CoV", "SPECIES", 151, 159], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 59, 104], ["the SARS", "TEST", 147, 155], ["CoV", "TEST", 156, 159], ["drugs", "TREATMENT", 196, 201], ["favipiravir", "TREATMENT", 208, 219], ["hydroxychloroquine", "TREATMENT", 257, 275], ["less binding affinity", "PROBLEM", 313, 334], ["the study", "TEST", 377, 386], ["severe", "OBSERVATION_MODIFIER", 59, 65], ["acute", "OBSERVATION_MODIFIER", 66, 71], ["respiratory syndrome", "OBSERVATION", 72, 92]]], ["The SARS-CoV-2 helicase and approved drug interaction using the modelled and validated druggable helicase protein predicted vapreotide and atazanavir as targets among the 23 approved drugs, as medications for HIV infection.", [["vapreotide", "CHEMICAL", 124, 134], ["atazanavir", "CHEMICAL", 139, 149], ["HIV infection", "DISEASE", 209, 222], ["vapreotide", "CHEMICAL", 124, 134], ["atazanavir", "CHEMICAL", 139, 149], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 4, 14], ["vapreotide", "SIMPLE_CHEMICAL", 124, 134], ["atazanavir", "SIMPLE_CHEMICAL", 139, 149], ["HIV", "ORGANISM", 209, 212], ["SARS-CoV-2 helicase", "PROTEIN", 4, 23], ["helicase protein", "PROTEIN", 97, 113], ["HIV", "SPECIES", 209, 212], ["HIV", "SPECIES", 209, 212], ["The SARS", "TEST", 0, 8], ["druggable helicase protein", "TREATMENT", 87, 113], ["vapreotide", "TREATMENT", 124, 134], ["atazanavir", "TREATMENT", 139, 149], ["the 23 approved drugs", "TREATMENT", 167, 188], ["medications", "TREATMENT", 193, 204], ["HIV infection", "PROBLEM", 209, 222], ["infection", "OBSERVATION", 213, 222]]], ["Atazanavir is a protease inhibitor that is used to treat HIV.", [["Atazanavir", "CHEMICAL", 0, 10], ["HIV", "DISEASE", 57, 60], ["Atazanavir", "CHEMICAL", 0, 10], ["Atazanavir", "SIMPLE_CHEMICAL", 0, 10], ["HIV", "ORGANISM", 57, 60], ["HIV", "SPECIES", 57, 60], ["HIV", "SPECIES", 57, 60], ["Atazanavir", "TREATMENT", 0, 10], ["a protease inhibitor", "TREATMENT", 14, 34], ["HIV", "PROBLEM", 57, 60]]], ["It inhibits HIV-1 protease, which is needed to cleave the viral polyprotein precursors.", [["HIV-1 protease", "GENE_OR_GENE_PRODUCT", 12, 26], ["HIV-1 protease", "PROTEIN", 12, 26], ["viral polyprotein precursors", "PROTEIN", 58, 86], ["HIV-1", "SPECIES", 12, 17], ["HIV-1", "SPECIES", 12, 17], ["HIV-1 protease", "TREATMENT", 12, 26], ["the viral polyprotein precursors", "PROBLEM", 54, 86], ["viral polyprotein precursors", "OBSERVATION", 58, 86]]], ["The absence of cleavage results in immature viral particles [29, 30].", [["immature viral particles", "PROBLEM", 35, 59]]], ["Vapreotide was used for treating patients with AIDS-related diarrhoea [31], which showed the lowest binding free energy interaction with SARS-CoV-2 helicase compared to other drug molecules.", [["Vapreotide", "CHEMICAL", 0, 10], ["AIDS", "DISEASE", 47, 51], ["diarrhoea", "DISEASE", 60, 69], ["Vapreotide", "CHEMICAL", 0, 10], ["Vapreotide", "SIMPLE_CHEMICAL", 0, 10], ["patients", "ORGANISM", 33, 41], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 137, 147], ["SARS-CoV-2 helicase", "PROTEIN", 137, 156], ["patients", "SPECIES", 33, 41], ["Vapreotide", "TREATMENT", 0, 10], ["AIDS", "PROBLEM", 47, 51], ["diarrhoea", "PROBLEM", 60, 69], ["SARS", "PROBLEM", 137, 141]]], ["The metabolism of atazanavir might decrease when used together with vapreotide; hence, detailed studies are needed for use of the combination [32].", [["atazanavir", "CHEMICAL", 18, 28], ["vapreotide", "CHEMICAL", 68, 78], ["atazanavir", "CHEMICAL", 18, 28], ["vapreotide", "CHEMICAL", 68, 78], ["atazanavir", "SIMPLE_CHEMICAL", 18, 28], ["vapreotide", "SIMPLE_CHEMICAL", 68, 78], ["atazanavir", "TREATMENT", 18, 28], ["vapreotide", "TREATMENT", 68, 78], ["detailed studies", "TEST", 87, 103]]], ["The lack of wet laboratory experimental works on the effect of drugs on viruses is considered to be a major limitation of the study.", [["drugs", "TREATMENT", 63, 68], ["viruses", "TREATMENT", 72, 79], ["the study", "TEST", 122, 131]]], ["It indicates that vapreotide is a potent inhibitor of SARS-CoV-2 helicase and may be an option for treating COVID-19 after detailed wet lab studies.DiscussionIn conclusion, this study identified vapreotide as a potential drug with the lowest binding free energy on interactions with SARS-CoV-2 helicase.", [["vapreotide", "CHEMICAL", 18, 28], ["vapreotide", "CHEMICAL", 195, 205], ["vapreotide", "CHEMICAL", 18, 28], ["vapreotide", "CHEMICAL", 195, 205], ["vapreotide", "SIMPLE_CHEMICAL", 18, 28], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 54, 64], ["vapreotide", "SIMPLE_CHEMICAL", 195, 205], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 283, 293], ["SARS-CoV-2 helicase", "PROTEIN", 54, 73], ["SARS-CoV-2 helicase", "PROTEIN", 283, 302], ["vapreotide", "TREATMENT", 18, 28], ["a potent inhibitor", "TREATMENT", 32, 50], ["CoV-2 helicase", "TREATMENT", 59, 73], ["COVID", "TEST", 108, 113], ["detailed wet lab studies", "TEST", 123, 147], ["this study", "TEST", 173, 183], ["vapreotide", "TREATMENT", 195, 205]]], ["The designed drug selection pipeline will serve in the future for novel usage of clinically approved drugs.", [["The designed drug selection pipeline", "TREATMENT", 0, 36]]], ["The prediction in the study may be beneficial to determine the best drugs to manage the fast spread of COVID-19.", [["COVID-19", "CHEMICAL", 103, 111], ["the study", "TEST", 18, 27], ["COVID", "TEST", 103, 108]]]], "032105168779fce0b02645ab1423fc1789323d97": [["INTRODUCTIONFeline coronaviruses (FCoV) are members of the family Coronaviridae in the newly established Order Nidovirales (de Vries et al., 1997) .", [["INTRODUCTIONFeline coronaviruses", "ORGANISM", 0, 32], ["FCoV", "GENE_OR_GENE_PRODUCT", 34, 38], ["FCoV", "SPECIES", 34, 38]]], ["The family Coronaviridae is divided into three distinct antigenic groups (Siddell et al., 1983; Horsburgh et al., 1992; Motokawa et al., 1996) ; FCoV belongs to the group which contains a human respiratory coronavirus (HCV 229E), transmissible gastroenteritis virus (TGEV) of swine, porcine respiratory coronavirus (PRCV), porcine epidemic diarrhoea virus (PEDV), and canine coronavirus (CCV).", [["respiratory coronavirus", "DISEASE", 194, 217], ["transmissible gastroenteritis", "DISEASE", 230, 259], ["porcine respiratory coronavirus", "DISEASE", 283, 314], ["porcine epidemic diarrhoea virus", "DISEASE", 323, 355], ["canine coronavirus", "DISEASE", 368, 386], ["FCoV", "GENE_OR_GENE_PRODUCT", 145, 149], ["human", "ORGANISM", 188, 193], ["respiratory coronavirus", "ORGANISM", 194, 217], ["HCV 229E", "ORGANISM", 219, 227], ["transmissible gastroenteritis virus", "ORGANISM", 230, 265], ["TGEV", "ORGANISM", 267, 271], ["swine", "ORGANISM", 276, 281], ["porcine respiratory coronavirus", "ORGANISM", 283, 314], ["porcine epidemic diarrhoea virus", "ORGANISM", 323, 355], ["canine coronavirus", "ORGANISM", 368, 386], ["human", "SPECIES", 188, 193], ["respiratory coronavirus", "SPECIES", 194, 217], ["transmissible gastroenteritis virus", "SPECIES", 230, 265], ["TGEV", "SPECIES", 267, 271], ["swine", "SPECIES", 276, 281], ["porcine respiratory coronavirus", "SPECIES", 283, 314], ["porcine epidemic diarrhoea virus", "SPECIES", 323, 355], ["canine coronavirus", "SPECIES", 368, 386], ["human respiratory coronavirus", "SPECIES", 188, 217], ["HCV", "SPECIES", 219, 222], ["transmissible gastroenteritis virus", "SPECIES", 230, 265], ["TGEV", "SPECIES", 267, 271], ["swine", "SPECIES", 276, 281], ["porcine respiratory coronavirus", "SPECIES", 283, 314], ["PRCV", "SPECIES", 316, 320], ["porcine epidemic diarrhoea virus", "SPECIES", 323, 355], ["PEDV", "SPECIES", 357, 361], ["canine coronavirus", "SPECIES", 368, 386], ["CCV", "SPECIES", 388, 391], ["a human respiratory coronavirus (HCV 229E", "PROBLEM", 186, 227], ["transmissible gastroenteritis virus", "PROBLEM", 230, 265], ["porcine respiratory coronavirus", "PROBLEM", 283, 314], ["porcine epidemic diarrhoea virus", "PROBLEM", 323, 355], ["PEDV", "PROBLEM", 357, 361], ["canine coronavirus", "PROBLEM", 368, 386], ["respiratory coronavirus", "ANATOMY", 194, 217], ["respiratory coronavirus", "OBSERVATION", 291, 314]]], ["Feline coronaviruses are enveloped viruses with at least 20kb long, single-stranded, positive-sense RNA genomes.", [["Feline coronaviruses", "DISEASE", 0, 20], ["Feline coronaviruses", "ORGANISM", 0, 20], ["20kb long, single-stranded, positive-sense RNA genomes", "DNA", 57, 111], ["Feline coronaviruses", "SPECIES", 0, 20], ["Feline coronaviruses", "PROBLEM", 0, 20], ["enveloped viruses", "PROBLEM", 25, 42], ["enveloped", "OBSERVATION_MODIFIER", 25, 34], ["viruses", "OBSERVATION", 35, 42], ["sense RNA genomes", "OBSERVATION", 94, 111]]], ["In addition to non-structural genes, the genome encodes four structural proteins termed S (spike or peplomer), E (envelope), M (matrix), and N (nucleocapsid; de Groot et al., 1987; Luytjes, 1995) .INTRODUCTIONTwo serotypes of FCoV have been discriminated (Hohdatsu et al., 1991a,b) which differ in their in vitro growth characteristics and in their prevalence in the field (Pedersen, 1987b; Hohdatsu et al., 1992) .", [["genome", "CELLULAR_COMPONENT", 41, 47], ["S (spike or peplomer)", "GENE_OR_GENE_PRODUCT", 88, 109], ["E (envelope)", "GENE_OR_GENE_PRODUCT", 111, 123], ["M (matrix)", "GENE_OR_GENE_PRODUCT", 125, 135], ["FCoV", "GENE_OR_GENE_PRODUCT", 226, 230], ["non-structural genes", "DNA", 15, 35], ["structural proteins", "PROTEIN", 61, 80], ["S", "PROTEIN", 88, 89], ["peplomer", "PROTEIN", 100, 108], ["E", "PROTEIN", 111, 112], ["FCoV", "PROBLEM", 226, 230], ["non-structural genes", "OBSERVATION", 15, 35]]], ["The replication of coronaviruses is characterized by a high frequency of RNA recombination (Lai et al., 1985; Makino et al., 1986; Keck et al., 1988; Baric et al., 1990; Kusters et al., 1990; Kottier et al., 1995; Lai, 1996) .", [["coronaviruses", "ORGANISM", 19, 32], ["coronaviruses", "PROBLEM", 19, 32], ["coronaviruses", "OBSERVATION", 19, 32]]], ["Recent findings suggest that type II feline coronaviruses have arisen from a recombination event between CCV and a type I FCoV (Herrewegh et al., 1998) .INTRODUCTIONBased on pathogenicity, FCoV has been divided into two biotypes, termed feline enteric coronavirus and feline infectious peritonitis virus (FECV and FIPV, respectively; Pedersen, 1987a) .INTRODUCTIONFeline infectious peritonitis virus (FIPV) is an important pathogen of cats, causing death among young animals, especially those originating from pure-bred catteries (Pedersen, 1987a; Foley et al., 1997a) .", [["type II feline coronaviruses", "DISEASE", 29, 57], ["FCoV", "CHEMICAL", 189, 193], ["enteric coronavirus", "DISEASE", 244, 263], ["feline infectious peritonitis", "DISEASE", 268, 297], ["infectious peritonitis", "DISEASE", 371, 393], ["death", "DISEASE", 449, 454], ["type II feline coronaviruses", "ORGANISM", 29, 57], ["FCoV", "GENE_OR_GENE_PRODUCT", 189, 193], ["feline enteric coronavirus", "ORGANISM", 237, 263], ["feline infectious peritonitis virus", "ORGANISM", 268, 303], ["INTRODUCTIONFeline infectious peritonitis virus", "ORGANISM", 352, 399], ["cats", "ORGANISM", 435, 439], ["FCoV", "DNA", 189, 193], ["feline enteric coronavirus", "SPECIES", 237, 263], ["feline infectious peritonitis virus", "SPECIES", 268, 303], ["infectious peritonitis virus", "SPECIES", 371, 399], ["cats", "SPECIES", 435, 439], ["type II feline coronaviruses", "SPECIES", 29, 57], ["CCV", "SPECIES", 105, 108], ["FCoV", "SPECIES", 189, 193], ["feline enteric coronavirus", "SPECIES", 237, 263], ["feline infectious peritonitis virus", "SPECIES", 268, 303], ["FECV", "SPECIES", 305, 309], ["INTRODUCTIONFeline infectious peritonitis virus", "SPECIES", 352, 399], ["FIPV", "SPECIES", 401, 405], ["type II feline coronaviruses", "PROBLEM", 29, 57], ["pathogenicity", "PROBLEM", 174, 187], ["FCoV", "PROBLEM", 189, 193], ["termed feline enteric coronavirus", "PROBLEM", 230, 263], ["feline infectious peritonitis virus", "PROBLEM", 268, 303], ["INTRODUCTIONFeline infectious peritonitis virus", "PROBLEM", 352, 399], ["death", "PROBLEM", 449, 454], ["type II", "OBSERVATION_MODIFIER", 29, 36], ["enteric coronavirus", "ANATOMY", 244, 263], ["infectious", "OBSERVATION_MODIFIER", 275, 285], ["peritonitis", "OBSERVATION", 286, 297], ["infectious", "OBSERVATION_MODIFIER", 371, 381], ["peritonitis", "OBSERVATION", 382, 393]]], ["The disease has either a classical wet/effusive or a dry/non-effusive clinical manifestation.", [["The disease", "PROBLEM", 0, 11], ["a classical wet/effusive", "PROBLEM", 23, 47], ["a dry/non-effusive clinical manifestation", "PROBLEM", 51, 92], ["disease", "OBSERVATION", 4, 11]]], ["Both forms are progressive and ultimately lethal .", [["progressive", "OBSERVATION_MODIFIER", 15, 26]]], ["However, initial signs are not pathognomonic; the affected cats show anorexia, chronic fever and malaise.", [["anorexia", "DISEASE", 69, 77], ["fever", "DISEASE", 87, 92], ["cats", "ORGANISM", 59, 63], ["cats", "SPECIES", 59, 63], ["pathognomonic", "PROBLEM", 31, 44], ["anorexia", "PROBLEM", 69, 77], ["chronic fever", "PROBLEM", 79, 92], ["malaise", "PROBLEM", 97, 104], ["anorexia", "OBSERVATION", 69, 77], ["chronic", "OBSERVATION_MODIFIER", 79, 86], ["fever", "OBSERVATION", 87, 92], ["malaise", "OBSERVATION", 97, 104]]], ["Occasionally, ocular and neurological disorders occur.", [["ocular", "ANATOMY", 14, 20], ["neurological", "ANATOMY", 25, 37], ["ocular and neurological disorders", "DISEASE", 14, 47], ["ocular and neurological disorders", "PROBLEM", 14, 47], ["ocular", "ANATOMY", 14, 20], ["neurological disorders", "OBSERVATION", 25, 47]]], ["The pathogenesis of the disease includes type III and IV hypersensitivity reaction of the immune system (Paltrinieri et al., 1998) .", [["immune system", "ANATOMY", 90, 103], ["hypersensitivity", "DISEASE", 57, 73], ["the disease", "PROBLEM", 20, 31], ["type III and IV hypersensitivity reaction", "PROBLEM", 41, 82], ["disease", "OBSERVATION", 24, 31], ["type III", "OBSERVATION_MODIFIER", 41, 49], ["hypersensitivity reaction", "OBSERVATION", 57, 82]]], ["The diagnosis and control is rather complicated and serological data are not always conclusive (Olsen, 1993) .", [["serological data", "TEST", 52, 68]]], ["Although a commercially available vaccine has had promising results (Fehr et al., 1997) , some other experimental vaccines seem not to be of great help; furthermore, by antibody-dependent enhancement of infection, early death may be provoked with their use (Vennema et al., 1990; Harvey et al., 1996) .INTRODUCTIONIn contrast, feline enteric coronaviruses are not an important cause of morbidity in cats.", [["infection", "DISEASE", 203, 212], ["death", "DISEASE", 220, 225], ["feline enteric coronaviruses", "DISEASE", 327, 355], ["feline enteric coronaviruses", "ORGANISM", 327, 355], ["cats", "ORGANISM", 399, 403], ["feline", "SPECIES", 327, 333], ["cats", "SPECIES", 399, 403], ["feline enteric coronaviruses", "SPECIES", 327, 355], ["experimental vaccines", "TREATMENT", 101, 122], ["infection", "PROBLEM", 203, 212], ["contrast", "TREATMENT", 317, 325], ["morbidity in cats", "PROBLEM", 386, 403], ["dependent enhancement", "OBSERVATION_MODIFIER", 178, 199], ["infection", "OBSERVATION", 203, 212], ["morbidity", "OBSERVATION", 386, 395]]], ["They may produce mild enteritis, but most cases of experimental and natural infections remain subclinical.", [["enteritis", "DISEASE", 22, 31], ["infections", "DISEASE", 76, 86], ["mild enteritis", "PROBLEM", 17, 31], ["experimental and natural infections", "PROBLEM", 51, 86], ["mild", "OBSERVATION_MODIFIER", 17, 21], ["enteritis", "OBSERVATION", 22, 31], ["natural", "OBSERVATION_MODIFIER", 68, 75], ["infections", "OBSERVATION", 76, 86]]], ["FECV can establish persistent infection in the large intestine .", [["intestine", "ANATOMY", 53, 62], ["FECV", "CHEMICAL", 0, 4], ["infection", "DISEASE", 30, 39], ["FECV", "SIMPLE_CHEMICAL", 0, 4], ["intestine", "ORGAN", 53, 62], ["FECV", "SPECIES", 0, 4], ["persistent infection in the large intestine", "PROBLEM", 19, 62], ["persistent", "OBSERVATION_MODIFIER", 19, 29], ["infection", "OBSERVATION", 30, 39], ["large", "ANATOMY_MODIFIER", 47, 52], ["intestine", "ANATOMY", 53, 62]]], ["By shedding the virus in the faeces, the asymptomatic FECVinfected carrier cats spread the infection to susceptible animals via the faecal-oral route.", [["faeces", "ANATOMY", 29, 35], ["faecal", "ANATOMY", 132, 138], ["oral", "ANATOMY", 139, 143], ["infection", "DISEASE", 91, 100], ["faeces", "ORGANISM_SUBDIVISION", 29, 35], ["cats", "ORGANISM", 75, 79], ["faecal", "ORGANISM_SUBDIVISION", 132, 138], ["oral", "ORGANISM_SUBDIVISION", 139, 143], ["cats", "SPECIES", 75, 79], ["the asymptomatic FECVinfected carrier cats", "PROBLEM", 37, 79], ["the infection", "PROBLEM", 87, 100], ["faeces", "ANATOMY", 29, 35], ["infection", "OBSERVATION", 91, 100]]], ["Although it is not considered a highly pathogenic agent, FECV presents a considerable health risk to cats because it is the parent of FIPV, which arises as a result of genetic alterations of FECV during the intestinal replicative phase of infection (Poland et al., 1996; Foley et al., 1997b; Vennema et al., 1998) .", [["intestinal", "ANATOMY", 207, 217], ["FECV", "CHEMICAL", 57, 61], ["infection", "DISEASE", 239, 248], ["cats", "ORGANISM", 101, 105], ["FIPV", "GENE_OR_GENE_PRODUCT", 134, 138], ["FECV", "GENE_OR_GENE_PRODUCT", 191, 195], ["intestinal", "ORGAN", 207, 217], ["cats", "SPECIES", 101, 105], ["FECV", "SPECIES", 57, 61], ["FIPV", "PROBLEM", 134, 138], ["genetic alterations of FECV", "PROBLEM", 168, 195], ["infection", "PROBLEM", 239, 248], ["Foley", "TREATMENT", 271, 276], ["not considered", "UNCERTAINTY", 15, 29], ["FIPV", "OBSERVATION", 134, 138], ["intestinal", "ANATOMY", 207, 217], ["infection", "OBSERVATION", 239, 248]]], ["The resultant FIPV causes systemic infection and, consequently, various clinical forms of the disease may develop (Evermann et al., 1991; Herrewegh et al., 1997) .", [["FIPV", "CHEMICAL", 14, 18], ["infection", "DISEASE", 35, 44], ["systemic infection", "PROBLEM", 26, 44], ["the disease", "PROBLEM", 90, 101], ["resultant", "OBSERVATION_MODIFIER", 4, 13], ["FIPV", "OBSERVATION", 14, 18], ["systemic", "OBSERVATION_MODIFIER", 26, 34], ["infection", "OBSERVATION", 35, 44], ["disease", "OBSERVATION", 94, 101]]], ["It has been suggested that the incidence of FIP in a cat population is more correlated to the FECV \u00ae FIPV mutation rate than to the presence of FIPV variants (Vennema et al., 1998) .", [["FIP", "DISEASE", 44, 47], ["cat", "ORGANISM", 53, 56], ["FIPV", "GENE_OR_GENE_PRODUCT", 144, 148], ["FIP", "PROBLEM", 44, 47], ["a cat population", "PROBLEM", 51, 67], ["FIPV variants", "PROBLEM", 144, 157], ["FIP", "OBSERVATION", 44, 47], ["FIPV variants", "OBSERVATION", 144, 157]]], ["Thus, it is recommended that a population be monitored for the prevalence of asymptomatic FECV carriers in order to estimate the probability of the occurrence of FIPV and the chances for development of the disease.", [["FIPV", "DISEASE", 162, 166], ["FIPV", "SPECIES", 162, 166], ["asymptomatic FECV carriers", "PROBLEM", 77, 103], ["FIPV", "PROBLEM", 162, 166], ["the disease", "PROBLEM", 202, 213], ["FIPV", "OBSERVATION", 162, 166], ["disease", "OBSERVATION", 206, 213]]], ["Since the detection of FCoV by virus isolation is difficult, the application of reverse-transcription polymerase chain reaction (RT-PCR) has been proposed for surveying asymptomatic FCoV carriers (Herrewegh et al., 1995; Foley et al., 1997a) .INTRODUCTIONThe aim of this study was to determine the prevalence of asymptomatic FCoV carriers and to investigate the phylogeny of coronaviruses in urban cat populations.Cat populationsThe 113 sampled cats lived in urban areas of Eastern Hungary.", [["FCoV", "GENE_OR_GENE_PRODUCT", 23, 27], ["coronaviruses", "ORGANISM", 375, 388], ["cat", "ORGANISM", 398, 401], ["cats", "ORGANISM", 445, 449], ["FCoV", "PROTEIN", 23, 27], ["cats", "SPECIES", 445, 449], ["FCoV", "SPECIES", 23, 27], ["FCoV", "PROBLEM", 23, 27], ["virus isolation", "TREATMENT", 31, 46], ["reverse-transcription polymerase chain reaction", "TREATMENT", 80, 127], ["RT-PCR", "TREATMENT", 129, 135], ["this study", "TEST", 266, 276], ["asymptomatic FCoV carriers", "PROBLEM", 312, 338], ["FCoV", "OBSERVATION", 23, 27], ["FCoV", "OBSERVATION", 325, 329], ["Eastern Hungary", "OBSERVATION", 474, 489]]], ["Approximately 60% of the animals were allowed outside and 40% were kept indoors.", [["animals", "ORGANISM", 25, 32]]], ["The majority of the cats (88 animals) are kept alone in a household.", [["cats", "ORGANISM", 20, 24], ["cats", "SPECIES", 20, 24]]], ["Two breeding stocks were involved in the investigations, comprising 4 and 11 breeding Persians, respectively.", [["the investigations", "TEST", 37, 55]]], ["Altogether, 71 mixed-bred (63%), 34 Persian (30%), and eight Siamese (7%) cats were sampled.Clinical specimens and sample preparationThe clinically healthy cats, presented to private veterinary clinics for routine examination, vaccination, or castration were sampled by rectal swabbing as described by Foley et al., (1997b) .", [["specimens", "ANATOMY", 101, 110], ["sample", "ANATOMY", 115, 121], ["rectal", "ANATOMY", 270, 276], ["cats", "ORGANISM", 74, 78], ["cats", "ORGANISM", 156, 160], ["rectal", "ORGANISM_SUBDIVISION", 270, 276], ["cats", "SPECIES", 74, 78], ["cats", "SPECIES", 156, 160], ["Clinical specimens", "TEST", 92, 110], ["sample preparation", "TEST", 115, 133], ["routine examination", "TEST", 206, 225], ["vaccination", "TREATMENT", 227, 238], ["castration", "TREATMENT", 243, 253], ["rectal swabbing", "TREATMENT", 270, 285], ["rectal", "ANATOMY", 270, 276]]], ["The RNA extraction was carried out according to Boom et al. (1990) and Cheung et al. (1994) , using size-fractionated silica and guanidine thiocyanate based buffers.Reverse transcriptionThe FCoV cDNA synthesis was performed in 28-mL reaction mixtures.", [["silica", "CHEMICAL", 118, 124], ["guanidine thiocyanate", "CHEMICAL", 129, 150], ["silica", "CHEMICAL", 118, 124], ["guanidine thiocyanate", "CHEMICAL", 129, 150], ["silica", "SIMPLE_CHEMICAL", 118, 124], ["guanidine thiocyanate", "SIMPLE_CHEMICAL", 129, 150], ["FCoV cDNA", "DNA", 190, 199], ["The RNA extraction", "TREATMENT", 0, 18], ["size-fractionated silica", "TREATMENT", 100, 124], ["guanidine thiocyanate based buffers", "TREATMENT", 129, 164], ["The FCoV cDNA synthesis", "TEST", 186, 209], ["FCoV cDNA", "OBSERVATION", 190, 199]]], ["A preliminary mixture containing 5 mL RNA, 5 mL diethyl pyrocarbonate-treated water, and 1 mL random hexamers (0.02 U; Pharmacia Biotech) was incubated at 65\u00b0C for 5 min to denature the RNA.", [["diethyl pyrocarbonate", "CHEMICAL", 48, 69], ["diethyl pyrocarbonate", "CHEMICAL", 48, 69], ["diethyl", "SIMPLE_CHEMICAL", 48, 55], ["pyrocarbonate", "SIMPLE_CHEMICAL", 56, 69], ["A preliminary mixture", "TREATMENT", 0, 21], ["5 mL RNA", "TREATMENT", 33, 41], ["5 mL diethyl pyrocarbonate", "TREATMENT", 43, 69], ["1 mL random hexamers", "TREATMENT", 89, 109], ["RNA", "ANATOMY", 186, 189]]], ["Subsequently, tubes were placed on ice, and 17 mL premixture was added containing 2.5 mL of each deoxynucleotide triphosphate (2 mM; Pharmacia), 5 mL of 5 X reaction buffer [0.25 M Tris-HCl (pH 8.3), 0.375 M KCl, 15 mM MgCl 2 ], 1 mL RNAguard (24 U; Pharmacia), and 1 mL Moloney murine leukaemia virus reverse transcriptase (200 U; Gibco BRL).", [["tubes", "ANATOMY", 14, 19], ["deoxynucleotide triphosphate", "CHEMICAL", 97, 125], ["Tris-HCl", "CHEMICAL", 181, 189], ["KCl", "CHEMICAL", 208, 211], ["MgCl", "CHEMICAL", 219, 223], ["deoxynucleotide triphosphate", "CHEMICAL", 97, 125], ["Tris-HCl", "CHEMICAL", 181, 189], ["KCl", "CHEMICAL", 208, 211], ["MgCl 2", "CHEMICAL", 219, 225], ["deoxynucleotide triphosphate", "SIMPLE_CHEMICAL", 97, 125], ["Tris-HCl", "SIMPLE_CHEMICAL", 181, 189], ["Moloney murine leukaemia virus", "ORGANISM", 271, 301], ["reverse transcriptase", "PROTEIN", 302, 323], ["murine", "SPECIES", 279, 285], ["Moloney murine leukaemia virus", "SPECIES", 271, 301], ["tubes", "TREATMENT", 14, 19], ["ice", "TREATMENT", 35, 38], ["each deoxynucleotide triphosphate (2 mM; Pharmacia)", "TREATMENT", 92, 143], ["pH", "TEST", 191, 193], ["Moloney murine leukaemia virus reverse transcriptase", "TREATMENT", 271, 323], ["tubes", "OBSERVATION", 14, 19]]], ["The reactions were incubated at 37\u00b0C for 90 min, followed by incubation at 98\u00b0C for 5 min to inactivate the enzyme.Primer selectionPrimers were selected from the highly conserved nucleocapsid (N) region of the FIP virus strain 79-1146 genome (Vennema et al., 1991; GenBank Acc.", [["FIP virus", "ORGANISM", 210, 219], ["enzyme", "PROTEIN", 108, 114], ["nucleocapsid (N) region", "DNA", 179, 202], ["FIP virus strain 79-1146 genome", "DNA", 210, 241], ["FIP virus strain 79-1146", "SPECIES", 210, 234], ["the enzyme", "TEST", 104, 114], ["Primer selection", "TEST", 115, 131], ["the FIP virus strain", "TEST", 206, 226], ["nucleocapsid", "OBSERVATION", 179, 191], ["FIP virus", "OBSERVATION", 210, 219]]], ["No: X56496) using the OLIGO 4.0 program (National Biosciences Inc.).", [["X56496", "CHEMICAL", 4, 10], ["the OLIGO 4.0 program", "TREATMENT", 18, 39]]], ["The sequences of the primers are shown in Table I .PCRThe PCR assays were carried out in 50-mL volumes.", [["PCRThe PCR assays", "TEST", 51, 68]]], ["The reaction mixtures contained 5 mL of 10 X GeneAmp PCR buffer II (Perkin-Elmer Cetus), 15 pmol of each primer (OFIP1A and OFIP2A in the first reaction), 2.5 mL of each deoxynucleotide triphosphate (10 mM; Pharmacia), 2.5 mM MgCl 2 , AmpliTaq DNA polymerase (1 U; Perkin-Elmer Cetus), and 5 mL of cDNA.", [["deoxynucleotide triphosphate", "CHEMICAL", 170, 198], ["deoxynucleotide triphosphate", "CHEMICAL", 170, 198], ["MgCl 2", "CHEMICAL", 226, 232], ["deoxynucleotide triphosphate", "SIMPLE_CHEMICAL", 170, 198], ["DNA", "CELLULAR_COMPONENT", 244, 247], ["cDNA", "DNA", 298, 302], ["The reaction mixtures", "TREATMENT", 0, 21], ["10 X GeneAmp PCR buffer II (Perkin-Elmer Cetus)", "TREATMENT", 40, 87], ["OFIP2A", "TREATMENT", 124, 130], ["each deoxynucleotide triphosphate", "TREATMENT", 165, 198], ["AmpliTaq DNA polymerase", "TREATMENT", 235, 258], ["Perkin-Elmer Cetus", "TREATMENT", 265, 283]]], ["Two drops of mineral oil (Sigma) were added to prevent evaporation.", [["mineral oil", "SIMPLE_CHEMICAL", 13, 24], ["Two drops of mineral oil (Sigma)", "TREATMENT", 0, 32]]], ["The second (nested) PCR was performed under similar conditions to the first PCR, using 15 pmol of each of the primers OFIP4 and OFIP3 and 2 mL of the first PCR product as target.", [["primers OFIP4", "DNA", 110, 123], ["OFIP3", "DNA", 128, 133], ["The second (nested) PCR", "TEST", 0, 23], ["the primers OFIP4", "TREATMENT", 106, 123], ["OFIP3", "TREATMENT", 128, 133], ["the first PCR product", "TREATMENT", 146, 167]]], ["Distilled water was used as negative control.PCRDuring the 35 cycles of the first round, the temperature profile was: 94\u00b0C for 45 s for denaturation, 45\u00b0C for 60 s for primer annealing, (50\u00b0C for 60 s for the first five cycles), and 72\u00b0C for 2 min for synthesis.", [["Distilled water", "TREATMENT", 0, 15], ["the temperature profile", "TEST", 89, 112], ["denaturation", "PROBLEM", 136, 148], ["primer annealing", "TREATMENT", 168, 184], ["synthesis", "PROBLEM", 252, 261]]], ["This cycle profile was repeated 30 times followed by a final extension step at 72\u00b0C for 7 min.PCRThe PCR products were detected by agarose gelelectrophoresis and ethidium bromide staining.Nucleotide sequencing and phylogenetic analysisA total of 36 nested PCR products were sequenced in both directions with primers OFIP3 and OFIP4, using an ABI PRISM sequencing device, based on the incorporation of fluorescent labelled dideoxynucleotide terminators.", [["ethidium bromide", "CHEMICAL", 162, 178], ["ethidium bromide", "CHEMICAL", 162, 178], ["agarose", "SIMPLE_CHEMICAL", 131, 138], ["ethidium bromide", "SIMPLE_CHEMICAL", 162, 178], ["OFIP3", "GENE_OR_GENE_PRODUCT", 316, 321], ["OFIP4", "GENE_OR_GENE_PRODUCT", 326, 331], ["dideoxynucleotide", "SIMPLE_CHEMICAL", 422, 439], ["PCR products", "DNA", 256, 268], ["primers OFIP3", "DNA", 308, 321], ["OFIP4", "DNA", 326, 331], ["fluorescent labelled dideoxynucleotide terminators", "DNA", 401, 451], ["This cycle profile", "TEST", 0, 18], ["PCR", "TEST", 94, 97], ["The PCR products", "TREATMENT", 97, 113], ["agarose gelelectrophoresis", "TREATMENT", 131, 157], ["ethidium bromide staining", "TREATMENT", 162, 187], ["Nucleotide sequencing", "TEST", 188, 209], ["phylogenetic analysisA", "TEST", 214, 236], ["nested PCR products", "TREATMENT", 249, 268], ["primers OFIP3", "TREATMENT", 308, 321], ["OFIP4", "TREATMENT", 326, 331], ["an ABI PRISM sequencing device", "TREATMENT", 339, 369], ["fluorescent labelled dideoxynucleotide terminators", "TREATMENT", 401, 451]]], ["The nucleotide sequences were aligned by the MegAlign program of the DNASTAR multiple program package (DNASTAR Inc.) using the Clustal method (Higgins et al., 1992) .PCR positive catsBy running the nested PCR, 36 (31.8%) out of the 113 examined animals were found to be positive.PCR positive catsThe PCR positivity of the pure-bred and the mixedbred animals was 45.2 and 23.9%, respectively.", [["nucleotide", "CHEMICAL", 4, 14], ["animals", "ORGANISM", 245, 252], ["cats", "ORGANISM", 292, 296], ["PCR positive catsBy", "DNA", 166, 185], ["The nucleotide sequences", "TEST", 0, 24], ["the Clustal method", "TREATMENT", 123, 141], ["PCR", "TEST", 166, 169], ["the nested PCR", "TEST", 194, 208], ["PCR", "TEST", 279, 282], ["The PCR positivity", "TEST", 296, 314], ["positive", "OBSERVATION", 270, 278]]], ["The virus was most frequently detected among the Persians (52.9%), and the two Persian breeding catteries showed 100% (all the four animals being positive) and 72.7% (eight positives out of the eleven cats) of prevalence.PCR positive catsThe PCR positivity was evenly distributed through the age categories, exemplified by 34.6% positive animals in cats younger than 1 year of age, 31.6% among animals aged 1-5 years, and 35.3% among cats older than 5 years.", [["cats", "ORGANISM", 201, 205], ["cats", "ORGANISM", 234, 238], ["cats", "ORGANISM", 349, 353], ["cats", "ORGANISM", 434, 438], ["cats", "SPECIES", 201, 205], ["cats", "SPECIES", 349, 353], ["cats", "SPECIES", 434, 438], ["The virus", "PROBLEM", 0, 9], ["the two Persian breeding catteries", "TEST", 71, 105], ["PCR", "TEST", 221, 224], ["The PCR positivity", "TEST", 238, 256], ["virus", "OBSERVATION", 4, 9]]], ["Figure 1 shows the dendrogram prepared from the sequence alignments and reveals the marked clustering of the detected viruses.", [["the dendrogram", "TEST", 15, 29], ["the sequence alignments", "TEST", 44, 67], ["the marked clustering of the detected viruses", "PROBLEM", 80, 125], ["marked", "OBSERVATION_MODIFIER", 84, 90], ["viruses", "OBSERVATION", 118, 125]]], ["Furthermore, FCoV originating from the two Persian breeding stocks showed a very close similarity to each other (with one or two nucleotide differences) and displayed separate clusters with some distance (due to four to six nucleotide alterations) from the majority of the examined viruses.", [["nucleotide", "CHEMICAL", 224, 234], ["nucleotide", "CHEMICAL", 129, 139], ["nucleotide", "CHEMICAL", 224, 234], ["FCoV", "GENE_OR_GENE_PRODUCT", 13, 17], ["FCoV", "PROTEIN", 13, 17], ["FCoV", "PROBLEM", 13, 17], ["six nucleotide alterations", "PROBLEM", 220, 246], ["FCoV", "OBSERVATION", 13, 17], ["viruses", "OBSERVATION", 282, 289]]], ["In this major group there is an apparent cluster comprising cats Nos. 72, 8, 48, 58, 49, 69P, and 36 (see Fig. 1 ).", [["cluster", "OBSERVATION_MODIFIER", 41, 48]]], ["The overall difference between the most disparate strains originating from the examined cats remained below 10 out of the examined 440 nucleotides.DISCUSSIONIn the present study a representative group of animals was investigated to estimate the prevalence of asymptomatic carriers and the genetic diversity of feline coronaviruses occurring in urban cat populations.", [["feline coronaviruses", "DISEASE", 310, 330], ["nucleotides", "CHEMICAL", 135, 146], ["cats", "ORGANISM", 88, 92], ["animals", "ORGANISM", 204, 211], ["feline coronaviruses", "ORGANISM", 310, 330], ["cat", "ORGANISM", 350, 353], ["feline", "SPECIES", 310, 316], ["feline coronaviruses", "SPECIES", 310, 330], ["the most disparate strains", "PROBLEM", 31, 57], ["the present study", "TEST", 160, 177], ["asymptomatic carriers", "PROBLEM", 259, 280], ["feline coronaviruses", "PROBLEM", 310, 330], ["overall", "OBSERVATION_MODIFIER", 4, 11], ["difference", "OBSERVATION_MODIFIER", 12, 22], ["feline coronaviruses", "OBSERVATION", 310, 330]]], ["Although other regions of the genome have been amplified by various groups (Li & Scott, 1994; Herrewegh et al., 1995; Gamble et al., 1997; Gunn-Moore et al., 1998) , we applied an RT-PCR assay which targeted the highly conserved N region of the FCoV genome in order to detect all possible Vennema et al. (1991) . variants of the virus.", [["genome", "CELLULAR_COMPONENT", 30, 36], ["N region", "DNA", 229, 237], ["FCoV genome", "DNA", 245, 256], ["an RT-PCR assay", "TEST", 177, 192], ["the virus", "PROBLEM", 325, 334], ["FCoV genome", "OBSERVATION", 245, 256], ["virus", "OBSERVATION", 329, 334]]], ["Using this assay, we found that approximately 30% of the clinically healthy cats carried FCoV in the monitored area.", [["cats", "ORGANISM", 76, 80], ["cats", "SPECIES", 76, 80], ["this assay", "TEST", 6, 16], ["FCoV", "OBSERVATION", 89, 93]]], ["The seroprevalence has not been determined in this study; however, 80-90% seropositivity against FCoV has been described in catteries and 10-50% of cats in single cat households (Pedersen, 1976; Addie & Jarrett, 1992a,b) .", [["FCoV", "CHEMICAL", 97, 101], ["FCoV", "CANCER", 97, 101], ["catteries", "CANCER", 124, 133], ["cats", "ORGANISM", 148, 152], ["cat", "ORGANISM", 163, 166], ["FCoV", "PROTEIN", 97, 101], ["cats", "SPECIES", 148, 152], ["FCoV", "SPECIES", 97, 101], ["this study", "TEST", 46, 56], ["FCoV", "PROBLEM", 97, 101]]], ["In accordance with previous studies (Foley et al., 1997a) , there was no significant correlation between positivity and the gender of the animals.", [["previous studies", "TEST", 19, 35]]], ["However, the pure-bred animals showed higher rate of positivity than the mixedbred groups, supporting the observation that purebred cats are more susceptible to FCoV infections .", [["infections", "DISEASE", 166, 176], ["animals", "ORGANISM", 23, 30], ["cats", "ORGANISM", 132, 136], ["FCoV", "GENE_OR_GENE_PRODUCT", 161, 165], ["cats", "SPECIES", 132, 136], ["FCoV", "SPECIES", 161, 165], ["FCoV infections", "PROBLEM", 161, 176], ["higher", "OBSERVATION_MODIFIER", 38, 44], ["FCoV infections", "OBSERVATION", 161, 176]]], ["Since the positivity in the examined groups of age was evenly distributed, the detection of some chronically infected asymptomatic carrier animals is assumed, in agreement with previous reports .", [["chronically infected", "DISEASE", 97, 117], ["the positivity", "TEST", 6, 20], ["some chronically infected asymptomatic carrier animals", "PROBLEM", 92, 146], ["some", "OBSERVATION_MODIFIER", 92, 96], ["chronically", "OBSERVATION_MODIFIER", 97, 108], ["infected", "OBSERVATION", 109, 117]]], ["It is known that FCoV, CCV, and TGEV are antigenically related.", [["FCoV", "GENE_OR_GENE_PRODUCT", 17, 21], ["CCV", "GENE_OR_GENE_PRODUCT", 23, 26], ["TGEV", "ORGANISM", 32, 36], ["FCoV", "PROTEIN", 17, 21], ["CCV", "PROTEIN", 23, 26], ["CCV", "SPECIES", 23, 26], ["TGEV", "SPECIES", 32, 36], ["FCoV", "PROBLEM", 17, 21], ["CCV", "PROBLEM", 23, 26], ["TGEV", "PROBLEM", 32, 36], ["FCoV", "OBSERVATION", 17, 21]]], ["However, based on the deduced amino acid sequences of N and M proteins, separation of FCoV from the other members of group I coronaviruses was shown (Motokawa et al., 1996) .", [["amino acid", "CHEMICAL", 30, 40], ["amino acid", "CHEMICAL", 30, 40], ["amino acid", "AMINO_ACID", 30, 40], ["FCoV", "GENE_OR_GENE_PRODUCT", 86, 90], ["N and M proteins", "PROTEIN", 54, 70], ["FCoV", "PROTEIN", 86, 90], ["I coronaviruses", "SPECIES", 123, 138], ["the deduced amino acid sequences", "TEST", 18, 50], ["FCoV", "PROBLEM", 86, 90], ["FCoV", "OBSERVATION", 86, 90]]], ["Considering antigenicity and pathogenicity, FCoV have been divided as two serotypes and two biotypes, respectively (Pedersen, 1987a, b; Hohdatsu et al., 1992) .", [["FCoV", "GENE_OR_GENE_PRODUCT", 44, 48], ["FCoV", "PROTEIN", 44, 48], ["FCoV", "SPECIES", 44, 48], ["pathogenicity", "PROBLEM", 29, 42], ["FCoV", "PROBLEM", 44, 48], ["pathogenicity", "OBSERVATION", 29, 42]]], ["Based on antigenicity, the separation of the two serotypes is clearly demonstrated (Hohdatsu et al., 1992) .", [["the two serotypes", "PROBLEM", 41, 58], ["separation", "OBSERVATION_MODIFIER", 27, 37], ["two", "OBSERVATION_MODIFIER", 45, 48], ["serotypes", "OBSERVATION", 49, 58]]], ["However, the discrimination between the two biotypes is complicated, although considerable research has been carried out to investigate the hypothesized evolution of FIPV from FECV Vennema et al., 1998) .", [["FIPV", "PROBLEM", 166, 170]]], ["For a better understanding of this process, large populations of clinically healthy cats should be screened and the presence of FCoV should be estimated.", [["cats", "ORGANISM", 84, 88], ["FCoV", "GENE_OR_GENE_PRODUCT", 128, 132], ["cats", "SPECIES", 84, 88], ["FCoV", "PROBLEM", 128, 132], ["large", "OBSERVATION_MODIFIER", 44, 49], ["populations", "OBSERVATION_MODIFIER", 50, 61], ["FCoV", "OBSERVATION", 128, 132]]], ["Subsequently, the genomes of the detected FCoV variants should be analysed in order to investigate the alterations leading to the switch of the biotype.DISCUSSIONThe present study aimed at the first main task, i.e. to survey populations of healthy urban cats of various breeds to reveal the prevalence of FCoV.", [["FCoV", "DISEASE", 305, 309], ["FCoV", "GENE_OR_GENE_PRODUCT", 42, 46], ["cats", "ORGANISM", 254, 258], ["FCoV", "GENE_OR_GENE_PRODUCT", 305, 309], ["FCoV variants", "DNA", 42, 55], ["FCoV", "PROTEIN", 305, 309], ["cats", "SPECIES", 254, 258], ["the detected FCoV variants", "PROBLEM", 29, 55], ["the alterations", "PROBLEM", 99, 114], ["The present study", "TEST", 162, 179], ["FCoV", "PROBLEM", 305, 309], ["FCoV variants", "OBSERVATION", 42, 55], ["FCoV", "OBSERVATION", 305, 309]]], ["Further, we performed a pilot phylogenetic analysis based on N gene sequences in order to investigate the genetic heterogeneity of the coronaviruses detected in the cat populations.", [["coronaviruses", "ORGANISM", 135, 148], ["cat", "ORGANISM", 165, 168], ["N gene sequences", "DNA", 61, 77], ["a pilot phylogenetic analysis", "TEST", 22, 51], ["N gene sequences", "TEST", 61, 77], ["the genetic heterogeneity of the coronaviruses", "PROBLEM", 102, 148], ["coronaviruses", "OBSERVATION", 135, 148]]], ["We demonstrated an interesting clustering of the feline coronaviruses: the two Persian breeding stocks composed separate clusters different from those of the prevalent viruses (see Fig. 1 ).", [["feline coronaviruses", "DISEASE", 49, 69], ["feline coronaviruses", "ORGANISM", 49, 69], ["feline", "SPECIES", 49, 55], ["feline coronaviruses", "SPECIES", 49, 69], ["the feline coronaviruses", "PROBLEM", 45, 69], ["interesting", "OBSERVATION_MODIFIER", 19, 30], ["clustering", "OBSERVATION_MODIFIER", 31, 41], ["feline coronaviruses", "OBSERVATION", 49, 69]]], ["Since it was hypothesized that cats infected with FCoV develop resistance against superinfection by other coronaviruses , the viruses carried by the Persian breeding animals could represent a unique variant of FCoV.", [["FCoV", "CHEMICAL", 50, 54], ["superinfection", "DISEASE", 82, 96], ["cats", "ORGANISM", 31, 35], ["FCoV", "GENE_OR_GENE_PRODUCT", 50, 54], ["FCoV", "CANCER", 210, 214], ["FCoV", "PROTEIN", 210, 214], ["cats", "SPECIES", 31, 35], ["FCoV", "SPECIES", 50, 54], ["FCoV", "PROBLEM", 50, 54], ["superinfection", "PROBLEM", 82, 96], ["other coronaviruses", "PROBLEM", 100, 119], ["the viruses", "PROBLEM", 122, 133], ["superinfection", "OBSERVATION", 82, 96], ["viruses", "OBSERVATION", 126, 133], ["FCoV", "OBSERVATION", 210, 214]]], ["Visiting exhibitions and mating abroad must have contributed to the infection of these otherwise closed stocks of Persian cats.", [["infection", "DISEASE", 68, 77], ["cats", "ORGANISM", 122, 126], ["cats", "SPECIES", 122, 126], ["the infection", "PROBLEM", 64, 77], ["infection", "OBSERVATION", 68, 77]]], ["Another noteworthy fact is that, since the establishment of the stocks (which was more than 10 years ago), the cats have not been affected seriously by viral diseases and the suspicion of FIP has never arisen.", [["viral diseases", "DISEASE", 152, 166], ["FIP", "DISEASE", 188, 191], ["cats", "ORGANISM", 111, 115], ["cats", "SPECIES", 111, 115], ["viral diseases", "PROBLEM", 152, 166], ["FIP", "PROBLEM", 188, 191], ["viral diseases", "OBSERVATION", 152, 166], ["FIP", "OBSERVATION", 188, 191]]], ["Thus, either the FCoV variants present in these Persian cats lack the ability to evolve into FIP virus, or these particular cats have a unique resistance against the circulating viruses.", [["FCoV", "GENE_OR_GENE_PRODUCT", 17, 21], ["Persian cats", "ORGANISM", 48, 60], ["FIP virus", "ORGANISM", 93, 102], ["cats", "ORGANISM", 124, 128], ["FCoV variants", "DNA", 17, 30], ["cats", "SPECIES", 56, 60], ["cats", "SPECIES", 124, 128], ["FIP virus", "SPECIES", 93, 102], ["the FCoV variants", "PROBLEM", 13, 30], ["FIP virus", "PROBLEM", 93, 102], ["the circulating viruses", "PROBLEM", 162, 185], ["FCoV", "OBSERVATION", 17, 21], ["circulating viruses", "OBSERVATION", 166, 185]]], ["The investigations of further genomic regions of the viruses (ORF3c, ORF7b; Vennema et al., 1998) will hope-fully provide more information to answer these questions.", [["ORF3c", "GENE_OR_GENE_PRODUCT", 62, 67], ["The investigations", "TEST", 0, 18], ["the viruses", "PROBLEM", 49, 60], ["viruses", "OBSERVATION", 53, 60]]], ["An additional cluster, consisting of seven viruses (cats Nos. 8, 36, 48, 49, 58, and 69P, see Fig. 1.) may also have the same source of infection since these cats are kept in a restricted area.DISCUSSIONIn conclusion, the nucleocapsid-based nested RT-PCR assay proved to be a useful tool for monitoring clinically healthy cat populations and to detect asymptomatic FCoV shedding.", [["infection", "DISEASE", 136, 145], ["cats", "ORGANISM", 158, 162], ["cat", "ORGANISM", 322, 325], ["FCoV", "GENE_OR_GENE_PRODUCT", 365, 369], ["cats", "SPECIES", 52, 56], ["cats", "SPECIES", 158, 162], ["FCoV", "SPECIES", 365, 369], ["infection", "PROBLEM", 136, 145], ["these cats", "TREATMENT", 152, 162], ["the nucleocapsid", "TEST", 218, 234], ["nested RT-PCR assay", "TEST", 241, 260], ["asymptomatic FCoV shedding", "PROBLEM", 352, 378], ["cluster", "OBSERVATION_MODIFIER", 14, 21], ["seven", "OBSERVATION_MODIFIER", 37, 42], ["viruses", "OBSERVATION", 43, 50], ["infection", "OBSERVATION", 136, 145], ["FCoV", "OBSERVATION", 365, 369]]], ["The obtained sequence data allowed the grouping of the viruses, even so, the differences remained below 10 nucleotides.", [["nucleotides", "CHEMICAL", 107, 118], ["The obtained sequence data", "TEST", 0, 26], ["the viruses", "PROBLEM", 51, 62], ["viruses", "OBSERVATION", 55, 62]]], ["Thus, the approaches of molecular virus detection and genetic characterization provide effective novel means to study the spread of FCoV variants.", [["FCoV", "GENE_OR_GENE_PRODUCT", 132, 136], ["FCoV variants", "DNA", 132, 145], ["molecular virus detection", "TEST", 24, 49], ["genetic characterization", "TEST", 54, 78], ["FCoV variants", "OBSERVATION", 132, 145]]], ["Hopefully, these assays and the collected genomic data will contribute in the understanding of the molecular events responsible for the development of infectious peritonitis in cat populations.DISCUSSION'A unique new book for the veterinary surgeon and other members of the veterinary practice team \u2026' is how this title is described on the back cover.", [["infectious peritonitis", "DISEASE", 151, 173], ["cat", "ORGANISM", 177, 180], ["these assays", "TEST", 11, 23], ["the collected genomic data", "TEST", 28, 54], ["the molecular events", "PROBLEM", 95, 115], ["infectious peritonitis in cat populations", "PROBLEM", 151, 192], ["infectious", "OBSERVATION_MODIFIER", 151, 161], ["peritonitis", "OBSERVATION", 162, 173]]], ["Mary Stewart brings a warm and instructive approach to this rather sad event.DISCUSSIONThe book observes the whole subject of euthanasia and death of a pet, but also looks further to the bereavement that follows.", [["death", "DISEASE", 141, 146], ["euthanasia", "PROBLEM", 126, 136], ["euthanasia", "OBSERVATION", 126, 136]]], ["Mary Stewart sets out to educate both the veterinary practice staff and students by discussing the nature of the human/companion animal bond, which is the basis for the very powerful emotion that can overcome owners at the death of a pet.DISCUSSIONShe discusses in detail the process of bereavement which, once understood, will give veterinary staff a much better chance of handling the situation competently and with compassion.", [["death", "DISEASE", 223, 228], ["human", "ORGANISM", 113, 118], ["human", "SPECIES", 113, 118], ["human", "SPECIES", 113, 118]]], ["The procedures that follow euthanasia (support for the owner, options for disposal of the body and practice sympathy correspondence) are clearly laid out and may give new ideas to help the practice achieve a caring attitude.", [["body", "ANATOMY", 90, 94], ["body", "ORGANISM_SUBDIVISION", 90, 94], ["The procedures", "TREATMENT", 0, 14]]], ["There is also acknowledgement, and discussion, of the stress and sadness felt by the veterinary team.", [["the stress", "PROBLEM", 50, 60], ["sadness", "PROBLEM", 65, 72]]], ["In the section 'Stress in veterinary practice' there is detailed information on the factors (unrelated to euthanasia) that can cause anxiety in practice, and some excellent advice on how to avoid becoming stressed, which should be read by all veterinarians.DISCUSSIONThe emphasis of the book throughout is on communication, sensitivity and attitude.", [["anxiety", "DISEASE", 133, 140], ["anxiety", "PROBLEM", 133, 140]]], ["The consequences of poor client management at the time of death or euthanasia of a pet are stated unequivocally as causing troublesome, unhappy clients who will 'spread the word' and may want to 'take the matter further'.", [["death", "DISEASE", 58, 63], ["poor client management", "TREATMENT", 20, 42], ["death", "PROBLEM", 58, 63]]]], "PMC7250091": [["INTRODUCTIONSince the COVID-19 outbreak started in China, most deaths occur in the elderly or people with underlying diseases.", [["deaths", "DISEASE", 63, 69], ["people", "ORGANISM", 94, 100], ["people", "SPECIES", 94, 100], ["the COVID", "TREATMENT", 18, 27], ["underlying diseases", "PROBLEM", 106, 125], ["diseases", "OBSERVATION", 117, 125]]], ["The pathogenesis of COVID-19 is still not well understood why the viral infections lead to respiratory failure with a high mortality rate(Gao et al., 2020).", [["respiratory", "ANATOMY", 91, 102], ["viral infections", "DISEASE", 66, 82], ["respiratory failure", "DISEASE", 91, 110], ["COVID", "TEST", 20, 25], ["the viral infections", "PROBLEM", 62, 82], ["respiratory failure", "PROBLEM", 91, 110], ["a high mortality rate", "PROBLEM", 116, 137], ["viral", "OBSERVATION_MODIFIER", 66, 71], ["infections", "OBSERVATION", 72, 82], ["respiratory failure", "OBSERVATION", 91, 110]]], ["An excessive immune response contributes to COVID-19 pathogenesis and lethality(Gao et al., 2020, Jin et al., 2020).", [["An excessive immune response", "PROBLEM", 0, 28], ["COVID", "TEST", 44, 49], ["lethality", "PROBLEM", 70, 79], ["excessive", "OBSERVATION_MODIFIER", 3, 12], ["immune response", "OBSERVATION", 13, 28]]], ["Recently, complement suppression may represent a therapeutic approach to treat COVID-19(Gao et al., 2020).INTRODUCTIONWhile COVID-19 was outbreak in Korea, no effective treatment for COVID-19 has been well established yet.INTRODUCTIONRecently, several journals mentioned the possibility of nafamostat(Guo et al., 2020, Hoffmann et al., 2020, Wang et al., 2020, Yamamoto et al., 2016).", [["COVID", "DISEASE", 79, 84], ["COVID-19", "CHEMICAL", 183, 191], ["nafamostat", "CHEMICAL", 290, 300], ["COVID-19", "CHEMICAL", 183, 191], ["nafamostat", "CHEMICAL", 290, 300], ["nafamostat", "SIMPLE_CHEMICAL", 290, 300], ["a therapeutic approach", "TREATMENT", 47, 69], ["COVID", "TEST", 79, 84], ["effective treatment", "TREATMENT", 159, 178], ["COVID", "TEST", 183, 188], ["nafamostat", "TREATMENT", 290, 300], ["may represent", "UNCERTAINTY", 33, 46]]], ["Nafamostat, serine protease inhibitor, can prevent the fusion of the envelope of the virus with host cell surface membranes, the first step in infection with the causative virus COVID-19 by inhibit TRPMSS2, a human cell surface serine protease(Guo et al., 2020, Hoffmann et al., 2020, Yamamoto et al., 2016).", [["cell surface membranes", "ANATOMY", 101, 123], ["cell surface", "ANATOMY", 215, 227], ["Nafamostat", "CHEMICAL", 0, 10], ["infection", "DISEASE", 143, 152], ["Nafamostat", "CHEMICAL", 0, 10], ["serine", "CHEMICAL", 12, 18], ["serine", "CHEMICAL", 228, 234], ["Nafamostat", "SIMPLE_CHEMICAL", 0, 10], ["serine", "AMINO_ACID", 12, 18], ["cell surface membranes", "CELLULAR_COMPONENT", 101, 123], ["TRPMSS2", "GENE_OR_GENE_PRODUCT", 198, 205], ["human", "ORGANISM", 209, 214], ["cell", "CELL", 215, 219], ["TRPMSS2", "PROTEIN", 198, 205], ["human", "SPECIES", 209, 214], ["human", "SPECIES", 209, 214], ["Nafamostat", "TREATMENT", 0, 10], ["serine protease inhibitor", "TREATMENT", 12, 37], ["the fusion", "TREATMENT", 51, 61], ["the virus", "PROBLEM", 81, 90], ["host cell surface membranes", "TREATMENT", 96, 123], ["the first step in infection", "PROBLEM", 125, 152], ["the causative virus COVID", "PROBLEM", 158, 183], ["a human cell surface serine protease", "TREATMENT", 207, 243], ["host cell", "OBSERVATION", 96, 105], ["surface membranes", "OBSERVATION", 106, 123], ["infection", "OBSERVATION", 143, 152]]], ["Nafamostat inhibits various enzyme systems, such as coagulation and fibrinolytic systems, the kallikrein\u2013kinin system, the complement system, and activation of protease-activated receptors(Drugbank, 2020, March 01).", [["Nafamostat", "CHEMICAL", 0, 10], ["Nafamostat", "CHEMICAL", 0, 10], ["Nafamostat", "SIMPLE_CHEMICAL", 0, 10], ["kallikrein\u2013kinin", "GENE_OR_GENE_PRODUCT", 94, 110], ["protease-activated receptors", "GENE_OR_GENE_PRODUCT", 160, 188], ["protease-activated receptors", "PROTEIN", 160, 188], ["Nafamostat", "TREATMENT", 0, 10], ["various enzyme systems", "TEST", 20, 42], ["coagulation and fibrinolytic systems", "TEST", 52, 88], ["protease", "TREATMENT", 160, 168]]], ["It also inhibits lipopolysaccharide-induced nitric oxide production, apoptosis, and interleukin (IL)-6 and IL-8 levels in cultured human trophoblasts(Drugbank, 2020, March 01).", [["trophoblasts", "ANATOMY", 137, 149], ["lipopolysaccharide", "CHEMICAL", 17, 35], ["nitric oxide", "CHEMICAL", 44, 56], ["nitric oxide", "CHEMICAL", 44, 56], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 17, 35], ["nitric oxide", "SIMPLE_CHEMICAL", 44, 56], ["interleukin (IL)-6", "GENE_OR_GENE_PRODUCT", 84, 102], ["IL-8", "GENE_OR_GENE_PRODUCT", 107, 111], ["human", "ORGANISM", 131, 136], ["trophoblasts", "CELL", 137, 149], ["cultured human trophoblasts", "CELL_LINE", 122, 149], ["human", "SPECIES", 131, 136], ["human", "SPECIES", 131, 136], ["lipopolysaccharide", "PROBLEM", 17, 35], ["nitric oxide production", "TREATMENT", 44, 67], ["apoptosis", "PROBLEM", 69, 78], ["interleukin (IL)", "TEST", 84, 100], ["IL", "TEST", 107, 109], ["lipopolysaccharide", "OBSERVATION_MODIFIER", 17, 35], ["nitric oxide production", "OBSERVATION", 44, 67]]], ["It is shown to act as an antioxidant in TNF-\u03b1-induced ROS production(Drugbank, 2020, March 01).", [["ROS", "CHEMICAL", 54, 57], ["TNF-\u03b1-", "GENE_OR_GENE_PRODUCT", 40, 46], ["ROS", "SIMPLE_CHEMICAL", 54, 57], ["TNF", "PROTEIN", 40, 43]]], ["Therefore, nafamostat is thought to have anti-inflammatory and anti-viral properties to COVID-19 (Figure 1).CASE DESCRIPTIONThree COVID-19 patients had the following conditions: pneumonia with progression despite antiviral treatment; were elderly, over 65 years; and had underlying diseases that were known as high risk factors.", [["nafamostat", "CHEMICAL", 11, 21], ["pneumonia", "DISEASE", 178, 187], ["nafamostat", "CHEMICAL", 11, 21], ["COVID-19", "CHEMICAL", 88, 96], ["nafamostat", "SIMPLE_CHEMICAL", 11, 21], ["patients", "ORGANISM", 139, 147], ["patients", "SPECIES", 139, 147], ["nafamostat", "TREATMENT", 11, 21], ["anti-inflammatory", "TREATMENT", 41, 58], ["anti-viral properties", "TREATMENT", 63, 84], ["COVID", "TEST", 88, 93], ["pneumonia", "PROBLEM", 178, 187], ["antiviral treatment", "TREATMENT", 213, 232], ["underlying diseases", "PROBLEM", 271, 290], ["high risk factors", "PROBLEM", 310, 327], ["pneumonia", "OBSERVATION", 178, 187], ["antiviral treatment", "OBSERVATION", 213, 232], ["diseases", "OBSERVATION", 282, 290]]], ["These three patients were continuously administered 200 mg of nafamostat for 24 hours.", [["nafamostat", "CHEMICAL", 62, 72], ["nafamostat", "CHEMICAL", 62, 72], ["patients", "ORGANISM", 12, 20], ["nafamostat", "SIMPLE_CHEMICAL", 62, 72], ["patients", "SPECIES", 12, 20], ["nafamostat", "TREATMENT", 62, 72]]], ["This study was approved by the Institutional Review Board of Dankook University Hospital (DKUH 2020-03-031-001).CASE DESCRIPTION", [["This study", "TEST", 0, 10]]]], "PMC7194908": [["Reasons for Child Psychiatric Consultation ::: Introduction and OverviewPsychiatric consultations are requested for children in the inpatient pediatric setting for a wide variety of reasons.", [["children", "ORGANISM", 116, 124], ["children", "SPECIES", 116, 124]]], ["While some reasons overlap with requests made of adult psychiatric consultants, others are unique to the pediatric population or require a specific developmental approach.", [["psychiatric", "DISEASE", 55, 66], ["a specific developmental approach", "TREATMENT", 137, 170]]], ["In 2016, Shaw and colleagues published the results of a survey of practice patterns completed by 64 independent pediatric C-L psychiatry services.2 The survey results highlighted the most common reasons for pediatric psychiatric consultation to include suicide risk assessment, assistance in the diagnosis and management of medically unexplained symptoms, adjustment to medical illness, assessment for psychopharmacologic intervention, delirium, treatment non-adherence, and the management of children admitted to pediatric units to await psychiatric hospital placement (boarding).2 Thus, the role of the pediatric psychiatry consultant is a varied one and involves components both of primary psychiatric management and of close collaboration with the pediatric medical team.", [["psychiatric", "DISEASE", 217, 228], ["illness", "DISEASE", 378, 385], ["delirium", "DISEASE", 436, 444], ["psychiatric", "DISEASE", 539, 550], ["psychiatric", "DISEASE", 693, 704], ["children", "ORGANISM", 493, 501], ["children", "SPECIES", 493, 501], ["pediatric psychiatric consultation", "TEST", 207, 241], ["suicide risk assessment", "TEST", 253, 276], ["management", "TREATMENT", 310, 320], ["medically unexplained symptoms", "PROBLEM", 324, 354], ["medical illness", "PROBLEM", 370, 385], ["assessment", "TEST", 387, 397], ["psychopharmacologic intervention", "TREATMENT", 402, 434], ["delirium", "PROBLEM", 436, 444], ["treatment", "TREATMENT", 446, 455], ["psychiatric hospital placement", "TREATMENT", 539, 569], ["primary psychiatric management", "TREATMENT", 685, 715]]], ["Moreover, child psychiatric consultants must be knowledgeable about the diagnosis and management of psychiatric diseases that are particularly prevalent in children, such as feeding and eating disorders or attention-deficit/hyperactivity disorder (ADHD).", [["psychiatric", "DISEASE", 16, 27], ["psychiatric diseases", "DISEASE", 100, 120], ["eating disorders", "DISEASE", 186, 202], ["attention-deficit/hyperactivity disorder", "DISEASE", 206, 246], ["ADHD", "DISEASE", 248, 252], ["children", "ORGANISM", 156, 164], ["children", "SPECIES", 156, 164], ["psychiatric diseases", "PROBLEM", 100, 120], ["eating disorders", "PROBLEM", 186, 202], ["hyperactivity disorder", "PROBLEM", 224, 246]]], ["In the subsequent sections, we review updates in common reasons for inpatient child psychiatric consultations and associated management strategies.", [["psychiatric", "DISEASE", 84, 95], ["associated management strategies", "TREATMENT", 114, 146]]], ["Of note, while consultation for treatment non-adherence is of great importance given its associated high morbidity and mortality,2 this topic has been addressed in detail in a recent Cochrane review and will therefore not be covered in this update.4", [["treatment", "TREATMENT", 32, 41]]]], "de38e596838a792c4d5f3f4186ece436b58232ea": [["BackgroundHand, foot, and mouth disease (HFMD), primarily a disease of young children, is caused by a virus belonging to the group enteroviruses.", [["foot", "ANATOMY", 16, 20], ["mouth", "ANATOMY", 26, 31], ["Hand, foot, and mouth disease", "DISEASE", 10, 39], ["HFMD", "DISEASE", 41, 45], ["enteroviruses", "DISEASE", 131, 144], ["foot", "ORGANISM_SUBDIVISION", 16, 20], ["mouth", "ORGAN", 26, 31], ["children", "ORGANISM", 77, 85], ["children", "SPECIES", 77, 85], ["BackgroundHand, foot, and mouth disease (HFMD", "PROBLEM", 0, 45], ["a virus", "PROBLEM", 100, 107], ["Hand", "ANATOMY", 10, 14], ["foot", "ANATOMY", 16, 20], ["mouth", "ANATOMY", 26, 31], ["disease", "OBSERVATION", 32, 39]]], ["EV71 is known to be a causative agent of HFMD, herpangina, aseptic meningitis, paralysis, and meningoencephalitis [1] .", [["EV71", "DISEASE", 0, 4], ["HFMD", "DISEASE", 41, 45], ["herpangina", "DISEASE", 47, 57], ["meningitis", "DISEASE", 67, 77], ["paralysis", "DISEASE", 79, 88], ["meningoencephalitis", "DISEASE", 94, 113], ["EV71", "ORGANISM", 0, 4], ["EV71", "SPECIES", 0, 4], ["EV71", "PROBLEM", 0, 4], ["HFMD", "PROBLEM", 41, 45], ["herpangina", "PROBLEM", 47, 57], ["aseptic meningitis", "PROBLEM", 59, 77], ["paralysis", "PROBLEM", 79, 88], ["meningoencephalitis", "PROBLEM", 94, 113], ["known to be", "UNCERTAINTY", 8, 19], ["HFMD", "OBSERVATION", 41, 45], ["aseptic", "OBSERVATION_MODIFIER", 59, 66], ["meningitis", "OBSERVATION", 67, 77], ["paralysis", "OBSERVATION", 79, 88], ["meningoencephalitis", "OBSERVATION", 94, 113]]], ["HFMD usually presents with symptoms including fever and a characteristic rash associated with the limbs, mouth and skin.", [["limbs", "ANATOMY", 98, 103], ["mouth", "ANATOMY", 105, 110], ["skin", "ANATOMY", 115, 119], ["HFMD", "DISEASE", 0, 4], ["fever", "DISEASE", 46, 51], ["rash", "DISEASE", 73, 77], ["limbs", "ORGANISM_SUBDIVISION", 98, 103], ["mouth", "ORGANISM_SUBDIVISION", 105, 110], ["skin", "ORGAN", 115, 119], ["HFMD", "PROBLEM", 0, 4], ["symptoms", "PROBLEM", 27, 35], ["fever", "PROBLEM", 46, 51], ["a characteristic rash", "PROBLEM", 56, 77], ["rash", "OBSERVATION", 73, 77], ["limbs", "ANATOMY", 98, 103], ["mouth", "ANATOMY", 105, 110], ["skin", "ANATOMY", 115, 119]]], ["In severe disease such as caused by EV71, however, the patients may develop nervous system diseases such as aseptic meningitis, encephalitis, brainstem encephalitis, encephalomyelitis, and poliomyelitis-like syndrome as well as neurogenic pulmonary edema and myocarditis, resulting in high morbidity and mortality [2] .", [["nervous system", "ANATOMY", 76, 90], ["pulmonary", "ANATOMY", 239, 248], ["EV71", "DISEASE", 36, 40], ["nervous system diseases", "DISEASE", 76, 99], ["aseptic meningitis", "DISEASE", 108, 126], ["encephalitis", "DISEASE", 128, 140], ["brainstem encephalitis", "DISEASE", 142, 164], ["encephalomyelitis", "DISEASE", 166, 183], ["poliomyelitis-like syndrome", "DISEASE", 189, 216], ["neurogenic pulmonary edema", "DISEASE", 228, 254], ["myocarditis", "DISEASE", 259, 270], ["EV71", "ORGANISM", 36, 40], ["patients", "ORGANISM", 55, 63], ["nervous system", "ANATOMICAL_SYSTEM", 76, 90], ["pulmonary", "ORGAN", 239, 248], ["patients", "SPECIES", 55, 63], ["EV71", "SPECIES", 36, 40], ["severe disease", "PROBLEM", 3, 17], ["EV71", "PROBLEM", 36, 40], ["nervous system diseases", "PROBLEM", 76, 99], ["aseptic meningitis", "PROBLEM", 108, 126], ["encephalitis", "PROBLEM", 128, 140], ["brainstem encephalitis", "PROBLEM", 142, 164], ["encephalomyelitis", "PROBLEM", 166, 183], ["poliomyelitis", "PROBLEM", 189, 202], ["syndrome", "PROBLEM", 208, 216], ["neurogenic pulmonary edema", "PROBLEM", 228, 254], ["myocarditis", "PROBLEM", 259, 270], ["high morbidity", "PROBLEM", 285, 299], ["severe", "OBSERVATION_MODIFIER", 3, 9], ["disease", "OBSERVATION", 10, 17], ["aseptic", "OBSERVATION_MODIFIER", 108, 115], ["meningitis", "OBSERVATION", 116, 126], ["encephalitis", "OBSERVATION", 128, 140], ["brainstem", "ANATOMY", 142, 151], ["encephalitis", "OBSERVATION", 152, 164], ["encephalomyelitis", "OBSERVATION", 166, 183], ["poliomyelitis", "OBSERVATION", 189, 202], ["neurogenic", "OBSERVATION_MODIFIER", 228, 238], ["pulmonary", "ANATOMY", 239, 248], ["edema", "OBSERVATION", 249, 254], ["myocarditis", "OBSERVATION", 259, 270], ["high", "OBSERVATION_MODIFIER", 285, 289], ["morbidity", "OBSERVATION_MODIFIER", 290, 299]]], ["EV71 was first isolated in the United States (California) in 1969 and by the mid-1970s, EV71 outbreaks, characterized by central nervous system complications occurred in succession in Bulgaria and Hungary [3] .", [["central nervous system", "ANATOMY", 121, 143], ["EV71", "DISEASE", 0, 4], ["EV71", "DISEASE", 88, 92], ["central nervous system complications", "DISEASE", 121, 157], ["EV71", "ORGANISM", 0, 4], ["central nervous system", "ANATOMICAL_SYSTEM", 121, 143], ["EV71", "SPECIES", 0, 4], ["EV71", "PROBLEM", 0, 4], ["central nervous system complications", "PROBLEM", 121, 157], ["central", "ANATOMY_MODIFIER", 121, 128], ["nervous system", "ANATOMY", 129, 143], ["complications", "OBSERVATION", 144, 157]]], ["In the late 1990s, EV71 emerged in East Asia.", [["EV71", "DISEASE", 19, 23], ["EV71", "ORGANISM", 19, 23], ["EV71", "SPECIES", 19, 23]]], ["In 1997, 2628 cases in Malaysia were reported, with 34 deaths [4] .", [["deaths", "DISEASE", 55, 61]]], ["One year later, an estimated 1.5 million cases occurred in Taiwan; 405 cases developed severe neuropathic complications with 78 deaths [5] .", [["neuropathic complications", "DISEASE", 94, 119], ["deaths", "DISEASE", 128, 134], ["severe neuropathic complications", "PROBLEM", 87, 119], ["severe", "OBSERVATION_MODIFIER", 87, 93], ["neuropathic", "OBSERVATION_MODIFIER", 94, 105]]], ["In 1999, an EV71 pandemic occurred in Perth, Australia; 6000 cases were reported in 6 months; 29 cases developed severe disease [6] .", [["EV71 pandemic", "DISEASE", 12, 25], ["EV71", "ORGANISM", 12, 16], ["severe disease", "PROBLEM", 113, 127], ["severe", "OBSERVATION_MODIFIER", 113, 119], ["disease", "OBSERVATION", 120, 127]]], ["In 2008, a large scale outbreak of HFMD occurred in Anhui Province, China; 3321 cases were reported with 22 deaths [12] .BackgroundHFMD outbreaks associated with EV71 exhibit a significant seasonal pattern with a peak in summer and low incidence in winter [13, 14] , however the number of HFMD cases increase significantly with increasing temperature and relative humidity [13, 15] .", [["HFMD", "DISEASE", 35, 39], ["deaths", "DISEASE", 108, 114], ["HFMD", "DISEASE", 131, 135], ["EV71", "DISEASE", 162, 166], ["HFMD", "DISEASE", 289, 293], ["EV71", "ORGANISM", 162, 166], ["EV71", "SPECIES", 162, 166], ["HFMD", "PROBLEM", 35, 39], ["BackgroundHFMD outbreaks", "PROBLEM", 121, 145], ["EV71", "PROBLEM", 162, 166], ["a significant seasonal pattern", "PROBLEM", 175, 205], ["increasing temperature", "PROBLEM", 328, 350], ["large", "OBSERVATION_MODIFIER", 11, 16], ["low incidence", "OBSERVATION_MODIFIER", 232, 245]]], ["In this study, we describe an atypical winter outbreak of HFMD from November 30 to December 28, 2010, in Linyi City, Shandong Province, China, during which 173 cases were admitted to the Linyi People's Hospital.", [["HFMD", "DISEASE", 58, 62], ["this study", "TEST", 3, 13], ["atypical", "OBSERVATION_MODIFIER", 30, 38]]], ["In this study, we analyzed the epidemiological characteristics of this outbreak and the molecular epidemiology of EV71, with an attempt to provide scientific evidence for the prevention and control of HFMD.Case information and clinical samplesOne hundred and seventy three patients admitted to Linyi City People's Hospital were enrolled in the study.", [["EV71", "DISEASE", 114, 118], ["HFMD", "DISEASE", 201, 205], ["EV71", "ORGANISM", 114, 118], ["patients", "ORGANISM", 273, 281], ["patients", "SPECIES", 273, 281], ["EV71", "SPECIES", 114, 118], ["this study", "TEST", 3, 13], ["EV71", "PROBLEM", 114, 118], ["HFMD", "PROBLEM", 201, 205], ["clinical samples", "TEST", 227, 243], ["the study", "TEST", 340, 349]]], ["All 173 cases were diagnosed according to a standardized clinical case definition of HMFD [16] .", [["HMFD", "DISEASE", 85, 89]]], ["HFMD was defined as fever, accompanied by herpangina and rashes on the hands and feet, with or without buttock involvement.", [["herpangina", "ANATOMY", 42, 52], ["feet", "ANATOMY", 81, 85], ["buttock", "ANATOMY", 103, 110], ["HFMD", "DISEASE", 0, 4], ["fever", "DISEASE", 20, 25], ["herpangina", "DISEASE", 42, 52], ["rashes", "DISEASE", 57, 63], ["hands", "ORGANISM_SUBDIVISION", 71, 76], ["feet", "ORGANISM_SUBDIVISION", 81, 85], ["buttock", "ORGANISM_SUBDIVISION", 103, 110], ["HFMD", "PROBLEM", 0, 4], ["fever", "PROBLEM", 20, 25], ["herpangina", "PROBLEM", 42, 52], ["rashes on the hands and feet", "PROBLEM", 57, 85], ["buttock involvement", "PROBLEM", 103, 122], ["rashes", "OBSERVATION", 57, 63], ["hands", "ANATOMY", 71, 76], ["feet", "ANATOMY", 81, 85], ["without", "UNCERTAINTY", 95, 102], ["buttock", "ANATOMY", 103, 110], ["involvement", "OBSERVATION", 111, 122]]], ["Severe HFMD patients presented with obvious symptoms of nervous system involvement and severe complication, such as myoclonus, encephalitis, acute flaccid paralysis, pulmonary edema, or heart failure.", [["nervous system", "ANATOMY", 56, 70], ["flaccid", "ANATOMY", 147, 154], ["pulmonary", "ANATOMY", 166, 175], ["heart", "ANATOMY", 186, 191], ["HFMD", "DISEASE", 7, 11], ["myoclonus", "DISEASE", 116, 125], ["encephalitis", "DISEASE", 127, 139], ["acute flaccid paralysis", "DISEASE", 141, 164], ["pulmonary edema", "DISEASE", 166, 181], ["heart failure", "DISEASE", 186, 199], ["patients", "ORGANISM", 12, 20], ["nervous", "ANATOMICAL_SYSTEM", 56, 63], ["system", "ANATOMICAL_SYSTEM", 64, 70], ["pulmonary", "ORGAN", 166, 175], ["heart", "ORGAN", 186, 191], ["patients", "SPECIES", 12, 20], ["Severe HFMD patients", "PROBLEM", 0, 20], ["obvious symptoms of nervous system involvement", "PROBLEM", 36, 82], ["severe complication", "PROBLEM", 87, 106], ["myoclonus", "PROBLEM", 116, 125], ["encephalitis", "PROBLEM", 127, 139], ["acute flaccid paralysis", "PROBLEM", 141, 164], ["pulmonary edema", "PROBLEM", 166, 181], ["heart failure", "PROBLEM", 186, 199], ["HFMD", "OBSERVATION", 7, 11], ["nervous system", "ANATOMY", 56, 70], ["severe", "OBSERVATION_MODIFIER", 87, 93], ["complication", "OBSERVATION", 94, 106], ["encephalitis", "OBSERVATION", 127, 139], ["acute", "OBSERVATION_MODIFIER", 141, 146], ["flaccid", "OBSERVATION_MODIFIER", 147, 154], ["paralysis", "OBSERVATION", 155, 164], ["pulmonary", "ANATOMY", 166, 175], ["edema", "OBSERVATION", 176, 181], ["heart", "ANATOMY", 186, 191], ["failure", "OBSERVATION", 192, 199]]], ["To confirm the diagnosis of HMFD, 213 specimens (173 stool and 40 throat swabs) were collected for enterovirus detection and molecular typing.", [["specimens", "ANATOMY", 38, 47], ["stool", "ANATOMY", 53, 58], ["throat swabs", "ANATOMY", 66, 78], ["HMFD", "DISEASE", 28, 32], ["HMFD", "CANCER", 28, 32], ["specimens", "CANCER", 38, 47], ["enterovirus", "SPECIES", 99, 110], ["HMFD", "TEST", 28, 32], ["213 specimens", "TEST", 34, 47], ["stool", "TEST", 53, 58], ["throat swabs", "TEST", 66, 78], ["enterovirus detection", "TEST", 99, 120], ["molecular typing", "TEST", 125, 141]]], ["Throat swabs were immediately immersed into sterile tubes containing viral transport medium (VTM).", [["Throat swabs", "ANATOMY", 0, 12], ["Throat swabs", "ORGANISM_SUBSTANCE", 0, 12], ["Throat swabs", "TEST", 0, 12], ["sterile tubes", "TREATMENT", 44, 57], ["viral transport medium", "TREATMENT", 69, 91]]], ["The study protocol was approved by the Medical Ethics Committee of Academy of Military Medical Sciences.Virus isolationApproximately 0.5 g of a fecal sample was put into a 1.5 ml centrifuge tube with a glass bead.", [["fecal sample", "ANATOMY", 144, 156], ["Virus", "ORGANISM", 104, 109], ["The study protocol", "TEST", 0, 18], ["Virus isolationApproximately", "TREATMENT", 104, 132], ["a fecal sample", "TREATMENT", 142, 156], ["a 1.5 ml centrifuge tube", "TREATMENT", 170, 194], ["a glass bead", "TREATMENT", 200, 212], ["fecal", "ANATOMY", 144, 149], ["glass bead", "OBSERVATION", 202, 212]]], ["After addition of 1 ml of phosphate buffer, the solution was vortexed for 1 min and centrifuged at 4000 rpm for 10 min.", [["phosphate", "CHEMICAL", 26, 35], ["phosphate", "CHEMICAL", 26, 35], ["phosphate", "SIMPLE_CHEMICAL", 26, 35], ["phosphate buffer", "TREATMENT", 26, 42], ["the solution", "TREATMENT", 44, 56]]], ["Fecal supernatants and the VTM from tubes containing throat samples were filtered through a 0.22 or 0.45 \u03bcm syringe filter (Pall, Ann Arbor, MI, USA).", [["Fecal supernatants", "ANATOMY", 0, 18], ["tubes", "ANATOMY", 36, 41], ["throat samples", "ANATOMY", 53, 67], ["Fecal", "ORGANISM_SUBSTANCE", 0, 5], ["tubes", "TISSUE", 36, 41], ["Fecal supernatants", "PROBLEM", 0, 18], ["the VTM from tubes containing throat samples", "PROBLEM", 23, 67], ["0.45 \u03bcm syringe filter", "TREATMENT", 100, 122], ["supernatants", "OBSERVATION", 6, 18], ["tubes", "OBSERVATION", 36, 41], ["throat", "ANATOMY", 53, 59]]], ["Filtrates were cultured with human rhabdomyosarcoma cells (RD cells) at 37\u00b0C and 5% CO 2 for 7 days.", [["rhabdomyosarcoma cells", "ANATOMY", 35, 57], ["RD cells", "ANATOMY", 59, 67], ["CO 2", "CHEMICAL", 84, 88], ["Filtrates", "SIMPLE_CHEMICAL", 0, 9], ["human", "ORGANISM", 29, 34], ["rhabdomyosarcoma cells", "CELL", 35, 57], ["RD cells", "CELL", 59, 67], ["human rhabdomyosarcoma cells", "CELL_TYPE", 29, 57], ["RD cells", "CELL_LINE", 59, 67], ["human", "SPECIES", 29, 34], ["human", "SPECIES", 29, 34], ["Filtrates", "TEST", 0, 9], ["human rhabdomyosarcoma cells", "PROBLEM", 29, 57], ["RD cells", "TEST", 59, 67], ["rhabdomyosarcoma cells", "OBSERVATION", 35, 57]]], ["Cells were observed daily for cytopathic effects (CPE).", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["Cells", "TEST", 0, 5], ["cytopathic effects", "PROBLEM", 30, 48]]], ["Each specimen was passaged blindly at least 3 times.", [["specimen", "ANATOMY", 5, 13]]], ["Cells demonstrating an observed CPE were repeatedly frozen and thawed 3 times to allow for RNA extraction and identification using molecular biology approaches, and then cell cultures and RNAs were stored at \u221280\u00b0C. If no specific CPE was observed cell culture was interpreted as negative.Virus isolationNucleic acid extraction and molecular typing Viral RNA was extracted from clinical specimens and viral cultures using a QIAamp Viral RNA Mini Kit (Qiagen, Germany) according to the manufacturer's instructions.", [["Cells", "ANATOMY", 0, 5], ["cell cultures", "ANATOMY", 170, 183], ["cell", "ANATOMY", 247, 251], ["specimens", "ANATOMY", 386, 395], ["Nucleic acid", "CHEMICAL", 303, 315], ["Cells", "CELL", 0, 5], ["cell cultures", "CELL", 170, 183], ["cell", "CELL", 247, 251], ["Virus", "ORGANISM", 288, 293], ["Nucleic acid", "SIMPLE_CHEMICAL", 303, 315], ["Viral RNA", "RNA", 348, 357], ["an observed CPE", "PROBLEM", 20, 35], ["RNA extraction", "TREATMENT", 91, 105], ["cell cultures", "TEST", 170, 183], ["RNAs", "TEST", 188, 192], ["specific CPE", "PROBLEM", 221, 233], ["cell culture", "TEST", 247, 259], ["Virus isolation", "TREATMENT", 288, 303], ["Nucleic acid extraction", "TREATMENT", 303, 326], ["molecular typing Viral RNA", "PROBLEM", 331, 357], ["clinical specimens", "TEST", 377, 395], ["viral cultures", "TEST", 400, 414], ["a QIAamp Viral RNA", "TREATMENT", 421, 439], ["acid", "OBSERVATION_MODIFIER", 311, 315]]], ["All RNA samples were examined by real time reverse-transcription PCR (rt RT-PCR) using a set of Pan-EV (EV universal primer) probe and primers; positive samples were tested by rt RT-PCR for EV71 and CA16 using specific primers and probes [17] .", [["samples", "ANATOMY", 8, 15], ["samples", "ANATOMY", 153, 160], ["EV71", "ORGANISM", 190, 194], ["Pan-EV (EV universal primer", "DNA", 96, 123], ["CA16", "DNA", 199, 203], ["EV71", "SPECIES", 190, 194], ["CA16", "SPECIES", 199, 203], ["All RNA samples", "TEST", 0, 15], ["transcription PCR", "TEST", 51, 68], ["rt RT-PCR", "TREATMENT", 70, 79], ["Pan-EV (EV universal primer", "TREATMENT", 96, 123], ["rt RT", "TEST", 176, 181], ["PCR", "TEST", 182, 185], ["EV71", "PROBLEM", 190, 194], ["CA16", "TEST", 199, 203], ["specific primers", "TEST", 210, 226]]], ["Rt RT-PCR was performed using AgPath-ID\u2122 One-Step RT-PCR reagents (Applied Biosystems, Foster, CA, USA).", [["AgPath", "PROTEIN", 30, 36], ["Rt RT-PCR", "TEST", 0, 9], ["Step RT-PCR reagents", "TREATMENT", 45, 65]]], ["Total DNA was extracted from 40 throat specimens using QIAamp DNA Blood Mini Kit (Qiagen, Germany).", [["throat specimens", "ANATOMY", 32, 48], ["DNA", "CELLULAR_COMPONENT", 6, 9], ["Total DNA", "TEST", 0, 9], ["throat specimens", "TEST", 32, 48], ["QIAamp DNA", "TEST", 55, 65]]], ["Commercial available multiplex PCR assays (Seeplex\u00ae RV12 ACE, Korea) was used for testing respiratory viruses of 40 throat specimens, including human adenovirus, coronaviruses, parainfluenza viruses, influenza A virus, influenza B virus, respiratory syncytial virus A and B, and bocavirus.", [["throat specimens", "ANATOMY", 116, 132], ["respiratory viruses", "DISEASE", 90, 109], ["parainfluenza viruses", "DISEASE", 177, 198], ["influenza A", "DISEASE", 200, 211], ["influenza B", "DISEASE", 219, 230], ["respiratory syncytial virus", "DISEASE", 238, 265], ["human", "ORGANISM", 144, 149], ["adenovirus", "ORGANISM", 150, 160], ["coronaviruses", "ORGANISM", 162, 175], ["parainfluenza viruses", "ORGANISM", 177, 198], ["influenza A virus", "ORGANISM", 200, 217], ["influenza B virus", "ORGANISM", 219, 236], ["respiratory syncytial virus A", "ORGANISM", 238, 267], ["B", "GENE_OR_GENE_PRODUCT", 272, 273], ["human", "SPECIES", 144, 149], ["parainfluenza", "SPECIES", 177, 190], ["influenza A virus", "SPECIES", 200, 217], ["influenza B virus", "SPECIES", 219, 236], ["respiratory syncytial virus", "SPECIES", 238, 265], ["human adenovirus", "SPECIES", 144, 160], ["influenza A virus", "SPECIES", 200, 217], ["influenza B virus", "SPECIES", 219, 236], ["respiratory syncytial virus A", "SPECIES", 238, 267], ["Commercial available multiplex PCR assays", "TEST", 0, 41], ["Seeplex", "TEST", 43, 50], ["ACE", "TEST", 57, 60], ["testing respiratory viruses", "TEST", 82, 109], ["40 throat specimens", "TEST", 113, 132], ["human adenovirus", "PROBLEM", 144, 160], ["coronaviruses", "PROBLEM", 162, 175], ["parainfluenza viruses", "PROBLEM", 177, 198], ["influenza A virus", "PROBLEM", 200, 217], ["influenza B virus", "PROBLEM", 219, 236], ["respiratory syncytial virus", "PROBLEM", 238, 265], ["bocavirus", "PROBLEM", 279, 288], ["parainfluenza viruses", "OBSERVATION", 177, 198]]], ["Amplification was performed using an IQ\u21225 quantitative real-time PCR system (BioRad, Hercules, CA, USA).Virus isolationFull-length VP1 sequences from EV71 isolates were amplified with the primers EV71-VP1-F, GGKGCRCC CAAYACWGCYT and EV71-VP1-R, CCVCCRCAAT CHCCWGGYT, resulting in a 981-bp amplicon.", [["Virus", "ORGANISM", 104, 109], ["VP1", "ORGANISM", 131, 134], ["EV71", "ORGANISM", 150, 154], ["Virus isolationFull-length VP1 sequences", "DNA", 104, 144], ["VP1", "DNA", 201, 204], ["GGKGCRCC", "DNA", 208, 216], ["EV71", "DNA", 233, 237], ["VP1", "DNA", 238, 241], ["R", "DNA", 242, 243], ["CCVCCRCAAT CHCCWGGYT", "DNA", 245, 265], ["981-bp amplicon", "DNA", 282, 297], ["EV71", "SPECIES", 150, 154], ["Virus isolationFull", "TEST", 104, 123], ["length VP1 sequences", "TEST", 124, 144], ["EV71 isolates", "TEST", 150, 163], ["the primers EV71", "TEST", 184, 200], ["VP1", "TEST", 201, 204], ["GGKGCRCC", "TEST", 208, 216], ["CAAYACWGCYT", "TEST", 217, 228], ["EV71", "TEST", 233, 237], ["VP1", "TEST", 238, 241], ["bp amplicon", "TEST", 286, 297]]], ["PCR was performed using a GeneAmp 9700 Thermal Cycler (Applied Biosystems).", [["PCR", "TEST", 0, 3], ["a GeneAmp 9700 Thermal Cycler (Applied Biosystems", "TREATMENT", 24, 73]]], ["PCR products were detected by agarose gel electrophoresis, and products were purified and sequenced with an ABI PRISM 3730 Genetic Analyzer (Applied Biosystems).", [["agarose", "SIMPLE_CHEMICAL", 30, 37], ["PCR products", "TREATMENT", 0, 12], ["agarose gel electrophoresis", "TEST", 30, 57], ["an ABI PRISM", "TEST", 105, 117], ["Genetic Analyzer", "TEST", 123, 139]]], ["An online Blast Search Tool (http://blast.ncbi.nlm.nih.gov/Blast.cgi) was used to compare the sequences and determine the types.", [["the sequences", "TEST", 90, 103]]], ["The constituent ratio of amino acid variation between severe cases and mild cases strains was compared with Chisquare test by SAS software (version 9.0; SAS Institute).Phylogenetic analysisMultiple sequence alignments were performed by using the MEGA software version 5.2 and the Clustal W program to determine nucleotide and amino acid sequence similarities.", [["amino acid", "CHEMICAL", 25, 35], ["nucleotide", "CHEMICAL", 311, 321], ["amino acid", "CHEMICAL", 326, 336], ["amino acid", "CHEMICAL", 25, 35], ["nucleotide", "CHEMICAL", 311, 321], ["amino acid", "CHEMICAL", 326, 336], ["amino acid", "AMINO_ACID", 25, 35], ["amino acid", "AMINO_ACID", 326, 336], ["amino acid variation", "PROBLEM", 25, 45], ["severe cases", "PROBLEM", 54, 66], ["mild cases strains", "PROBLEM", 71, 89], ["Chisquare test", "TEST", 108, 122], ["SAS software", "TEST", 126, 138], ["version", "TEST", 140, 147], ["Phylogenetic analysisMultiple sequence alignments", "TEST", 168, 217], ["the MEGA software version", "TEST", 242, 267], ["the Clustal W program", "TREATMENT", 276, 297], ["nucleotide and amino acid sequence similarities", "TEST", 311, 358], ["amino acid", "OBSERVATION", 25, 35], ["mild", "OBSERVATION_MODIFIER", 71, 75]]], ["Phylogenetic trees were constructed in MEGA using the neighbor-joining (NJ) cluster algorithm with evolutionary distances estimated using the Kimura 2-parameter model; bootstrapping was performed using 1,000 pseudo-replicates [18] .Nucleotide sequence accession numbersThe full sequences of VP1 from this study are deposited in GenBank with the following accession numbers: KF853482-KF853549, KJ185132-KJ185170.Epidemiological analysis and clinical symptomsA total of 173 HFMD cases (including 23 with severe presentation) were diagnosed and treated in Linyi People's Hospital from November 30 to December 28, 2010 ( Figure 1 ).", [["HFMD", "DISEASE", 472, 476], ["VP1", "GENE_OR_GENE_PRODUCT", 291, 294], ["neighbor-joining (NJ) cluster algorithm", "DNA", 54, 93], ["VP1", "DNA", 291, 294], ["evolutionary distances", "PROBLEM", 99, 121], ["the Kimura", "TREATMENT", 138, 148], ["bootstrapping", "TEST", 168, 181], ["this study", "TEST", 300, 310], ["Epidemiological analysis", "TEST", 411, 435]]], ["The majority of patients were children aged < 5 years (95.4%) with the male-female ratio of 1.88:1.", [["patients", "ORGANISM", 16, 24], ["children", "ORGANISM", 30, 38], ["patients", "SPECIES", 16, 24], ["children", "SPECIES", 30, 38]]], ["Cases presented from 9 counties or districts; although the incidence was greatest in Lanshan District (35.8%) and Fei County (31.2%).Epidemiological analysis and clinical symptomsAll cases had fever and the characteristic rashes associated with the limbs, mouth and skin.", [["limbs", "ANATOMY", 249, 254], ["mouth", "ANATOMY", 256, 261], ["skin", "ANATOMY", 266, 270], ["fever", "DISEASE", 193, 198], ["rashes", "DISEASE", 222, 228], ["rashes", "PATHOLOGICAL_FORMATION", 222, 228], ["limbs", "ORGANISM_SUBDIVISION", 249, 254], ["mouth", "ORGANISM_SUBDIVISION", 256, 261], ["skin", "ORGAN", 266, 270], ["Epidemiological analysis", "TEST", 133, 157], ["clinical symptoms", "PROBLEM", 162, 179], ["fever", "PROBLEM", 193, 198], ["the characteristic rashes", "PROBLEM", 203, 228], ["rashes", "OBSERVATION", 222, 228], ["limbs", "ANATOMY", 249, 254], ["mouth", "ANATOMY", 256, 261], ["skin", "ANATOMY", 266, 270]]], ["Severe cases were associated with meningitis (n = 15) or more severe neurological complications (meningoencephalitis, n = 3; neurogenic pulmonary edema, n = 5); no deaths were observed.", [["neurological", "ANATOMY", 69, 81], ["pulmonary", "ANATOMY", 136, 145], ["meningitis", "DISEASE", 34, 44], ["neurological complications", "DISEASE", 69, 95], ["meningoencephalitis", "DISEASE", 97, 116], ["neurogenic pulmonary edema", "DISEASE", 125, 151], ["deaths", "DISEASE", 164, 170], ["pulmonary", "ORGAN", 136, 145], ["Severe cases", "PROBLEM", 0, 12], ["meningitis", "PROBLEM", 34, 44], ["more severe neurological complications", "PROBLEM", 57, 95], ["meningoencephalitis", "PROBLEM", 97, 116], ["neurogenic pulmonary edema", "PROBLEM", 125, 151], ["deaths", "PROBLEM", 164, 170], ["meningitis", "OBSERVATION", 34, 44], ["severe", "OBSERVATION_MODIFIER", 62, 68], ["neurological", "OBSERVATION_MODIFIER", 69, 81], ["complications", "OBSERVATION", 82, 95], ["meningoencephalitis", "OBSERVATION", 97, 116], ["pulmonary", "ANATOMY", 136, 145], ["edema", "OBSERVATION", 146, 151]]], ["Although some patients developed respiratory symptoms including runny nose (38.2%), cough (20.2%), and sore throat (14.5%), testing with multiplex PCR assays of a subset of throat samples (n = 40) for respiratory viruses including human adenovirus, coronaviruses, parainfluenza viruses, influenza A virus, influenza B virus, respiratory syncytial virus A and B, and bocavirus were all negative.", [["respiratory", "ANATOMY", 33, 44], ["throat samples", "ANATOMY", 173, 187], ["respiratory symptoms", "DISEASE", 33, 53], ["runny nose", "DISEASE", 64, 74], ["cough", "DISEASE", 84, 89], ["sore throat", "DISEASE", 103, 114], ["respiratory viruses", "DISEASE", 201, 220], ["parainfluenza viruses", "DISEASE", 264, 285], ["influenza A", "DISEASE", 287, 298], ["influenza B", "DISEASE", 306, 317], ["respiratory syncytial virus", "DISEASE", 325, 352], ["patients", "ORGANISM", 14, 22], ["throat samples", "CANCER", 173, 187], ["human", "ORGANISM", 231, 236], ["adenovirus", "ORGANISM", 237, 247], ["coronaviruses", "ORGANISM", 249, 262], ["parainfluenza viruses", "ORGANISM", 264, 285], ["influenza A virus", "ORGANISM", 287, 304], ["influenza B virus", "ORGANISM", 306, 323], ["respiratory syncytial virus A", "ORGANISM", 325, 354], ["B", "GENE_OR_GENE_PRODUCT", 359, 360], ["bocavirus", "CANCER", 366, 375], ["patients", "SPECIES", 14, 22], ["human", "SPECIES", 231, 236], ["parainfluenza", "SPECIES", 264, 277], ["influenza A virus", "SPECIES", 287, 304], ["influenza B virus", "SPECIES", 306, 323], ["respiratory syncytial virus", "SPECIES", 325, 352], ["human adenovirus", "SPECIES", 231, 247], ["influenza A virus", "SPECIES", 287, 304], ["influenza B virus", "SPECIES", 306, 323], ["respiratory syncytial virus", "SPECIES", 325, 352], ["respiratory symptoms", "PROBLEM", 33, 53], ["runny nose", "PROBLEM", 64, 74], ["cough", "PROBLEM", 84, 89], ["sore throat", "PROBLEM", 103, 114], ["testing", "TEST", 124, 131], ["multiplex PCR assays", "TEST", 137, 157], ["throat samples", "TEST", 173, 187], ["respiratory viruses", "PROBLEM", 201, 220], ["human adenovirus", "PROBLEM", 231, 247], ["coronaviruses", "PROBLEM", 249, 262], ["parainfluenza viruses", "PROBLEM", 264, 285], ["influenza A virus", "PROBLEM", 287, 304], ["influenza B virus", "PROBLEM", 306, 323], ["respiratory syncytial virus A", "PROBLEM", 325, 354], ["bocavirus", "PROBLEM", 366, 375], ["respiratory", "ANATOMY", 33, 44], ["sore throat", "ANATOMY", 103, 114], ["throat", "ANATOMY", 173, 179], ["respiratory", "ANATOMY", 201, 212], ["viruses", "OBSERVATION", 213, 220], ["parainfluenza viruses", "OBSERVATION", 264, 285], ["respiratory syncytial", "ANATOMY", 325, 346]]], ["A small number of patients also reported nausea, or experienced vomiting, diarrhea, and other gastrointestinal symptoms.", [["gastrointestinal", "ANATOMY", 94, 110], ["nausea", "DISEASE", 41, 47], ["vomiting", "DISEASE", 64, 72], ["diarrhea", "DISEASE", 74, 82], ["gastrointestinal symptoms", "DISEASE", 94, 119], ["patients", "ORGANISM", 18, 26], ["gastrointestinal", "ORGANISM_SUBDIVISION", 94, 110], ["patients", "SPECIES", 18, 26], ["nausea", "PROBLEM", 41, 47], ["vomiting", "PROBLEM", 64, 72], ["diarrhea", "PROBLEM", 74, 82], ["other gastrointestinal symptoms", "PROBLEM", 88, 119], ["small", "OBSERVATION_MODIFIER", 2, 7], ["number", "OBSERVATION_MODIFIER", 8, 14], ["gastrointestinal", "ANATOMY", 94, 110], ["symptoms", "OBSERVATION", 111, 119]]], ["Most cases were accompanied by characteristic neurological symptoms including drowsiness and convulsions (Table 1) .Laboratory identificationAll RNA samples were examined by rt RT-PCR for the presence of any detectable enterovirus (Pan EV screen) and then specifically for EV71 and CA16.", [["neurological", "ANATOMY", 46, 58], ["samples", "ANATOMY", 149, 156], ["convulsions", "DISEASE", 93, 104], ["enterovirus", "ORGANISM", 219, 230], ["EV71", "ORGANISM", 273, 277], ["EV71", "SPECIES", 273, 277], ["CA16", "SPECIES", 282, 286], ["characteristic neurological symptoms", "PROBLEM", 31, 67], ["drowsiness", "PROBLEM", 78, 88], ["convulsions", "PROBLEM", 93, 104], ["Laboratory identificationAll RNA samples", "TEST", 116, 156], ["rt RT-PCR", "TEST", 174, 183], ["any detectable enterovirus", "PROBLEM", 204, 230], ["Pan EV screen", "TEST", 232, 245], ["EV71", "PROBLEM", 273, 277], ["CA16", "TEST", 282, 286], ["enterovirus", "OBSERVATION", 219, 230]]], ["Among the 213 specimens, an amplicon was evident in 148 of the samples, taken from 138 cases, using the Pan-EV primers and probes.", [["specimens", "ANATOMY", 14, 23], ["samples", "ANATOMY", 63, 70], ["specimens", "CANCER", 14, 23], ["samples", "CANCER", 63, 70], ["Pan-EV primers", "DNA", 104, 118], ["an amplicon", "TEST", 25, 36], ["the samples", "TEST", 59, 70], ["the Pan-EV primers", "TREATMENT", 100, 118]]], ["Using primers and probes specific for EV71, the 148 Pan EV-positive specimens were also positive; stool specimens were positive from 138 cases, and 10 cases who had a throat swab and fecal sample both tested positive.", [["specimens", "ANATOMY", 68, 77], ["stool specimens", "ANATOMY", 98, 113], ["throat swab", "ANATOMY", 167, 178], ["fecal sample", "ANATOMY", 183, 195], ["EV71", "ORGANISM", 38, 42], ["Pan EV", "ORGANISM", 52, 58], ["stool specimens", "ORGANISM_SUBSTANCE", 98, 113], ["fecal", "ORGANISM_SUBSTANCE", 183, 188], ["EV71", "SPECIES", 38, 42], ["primers", "TREATMENT", 6, 13], ["EV71", "TEST", 38, 42], ["Pan EV", "TEST", 52, 58], ["stool specimens", "TEST", 98, 113], ["a throat swab", "TEST", 165, 178], ["fecal sample", "TEST", 183, 195], ["throat", "ANATOMY", 167, 173], ["fecal", "ANATOMY", 183, 188]]], ["Primers and probes specific for CA16 were negative in all the samples.", [["samples", "ANATOMY", 62, 69], ["CA16", "GENE_OR_GENE_PRODUCT", 32, 36], ["CA16", "DNA", 32, 36], ["CA16", "TEST", 32, 36]]], ["Viral samples from the ten patients with two positive samples were indistinguishable.", [["samples", "ANATOMY", 6, 13], ["samples", "ANATOMY", 54, 61], ["patients", "ORGANISM", 27, 35], ["patients", "SPECIES", 27, 35], ["Viral samples", "TEST", 0, 13], ["two positive samples", "TEST", 41, 61]]], ["In total, 107/213 (50.2%) samples from 107 individual cases were culture-positive for EV71; identification was confirmed by rt RT-PCR amplification and sequencing of VP1 regions; 23 isolates (10.8%) were recovered from severe cases and 84 isolates (39.4%) from mild cases.EV71 phylogenetic analysisIn order to analyze molecular epidemiological characteristics of the EV71 isolates in this study, 107 EV71 isolates were selected from this outbreak, and VP1 sequences were compared to those from 10 EV71 isolates circulating in China and 19 additional EV71 strains (A, B1-B5, and C1 -C5) isolated from children living in other countries (Figure 2 ).", [["samples", "ANATOMY", 26, 33], ["EV71", "DISEASE", 86, 90], ["samples", "CANCER", 26, 33], ["EV71", "ORGANISM", 86, 90], ["VP1", "ORGANISM", 166, 169], ["EV71", "ORGANISM", 367, 371], ["EV71", "ORGANISM", 400, 404], ["VP1", "ORGANISM", 452, 455], ["EV71", "ORGANISM", 497, 501], ["EV71", "ORGANISM", 550, 554], ["B1-B5", "CELL", 567, 572], ["C1 -C5", "CELL", 578, 584], ["children", "ORGANISM", 600, 608], ["VP1 regions", "DNA", 166, 177], ["VP1 sequences", "DNA", 452, 465], ["children", "SPECIES", 600, 608], ["EV71", "SPECIES", 86, 90], ["EV71", "SPECIES", 367, 371], ["EV71", "SPECIES", 400, 404], ["EV71", "SPECIES", 497, 501], ["EV71", "SPECIES", 550, 554], ["samples", "TEST", 26, 33], ["individual cases", "TEST", 43, 59], ["culture", "TEST", 65, 72], ["EV71", "PROBLEM", 86, 90], ["rt RT-PCR amplification", "TEST", 124, 147], ["sequencing of VP1 regions", "TEST", 152, 177], ["isolates", "TEST", 182, 190], ["severe cases", "PROBLEM", 219, 231], ["isolates", "TEST", 239, 247], ["mild cases", "PROBLEM", 261, 271], ["EV71 phylogenetic analysis", "TEST", 272, 298], ["this study", "TEST", 384, 394], ["EV71 isolates", "TEST", 400, 413], ["this outbreak", "TEST", 433, 446], ["VP1 sequences", "TEST", 452, 465], ["EV71 isolates", "TEST", 497, 510], ["EV71 strains", "TEST", 550, 562], ["A", "TEST", 564, 565], ["B1-B5, and C1 -C5)", "TREATMENT", 567, 585], ["severe", "OBSERVATION_MODIFIER", 219, 225], ["mild", "OBSERVATION_MODIFIER", 261, 265], ["C1", "ANATOMY", 578, 580], ["C5", "ANATOMY_MODIFIER", 582, 584]]], ["Sequence alignments showed the 107 Linyi EV71 VP1 sequences shared 96.2-100% nucleotide identity.", [["nucleotide", "CHEMICAL", 77, 87], ["nucleotide", "CHEMICAL", 77, 87], ["107 Linyi EV71 VP1 sequences", "DNA", 31, 59], ["Sequence alignments", "TEST", 0, 19], ["Linyi EV71 VP1 sequences", "TEST", 35, 59]]], ["Sequences of the VP1 region of the Linyi EV71 isolates were closely related to the predominant EV71 isolates from China, and all isolates belonged to subgenotype C4.", [["VP1", "GENE_OR_GENE_PRODUCT", 17, 20], ["Linyi EV71", "ORGANISM", 35, 45], ["EV71", "ORGANISM", 95, 99], ["VP1 region", "DNA", 17, 27], ["subgenotype C4", "PROTEIN", 150, 164], ["Linyi EV71", "SPECIES", 35, 45], ["the Linyi EV71 isolates", "TEST", 31, 54], ["VP1", "ANATOMY", 17, 20], ["region", "ANATOMY_MODIFIER", 21, 27], ["subgenotype C4", "OBSERVATION", 150, 164]]], ["Subgenotype C4 can be divided into two groups (C4a and C4b) [19] .", [["Subgenotype C4", "GENE_OR_GENE_PRODUCT", 0, 14], ["Subgenotype C4", "PROTEIN", 0, 14], ["Subgenotype C4", "PROBLEM", 0, 14]]], ["According to the phylogenetic analysis (Figures 2 and 3) , all of the Linyi EV71 isolates belong to C4a; isolates were further divided into three lineages (lineage I, II, and III) with mean intralineage p-distances of 0.007, 0.017 and 0.016, respectively.", [["Linyi EV71", "ORGANISM", 70, 80], ["C4a", "GENE_OR_GENE_PRODUCT", 100, 103], ["C4a", "DNA", 100, 103], ["the phylogenetic analysis", "TEST", 13, 38], ["Figures", "TEST", 40, 47], ["the Linyi EV71 isolates", "TEST", 66, 89], ["isolates", "TEST", 105, 113], ["mean intralineage p-distances", "TEST", 185, 214]]], ["The majority of the outbreak isolates (97/107) belonged to lineage I which contained all of the isolates from the severe cases; these isolates were mainly found in three districts or counties of Linyi City, Shandong Province (Lanshan District, Fei County and Hedong District).", [["the severe cases", "PROBLEM", 110, 126], ["these isolates", "TEST", 128, 142], ["majority", "OBSERVATION_MODIFIER", 4, 12], ["severe", "OBSERVATION_MODIFIER", 114, 120]]], ["Lineage II and lineage III had three and seven outbreak isolates, respectively.", [["Lineage II", "CELL", 0, 10], ["lineage III", "CELL", 15, 26], ["lineage", "OBSERVATION_MODIFIER", 15, 22], ["III", "OBSERVATION_MODIFIER", 23, 26], ["seven", "OBSERVATION_MODIFIER", 41, 46], ["outbreak", "OBSERVATION_MODIFIER", 47, 55], ["isolates", "OBSERVATION_MODIFIER", 56, 64]]], ["VP1 nucleic acid dissimilarity among the three subgroups ranged from 2.2%-3.3%; these results suggest that the outbreak likely consisted of three main transmission chains, with lineage I being the predominant contributor.Amino acid sequence analysisComparison of the translated VP1 amino acid sequences (297 aa) of the EV71 isolates used in this study indicated that the isolates were 98.6% identical to one another; variable amino acid residues were at positions 31, 43, 98, 145, 282, 262 and 293.", [["nucleic acid", "CHEMICAL", 4, 16], ["Amino acid", "CHEMICAL", 221, 231], ["amino acid", "CHEMICAL", 282, 292], ["amino acid", "CHEMICAL", 426, 436], ["Amino acid", "CHEMICAL", 221, 231], ["amino acid", "CHEMICAL", 282, 292], ["amino acid", "CHEMICAL", 426, 436], ["Amino acid", "AMINO_ACID", 221, 231], ["amino acid", "AMINO_ACID", 282, 292], ["EV71", "ORGANISM", 319, 323], ["amino acid", "AMINO_ACID", 426, 436], ["VP1 amino acid sequences", "PROTEIN", 278, 302], ["VP1 nucleic acid dissimilarity", "TEST", 0, 30], ["the outbreak", "PROBLEM", 107, 119], ["Amino acid sequence analysisComparison", "TEST", 221, 259], ["the translated VP1 amino acid sequences", "TEST", 263, 302], ["the EV71 isolates", "TEST", 315, 332], ["this study", "TEST", 341, 351], ["the isolates", "TEST", 367, 379], ["variable amino acid residues", "TEST", 417, 445], ["acid dissimilarity", "OBSERVATION", 12, 30], ["three", "OBSERVATION_MODIFIER", 41, 46], ["subgroups", "OBSERVATION_MODIFIER", 47, 56], ["acid residues", "OBSERVATION", 432, 445]]], ["Substitution at amino acid position 145 of VP1 appeared to be significantly different between severe cases and mild cases strains.", [["amino acid", "CHEMICAL", 16, 26], ["amino acid", "CHEMICAL", 16, 26], ["amino acid", "AMINO_ACID", 16, 26], ["position 145", "AMINO_ACID", 27, 39], ["VP1", "GENE_OR_GENE_PRODUCT", 43, 46], ["VP1", "PROTEIN", 43, 46], ["Substitution at amino acid position", "TREATMENT", 0, 35], ["VP1", "PROBLEM", 43, 46], ["severe cases and mild cases strains", "PROBLEM", 94, 129], ["severe", "OBSERVATION_MODIFIER", 94, 100], ["mild", "OBSERVATION_MODIFIER", 111, 115]]], ["Two amino acids, Gly and Gln, were significantly more likely to appear in the VP1 of EV71 recovered from severe cases Figure 2 Dendrogram showing the phylogenetic relationships of 107 EV71 isolates in this outbreak and other genotypes of EV71 isolates from GenBank based on VP1 sequence alignment, which was constructed using Mega software (version 5.2).Amino acid sequence analysis(12/23, 52.2%) than in mild cases (7/84, 8.3%; P < 0.001) (Figure 4 ).DiscussionHFMD epidemics in China mainly occur in the spring and summer [20] [21] [22] , when hot and humid weather is conducive to the propagation and spread of the virus [23] .", [["amino acids", "CHEMICAL", 4, 15], ["Gln", "CHEMICAL", 25, 28], ["EV71", "DISEASE", 85, 89], ["Amino acid", "CHEMICAL", 354, 364], ["amino acids", "CHEMICAL", 4, 15], ["Gly", "CHEMICAL", 17, 20], ["Gln", "CHEMICAL", 25, 28], ["Amino acid", "CHEMICAL", 354, 364], ["amino acids", "AMINO_ACID", 4, 15], ["Gly", "AMINO_ACID", 17, 20], ["Gln", "AMINO_ACID", 25, 28], ["EV71", "ORGANISM", 85, 89], ["EV71", "ORGANISM", 184, 188], ["EV71", "ORGANISM", 238, 242], ["Amino acid", "AMINO_ACID", 354, 364], ["VP1", "PROTEIN", 78, 81], ["EV71", "SPECIES", 238, 242], ["Two amino acids", "TEST", 0, 15], ["Gln", "TEST", 25, 28], ["the VP1 of EV71", "TEST", 74, 89], ["EV71 isolates", "TEST", 184, 197], ["EV71 isolates", "TEST", 238, 251], ["VP1 sequence alignment", "TEST", 274, 296], ["Mega software", "TEST", 326, 339], ["Amino acid sequence analysis", "TEST", 354, 382], ["P", "TEST", 429, 430], ["severe", "OBSERVATION_MODIFIER", 105, 111]]], ["However, the Linyi 2010 HFMD outbreak occurred in December, which is relatively uncommon.", [["HFMD", "DISEASE", 24, 28], ["relatively", "OBSERVATION_MODIFIER", 69, 79], ["uncommon", "OBSERVATION_MODIFIER", 80, 88]]], ["According to meteorological parameters provided by the Meteorological Bureau of Shandong Province, the mean temperature of Linyi City during the winter of 2010 was 0.6\u00b0C higher than that in 2009.", [["higher", "OBSERVATION_MODIFIER", 170, 176]]], ["Flett et al. suggested that atypical seasonality of HFMD outbreaks during winter might be related to unusually mild temperatures [24] .", [["HFMD", "DISEASE", 52, 56], ["HFMD", "PROBLEM", 52, 56], ["unusually mild temperatures", "PROBLEM", 101, 128], ["atypical", "OBSERVATION_MODIFIER", 28, 36]]], ["Research in Hong Kong has also indicated that altered disease etiology of HFMD might be explained by increased winter temperatures [25] .", [["HFMD", "DISEASE", 74, 78], ["altered disease", "PROBLEM", 46, 61], ["HFMD", "PROBLEM", 74, 78], ["increased winter temperatures", "PROBLEM", 101, 130], ["altered", "OBSERVATION_MODIFIER", 46, 53], ["disease", "OBSERVATION", 54, 61]]], ["It is reasonable to speculate that the short-term changes in weather variables may affect the seasonality of HFMD.", [["HFMD", "DISEASE", 109, 113], ["the short-term changes", "PROBLEM", 35, 57], ["HFMD", "PROBLEM", 109, 113]]], ["However, cold weather increases the probability that populations will gather in confined spaces such as houses and indoor play areas; increasing the likelihood of unwanted exposures.", [["cold weather", "PROBLEM", 9, 21]]], ["In addition, more upper respiratory tract infections occur during the winter, resulting in a decrease in immune functions among pediatric patients, which might contribute to increasing incidence of HFMD.", [["upper respiratory tract", "ANATOMY", 18, 41], ["respiratory tract infections", "DISEASE", 24, 52], ["HFMD", "DISEASE", 198, 202], ["upper", "ORGANISM_SUBDIVISION", 18, 23], ["respiratory tract", "ORGANISM_SUBDIVISION", 24, 41], ["patients", "ORGANISM", 138, 146], ["patients", "SPECIES", 138, 146], ["more upper respiratory tract infections", "PROBLEM", 13, 52], ["a decrease in immune functions", "PROBLEM", 91, 121], ["HFMD", "PROBLEM", 198, 202], ["upper", "ANATOMY_MODIFIER", 18, 23], ["respiratory tract", "ANATOMY", 24, 41], ["infections", "OBSERVATION", 42, 52], ["decrease", "OBSERVATION_MODIFIER", 93, 101], ["immune functions", "OBSERVATION", 105, 121]]], ["The epidemiology of EV71 in China since this virus was first detected in 1998 has shown that only subgenotype C4 is in endemic circulation [19] .", [["EV71", "DISEASE", 20, 24], ["EV71", "ORGANISM", 20, 24], ["subgenotype C4", "PROTEIN", 98, 112], ["EV71", "SPECIES", 20, 24], ["EV71", "PROBLEM", 20, 24], ["this virus", "PROBLEM", 40, 50], ["subgenotype C4", "PROBLEM", 98, 112], ["subgenotype C4", "OBSERVATION", 98, 112]]], ["Phylogenetic analysis suggests that three EV71 variants contributed to the 2010 Linyi outbreak and share strong similarities to some EV71 viruses circulating previously in Shandong Province.", [["EV71 viruses", "DISEASE", 133, 145], ["EV71", "ORGANISM", 42, 46], ["EV71 viruses", "ORGANISM", 133, 145], ["EV71 viruses", "SPECIES", 133, 145], ["Phylogenetic analysis", "TEST", 0, 21], ["three EV71 variants", "PROBLEM", 36, 55], ["some EV71 viruses", "PROBLEM", 128, 145]]], ["However, no obvious evidence revealed the transmission relationship between strains from this outbreak and other provinces in China.", [["strains", "PROBLEM", 76, 83], ["this outbreak", "PROBLEM", 89, 102], ["no obvious", "UNCERTAINTY", 9, 19]]], ["Therefore, we speculate that this uncommon winter outbreak did not occur in isolation, but was related with local epidemic occurring in the region during the spring and summer of 2010.", [["local", "OBSERVATION_MODIFIER", 108, 113], ["epidemic", "OBSERVATION", 114, 122]]], ["It is probable that the change of climatic parameters contributed to the occurrence of this atypical seasonal outbreak but the extent of this contribution needs to be further examined.DiscussionSubgenotype C4a is geographically broadly distributed and genetically variable; it is estimated to undergo 4.97 \u00d7 10 \u22123 substitutions per nucleotide per year, a rapid rate of change [26] .", [["nucleotide", "CHEMICAL", 332, 342], ["nucleotide", "CHEMICAL", 332, 342], ["this atypical seasonal outbreak", "PROBLEM", 87, 118], ["DiscussionSubgenotype C4a", "PROBLEM", 184, 209], ["probable", "UNCERTAINTY", 6, 14], ["atypical", "OBSERVATION_MODIFIER", 92, 100], ["seasonal", "OBSERVATION_MODIFIER", 101, 109], ["outbreak", "OBSERVATION", 110, 118]]], ["Phylogenetic analysis shows that subgenotype C4 should be re-designated as a novel Figure 3 Phylogenetic tree of 107 EV71 isolates in this outbreak and related C4a subgenotype strains.", [["EV71", "ORGANISM", 117, 121], ["C4a", "GENE_OR_GENE_PRODUCT", 160, 163], ["Phylogenetic analysis", "TEST", 0, 21], ["subgenotype C4", "PROBLEM", 33, 47], ["EV71 isolates", "TEST", 117, 130], ["this outbreak", "PROBLEM", 134, 147], ["C4a subgenotype strains", "PROBLEM", 160, 183]]], ["Accession numbers are given in parentheses. \u25b2, isolates from severe cases.", [["severe cases", "PROBLEM", 61, 73], ["severe", "OBSERVATION_MODIFIER", 61, 67], ["cases", "OBSERVATION", 68, 73]]], ["LY, isolates from this study; SD, Shandong Province; ZJ, Zhejiang Province; BJ, Beijing City; JS, Jiangsu Province; CQ, Chongqing City. genotype, D [27, 28] .", [["LY", "CHEMICAL", 0, 2], ["SD", "DISEASE", 30, 32], ["LY", "SIMPLE_CHEMICAL", 0, 2], ["this study", "TEST", 18, 28], ["JS", "ANATOMY", 94, 96]]], ["Thus, the three lineages may represent different EV71 transmission modes in this region; this hypothesis should be clarified by further molecular epidemiological studies.DiscussionAmino sequence analysis showed one primary variation between viruses isolated from severe and mild cases of HFMD, substitution of the amino acid residue at position 145.", [["HFMD", "DISEASE", 288, 292], ["amino acid", "CHEMICAL", 314, 324], ["amino acid", "CHEMICAL", 314, 324], ["amino acid", "AMINO_ACID", 314, 324], ["different EV71 transmission modes", "PROBLEM", 39, 72], ["further molecular epidemiological studies", "TEST", 128, 169], ["Amino sequence analysis", "TEST", 180, 203], ["one primary variation between viruses", "PROBLEM", 211, 248], ["severe and mild cases of HFMD", "PROBLEM", 263, 292], ["the amino acid residue", "TREATMENT", 310, 332], ["may represent", "UNCERTAINTY", 25, 38], ["different", "OBSERVATION_MODIFIER", 39, 48], ["EV71", "OBSERVATION", 49, 53], ["viruses", "OBSERVATION", 241, 248], ["severe", "OBSERVATION_MODIFIER", 263, 269], ["mild", "OBSERVATION_MODIFIER", 274, 278], ["HFMD", "OBSERVATION", 288, 292], ["amino acid", "OBSERVATION", 314, 324]]], ["Several studies have revealed that this change in the VP1 region of EV71 may play an important role in virulence.", [["EV71", "DISEASE", 68, 72], ["VP1", "GENE_OR_GENE_PRODUCT", 54, 57], ["EV71", "ORGANISM", 68, 72], ["VP1 region", "DNA", 54, 64], ["Several studies", "TEST", 0, 15], ["this change in the VP1 region of EV71", "PROBLEM", 35, 72]]], ["Residue 145 is reported to be located in the DE loop which contains neutralizing antigenic sites; this loop is located in the canyon rim, a region involved in the receptor binding for enterovirus and rhinovirus [29] [30] [31] [32] .", [["enterovirus", "ORGANISM", 184, 195], ["rhinovirus", "ORGANISM", 200, 210], ["neutralizing antigenic sites", "PROBLEM", 68, 96], ["this loop", "TREATMENT", 98, 107], ["enterovirus", "PROBLEM", 184, 195], ["rhinovirus", "PROBLEM", 200, 210], ["neutralizing", "OBSERVATION_MODIFIER", 68, 80], ["antigenic sites", "OBSERVATION", 81, 96], ["canyon rim", "ANATOMY", 126, 136]]], ["Selection pressure analysis of many VP1 sequences of EV71 showed that amino acid 145 was a positive selection site [33, 34] .", [["EV71", "DISEASE", 53, 57], ["amino acid", "CHEMICAL", 70, 80], ["amino acid", "CHEMICAL", 70, 80], ["EV71", "ORGANISM", 53, 57], ["amino acid 145", "AMINO_ACID", 70, 84], ["VP1 sequences", "DNA", 36, 49], ["positive selection site", "DNA", 91, 114], ["Selection pressure analysis", "TEST", 0, 27], ["many VP1 sequences of EV71", "TEST", 31, 57], ["amino acid", "TEST", 70, 80], ["a positive selection site", "PROBLEM", 89, 114]]], ["Mutation of glutamine to glutamic acid on VP1 145 region cooperatively promote viral binding and RNA accumulation of EV71, contributing to viral infectivity in vitro and mouse lethality in vivo [35] .", [["glutamine", "CHEMICAL", 12, 21], ["glutamic acid", "CHEMICAL", 25, 38], ["EV71", "DISEASE", 117, 121], ["glutamine", "CHEMICAL", 12, 21], ["glutamic acid", "CHEMICAL", 25, 38], ["glutamine", "AMINO_ACID", 12, 21], ["glutamic acid", "AMINO_ACID", 25, 38], ["VP1", "AMINO_ACID", 42, 45], ["145", "AMINO_ACID", 46, 49], ["EV71", "ORGANISM", 117, 121], ["mouse", "ORGANISM", 170, 175], ["VP1 145 region", "PROTEIN", 42, 56], ["mouse", "SPECIES", 170, 175], ["mouse", "SPECIES", 170, 175], ["Mutation of glutamine", "TREATMENT", 0, 21], ["glutamic acid", "TEST", 25, 38], ["viral binding", "PROBLEM", 79, 92], ["RNA accumulation of EV71", "PROBLEM", 97, 121], ["viral infectivity", "PROBLEM", 139, 156], ["vitro and mouse lethality", "TREATMENT", 160, 185], ["viral binding", "OBSERVATION", 79, 92], ["viral infectivity", "OBSERVATION", 139, 156]]], ["Substitution of glycine to glutamic acid at the same position might increase the efficiency of uncoating upon specific binding of the virion to the receptor molecule on the target cells in NOD/SCID mice and subsequently facilitate the infection of a mouse adapted EV71 strain [36] .", [["cells", "ANATOMY", 180, 185], ["glycine", "CHEMICAL", 16, 23], ["glutamic acid", "CHEMICAL", 27, 40], ["infection", "DISEASE", 235, 244], ["glycine", "CHEMICAL", 16, 23], ["glutamic acid", "CHEMICAL", 27, 40], ["glycine", "AMINO_ACID", 16, 23], ["glutamic acid", "AMINO_ACID", 27, 40], ["virion", "CELLULAR_COMPONENT", 134, 140], ["cells", "CELL", 180, 185], ["NOD/SCID mice", "ORGANISM", 189, 202], ["mouse", "ORGANISM", 250, 255], ["EV71", "ORGANISM", 264, 268], ["receptor molecule", "PROTEIN", 148, 165], ["target cells", "CELL_TYPE", 173, 185], ["mice", "SPECIES", 198, 202], ["mouse", "SPECIES", 250, 255], ["mice", "SPECIES", 198, 202], ["mouse", "SPECIES", 250, 255], ["Substitution of glycine to glutamic acid", "TREATMENT", 0, 40], ["NOD/SCID mice", "TREATMENT", 189, 202], ["the infection", "PROBLEM", 231, 244], ["EV71 strain", "PROBLEM", 264, 275], ["efficiency", "OBSERVATION_MODIFIER", 81, 91], ["infection", "OBSERVATION", 235, 244]]], ["Although it has been demonstrated that the amino acid substitution of Gly to Glu at position 145 of VP1 could increase EV71 virulence in mice, Glu to Gly/Gln/Arg substitutions may enhance virulence in humans [37] .", [["amino acid", "CHEMICAL", 43, 53], ["Gly", "CHEMICAL", 70, 73], ["Glu", "CHEMICAL", 77, 80], ["EV71", "DISEASE", 119, 123], ["Glu", "CHEMICAL", 143, 146], ["Gly", "CHEMICAL", 150, 153], ["Gln", "CHEMICAL", 154, 157], ["amino acid", "CHEMICAL", 43, 53], ["Gly", "CHEMICAL", 70, 73], ["Glu", "CHEMICAL", 77, 80], ["Glu", "CHEMICAL", 143, 146], ["Gly", "CHEMICAL", 150, 153], ["Gln", "CHEMICAL", 154, 157], ["Arg", "CHEMICAL", 158, 161], ["amino acid", "AMINO_ACID", 43, 53], ["Gly", "AMINO_ACID", 70, 73], ["Glu", "AMINO_ACID", 77, 80], ["VP1", "AMINO_ACID", 100, 103], ["mice", "ORGANISM", 137, 141], ["Glu", "AMINO_ACID", 143, 146], ["Gly", "AMINO_ACID", 150, 153], ["Gln", "AMINO_ACID", 154, 157], ["Arg", "AMINO_ACID", 158, 161], ["humans", "ORGANISM", 201, 207], ["VP1", "PROTEIN", 100, 103], ["mice", "SPECIES", 137, 141], ["humans", "SPECIES", 201, 207], ["mice", "SPECIES", 137, 141], ["humans", "SPECIES", 201, 207], ["the amino acid substitution of Gly", "TREATMENT", 39, 73], ["Glu", "TEST", 77, 80], ["VP1", "TEST", 100, 103], ["EV71 virulence", "TEST", 119, 133], ["Glu to Gly", "TEST", 143, 153], ["Gln/Arg substitutions", "TREATMENT", 154, 175]]], ["Consistent with this result, isolates from severe cases in our investigation were significantly more likely to carry the Gly/Gln at amino acid 145 than those from mild cases.", [["Gln", "CHEMICAL", 125, 128], ["amino acid", "CHEMICAL", 132, 142], ["Gly", "CHEMICAL", 121, 124], ["Gln", "CHEMICAL", 125, 128], ["amino acid", "CHEMICAL", 132, 142], ["Gln", "AMINO_ACID", 125, 128], ["amino acid 145", "AMINO_ACID", 132, 146], ["severe cases", "PROBLEM", 43, 55], ["our investigation", "TEST", 59, 76], ["amino acid", "TEST", 132, 142], ["severe", "OBSERVATION_MODIFIER", 43, 49], ["mild", "OBSERVATION_MODIFIER", 163, 167]]], ["This substitution may influence the virus binding to antibody or receptor, thereby affecting the virulence of the virus [37] .ConclusionsIn conclusion, HFMD caused by EV71 has become a global concern in recent years.", [["HFMD", "DISEASE", 152, 156], ["EV71", "DISEASE", 167, 171], ["EV71", "ORGANISM", 167, 171], ["antibody or receptor", "PROTEIN", 53, 73], ["EV71", "SPECIES", 167, 171], ["This substitution", "TREATMENT", 0, 17], ["the virus binding", "PROBLEM", 32, 49], ["receptor", "TREATMENT", 65, 73], ["the virus", "PROBLEM", 110, 119], ["HFMD", "PROBLEM", 152, 156], ["EV71", "PROBLEM", 167, 171]]], ["In February 2008, HFMD Figure 4 Amino acid sequence alignment of the full length VP1 region of the EV71 virus isolates in Linyi City, Shandong Province, 2010.", [["HFMD", "DISEASE", 18, 22], ["Amino acid", "CHEMICAL", 32, 42], ["Amino acid", "CHEMICAL", 32, 42], ["EV71 virus", "ORGANISM", 99, 109], ["full length VP1 region", "DNA", 69, 91], ["EV71 virus", "SPECIES", 99, 109], ["Amino acid sequence alignment", "TEST", 32, 61], ["EV71 virus", "OBSERVATION", 99, 109]]], ["Amino acid sequences were numbered according to the sequence of EV71_BrCr (Genbank accession number: ETU22521).", [["Amino acid", "CHEMICAL", 0, 10], ["Amino acid", "CHEMICAL", 0, 10], ["Amino acid", "AMINO_ACID", 0, 10], ["EV71_BrCr", "DNA", 64, 73], ["Amino acid sequences", "TEST", 0, 20]]], ["Identical residues are indicated as dots.", [["Identical residues", "PROBLEM", 0, 18], ["residues", "OBSERVATION", 10, 18]]], ["Amino acids that differ from the consensus sequence are shaded. \u25b2, isolates of severe cases.Conclusionswas officially categorized as a Class C infectious disease in China.", [["Amino acids", "CHEMICAL", 0, 11], ["Class C infectious disease", "DISEASE", 135, 161], ["Amino acids", "CHEMICAL", 0, 11], ["Amino acids", "AMINO_ACID", 0, 11], ["consensus sequence", "DNA", 33, 51], ["Amino acids", "TEST", 0, 11], ["the consensus sequence", "TEST", 29, 51], ["severe cases", "PROBLEM", 79, 91], ["a Class C infectious disease in China", "PROBLEM", 133, 170], ["severe", "OBSERVATION_MODIFIER", 79, 85], ["cases", "OBSERVATION", 86, 91], ["infectious", "OBSERVATION", 143, 153]]], ["Further studies on the transmission patterns of EV71 using approaches in molecular biology are therefore warranted, and recognizing EV71 isolates with increased virulence should be a priority for HFMD prevention and control efforts.", [["EV71", "DISEASE", 48, 52], ["HFMD", "DISEASE", 196, 200], ["EV71", "ORGANISM", 48, 52], ["EV71", "ORGANISM", 132, 136], ["EV71", "SPECIES", 48, 52], ["EV71", "SPECIES", 132, 136], ["Further studies", "TEST", 0, 15], ["EV71", "PROBLEM", 48, 52], ["increased virulence", "PROBLEM", 151, 170], ["HFMD prevention", "TREATMENT", 196, 211]]], ["Moreover, monitoring the genetic variation of EV71 may be useful in facilitating the development of effective EV71 vaccine candidates on Chinese market and evaluating their effects of prevention and control of the EV71 infections.", [["EV71", "DISEASE", 46, 50], ["EV71 infections", "DISEASE", 214, 229], ["EV71", "ORGANISM", 46, 50], ["EV71", "ORGANISM", 110, 114], ["EV71", "ORGANISM", 214, 218], ["EV71", "SPECIES", 46, 50], ["EV71", "SPECIES", 110, 114], ["EV71", "SPECIES", 214, 218], ["EV71", "PROBLEM", 46, 50], ["effective EV71 vaccine", "TREATMENT", 100, 122], ["Chinese market", "TREATMENT", 137, 151], ["prevention", "TREATMENT", 184, 194], ["the EV71 infections", "PROBLEM", 210, 229], ["infections", "OBSERVATION", 219, 229]]]], "f6973b3421917acac9b01faa3401043a522f5c6c": [["Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below: N/A All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.", [["body", "ANATOMY", 193, 197], ["body", "ORGANISM_SUBDIVISION", 193, 197], ["patient", "ORGANISM", 296, 303], ["patient", "SPECIES", 296, 303]]], ["I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).", [["any such study", "TEST", 15, 29], ["a prospective study", "TEST", 137, 156], ["the study", "TEST", 249, 258]]], ["We will stay away from predicting the future, but instead, try to understand the immediate past by using some biology, stats, and analysis, to develop a transparent formula to estimate the proportion P (t) of the US population that have ever been infected by the Coronavirus 19 at time t (months, where zero is March 20).", [["a transparent formula", "TREATMENT", 151, 172], ["the US population", "TEST", 209, 226]]], ["This uses the number y(s) of those tested/million, and cases x(s)/million testing positive, over the time interval 0 \u2264 s \u2264 t.", [["million testing", "TEST", 66, 81]]], ["The aim is to overcome the problem that testing misses those past the 1 \u2212 3(?) week period of infection.", [["infection", "DISEASE", 94, 103], ["infection", "PROBLEM", 94, 103], ["infection", "OBSERVATION", 94, 103]]], ["The other problem is that asymptomatics are often not being tested, [14] , [17] , [18], [13] .", [["[17] , [18]", "SIMPLE_CHEMICAL", 75, 86], ["[13]", "SIMPLE_CHEMICAL", 88, 92]]], ["Asymptomatics represent proportion r = \u03c1/(1 + \u03c1) of all infected, with the wide estimate 0.5 < r < 0.95.", [["all infected", "PROBLEM", 52, 64], ["the wide estimate", "TEST", 71, 88], ["infected", "OBSERVATION", 56, 64], ["wide", "OBSERVATION_MODIFIER", 75, 79]]], ["Ideally, one might try large scale testing for anti-bodies.", [["large scale testing", "TEST", 23, 42], ["anti-bodies", "PROBLEM", 47, 58]]], ["However, many anti-bodies tests are unreliable, some infected do not develop antibodies.", [["antibodies", "PROTEIN", 77, 87], ["many anti-bodies tests", "TEST", 9, 31]]], ["A recent study by King's College [5] showed that a majority of post infection patients loose most of their anti-bodies within a month.", [["infection", "DISEASE", 68, 77], ["patients", "ORGANISM", 78, 86], ["patients", "SPECIES", 78, 86], ["A recent study", "TEST", 0, 14], ["post infection patients loose", "PROBLEM", 63, 92], ["infection", "OBSERVATION", 68, 77]]], ["In any case, there has been no widespread testing for anti-bodies.", [["widespread testing", "TEST", 31, 49], ["anti-bodies", "PROBLEM", 54, 65], ["no", "UNCERTAINTY", 28, 30], ["widespread", "OBSERVATION_MODIFIER", 31, 41]]], ["On June 24, the CDC [9] announced new estimates using sampling from regional US blood labs, where on average, 8% had anti-bodies.", [["blood", "ANATOMY", 80, 85], ["blood", "ORGANISM_SUBSTANCE", 80, 85], ["regional US blood labs", "TEST", 68, 90], ["anti-bodies", "PROBLEM", 117, 128]]], ["Considering the numbers testing positive in those regions, this implied \u03c1 \u223c 11.", [["the numbers testing", "TEST", 12, 31]]], ["So, it is important to have a good estimate of P .IntroductionTo reiterate, we introduce a new method to estimate P (t), the proportion of the population who would test positive for the virus at any time before time t, i.e. all those who have ever been infected.", [["P", "DNA", 47, 48], ["the virus", "PROBLEM", 182, 191], ["infected", "OBSERVATION", 253, 261]]], ["This is a more robust measure as the pcr test, etc., for the virus is fairly reliable.", [["the pcr test", "TEST", 33, 45], ["the virus", "PROBLEM", 57, 66]]], ["Our method also requires parameter \u03c4 , the time period during which individuals test positive.", [["individuals test", "TEST", 68, 84]]], ["We show \u03c4 is quite significant, indeed, we show how it affects the CDC estimate of \u03c1.IntroductionAs \" for every infection only \u03c1/(1 + \u03c1) is symptomatic\", a simple estimate isIntroductionwith PRE standing for \"pandemic rate equation\".", [["infection", "DISEASE", 112, 121], ["every infection", "PROBLEM", 106, 121], ["symptomatic", "PROBLEM", 140, 151]]], ["However, this assumes only symptomatic cases are counted, and ignores large scale testing which uncovers and counts asymptomatic cases.IntroductionAll rights reserved.", [["symptomatic cases", "PROBLEM", 27, 44], ["large scale testing", "TEST", 70, 89], ["symptomatic", "OBSERVATION_MODIFIER", 27, 38], ["cases", "OBSERVATION", 39, 44]]], ["No reuse allowed without permission.Introduction(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.IntroductionThe copyright holder for this preprint this version posted August 21, 2020. . https://doi.org/10.1101/2020.08.", [["med", "ANATOMY", 127, 130]]], ["17.20176602 doi: medRxiv preprint Trying to count the asymptomatic cases, leads to the quadraticIntroductionThis second estimate assumes all testing done once at time t, whereas testing is spread over time.", [["medRxiv", "TREATMENT", 17, 24], ["all testing", "TEST", 137, 148], ["testing", "TEST", 178, 185]]], ["Furthermore, those who have been infected test positive only for a relatively short time, and testing past this period will not count them.", [["infected test", "TEST", 33, 46], ["infected", "OBSERVATION", 33, 41]]], ["Nevertheless, at the beginning of the pandemic, the bounds P 1 and P 2 were close.", [["P 1", "DNA", 59, 62], ["P 2", "DNA", 67, 70], ["the bounds P", "TEST", 48, 60]]], ["Now (at t = 4.6), we find for the US, assuming r \u223c .93 with x(4.6) = 1.5% and y(4.6) = 19.5%, that P 1 \u223c 21.4% while P 2 \u223c 6%.IntroductionOur main result models P as the solution of the \"pandemic rate equation\":Introductionwith initial conditions x(t) = y(t) = P (t) = 0, t \u2264 0.", [["the US", "TEST", 30, 36], ["y", "TEST", 78, 79], ["P", "TEST", 99, 100], ["P", "TEST", 117, 118]]], ["Our assumption is that symptomatic cases are immediately treated, and thus tested (and counted).", [["symptomatic cases", "PROBLEM", 23, 40], ["symptomatic", "OBSERVATION_MODIFIER", 23, 34]]], ["In actual fact, symptomatic cases take about a week before going for treatment/testing 2 .", [["treatment/testing", "TEST", 69, 86]]], ["Also, we assume that asymptomatic cases are discovered by essentially random testing from the entire population.IntroductionOn June 24, the CDC[10] estimated r = .9125, i.e. the ratio of asymptomatic cases to symptomatic is about \u03c1 = 11.", [["asymptomatic cases", "PROBLEM", 21, 39], ["random testing", "TEST", 70, 84], ["asymptomatic cases", "PROBLEM", 187, 205]]], ["Simulations with lognormal distributed \u03c4 = 0.5 \u00b1 0.25, r = 0.93 \u00b1 0.03 (68% CI), our best estimate isIntroductionwith the main error coming from uncertainty in \u03c1.Introduction2 Our first version [1] used another model, where symptomatic cases are not immediately tested.", [["Simulations", "TEST", 0, 11], ["r", "TEST", 55, 56], ["CI", "TEST", 76, 78], ["symptomatic cases", "PROBLEM", 224, 241], ["main error", "OBSERVATION", 122, 132]]], ["We found that even with a delay of two weeks, there was no significant difference from the present immediate response model-whose mathematics is much easier to handle.", [["significant difference", "PROBLEM", 59, 81], ["no", "UNCERTAINTY", 56, 58], ["significant", "OBSERVATION_MODIFIER", 59, 70], ["difference", "OBSERVATION", 71, 81]]], ["No reuse allowed without permission.Introduction(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.IntroductionThe copyright holder for this preprint this version posted August 21, 2020. . https://doi.org/10.1101/2020.08.17.20176602 doi: medRxiv preprintThe TheoryNow for the mathematics, first the complete statements, then the proof.The FormulaeAs before, P = P (t) is the proportion of those in the population who would ever test positive for the virus in time interval [0, t] months, with initial time t = 0, March 20.", [["medRxiv", "TREATMENT", 322, 329], ["med", "ANATOMY", 127, 130]]], ["As before, the parameters r and \u03c4 denote the proportion of the infected who are asymptomatic, and the length of infection, respectively.", [["infection", "DISEASE", 112, 121], ["the parameters r", "TEST", 11, 27], ["asymptomatic", "PROBLEM", 80, 92], ["infection", "PROBLEM", 112, 121], ["infected", "OBSERVATION", 63, 71], ["asymptomatic", "OBSERVATION_MODIFIER", 80, 92], ["length", "OBSERVATION_MODIFIER", 102, 108], ["infection", "OBSERVATION", 112, 121]]], ["The functions x, y, are smoothed with derivatives x , y .The FormulaeWe prove that P satisfies a nonlinear difference-differential equation:The FormulaeThe two simple minded estimates are essential bounds for the general case.The FormulaeTHEOREM Suppose that x, y, P , are increasing functions.", [["P", "DNA", 83, 84], ["Formulae", "CELL_LINE", 144, 152], ["The Formulae", "TREATMENT", 140, 152], ["two", "OBSERVATION_MODIFIER", 156, 159], ["simple", "OBSERVATION_MODIFIER", 160, 166], ["minded", "OBSERVATION_MODIFIER", 167, 173]]], ["Then, for fixed \u03c1, independently of \u03c4 the solution of (3) satisfies the boundsThe Formulaeand, furthermore, these bounds are best possible.The FormulaeUpper & L ower bounds for P(t) t month.The Formulaepop.pro.The FormulaeUSA data: r = 0.93, \u03c4 = 0.5 All rights reserved.", [["The FormulaeUpper & L ower bounds", "TREATMENT", 139, 172], ["The FormulaeUSA data", "TEST", 210, 230], ["\u03c4", "TEST", 242, 243]]], ["No reuse allowed without permission.The Formulae(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The FormulaeThe copyright holder for this preprint this version posted August 21, 2020. . https://doi.org/10.1101/2020.08.17.20176602 doi: medRxiv preprintDerivation of Pandemic Rate EquationWe prove PRE.", [["Formulae", "CELL_LINE", 187, 195], ["The Formulae", "TREATMENT", 183, 195], ["med", "ANATOMY", 127, 130]]], ["There is a large population of total size n million.", [["total size n million", "TREATMENT", 31, 51], ["large", "OBSERVATION_MODIFIER", 11, 16], ["population", "OBSERVATION_MODIFIER", 17, 27], ["total", "OBSERVATION_MODIFIER", 31, 36], ["size", "OBSERVATION_MODIFIER", 37, 41], ["million", "OBSERVATION", 44, 51]]], ["As before, the parameters r, \u03c4 , denote the proportion of the infected who are asymptomatic, and the length of infection, respectively.", [["infection", "DISEASE", 111, 120], ["asymptomatic", "PROBLEM", 79, 91], ["infection", "PROBLEM", 111, 120], ["infected", "OBSERVATION", 62, 70], ["asymptomatic", "OBSERVATION_MODIFIER", 79, 91], ["length", "OBSERVATION_MODIFIER", 101, 107], ["infection", "OBSERVATION", 111, 120]]], ["We now assume the parameters r, \u03c4 , are fixed for the population of size n.", [["size", "OBSERVATION_MODIFIER", 68, 72]]], ["People are sick for a time interval [t \u2212 \u03c4, t] when they test positive.", [["People", "ORGANISM", 0, 6], ["People", "SPECIES", 0, 6]]], ["So, it is only during this time interval that the virus can be detected.", [["the virus", "PROBLEM", 46, 55], ["virus", "OBSERVATION", 50, 55]]], ["Consider a very short time interval [t \u2212 \u2206t, t], during which the quantities x, y change by \u2206x =Derivation of Pandemic Rate Equation.", [["Pandemic Rate Equation", "TEST", 110, 132]]], ["The data for testing y and cases x is discrete and discontinuous, but we assume to be differentiable.", [["The data", "TEST", 0, 8], ["testing y", "TEST", 13, 22]]], ["Thus \u2206x \u223c x (t)\u2206t , \u2206y \u223c y (t)\u2206t.Derivation of Pandemic Rate EquationThe total number of cases comes from those who are symptomatic, take themselves for treatment and hence are tested; and those, who we assume are randomly tested, and a certain proportion turn out to be infected (but asymptomatic).", [["Pandemic Rate Equation", "TEST", 47, 69], ["symptomatic", "PROBLEM", 120, 131], ["treatment", "TREATMENT", 153, 162], ["infected", "PROBLEM", 271, 279], ["total", "OBSERVATION_MODIFIER", 73, 78], ["infected", "OBSERVATION", 271, 279]]], ["We assume symptomatic and asymptomatic are only infected for a time period of length \u03c4 during which they test positive.", [["symptomatic and asymptomatic", "PROBLEM", 10, 38], ["symptomatic", "OBSERVATION_MODIFIER", 10, 21], ["asymptomatic", "OBSERVATION_MODIFIER", 26, 38], ["infected", "OBSERVATION", 48, 56]]], ["There is the question of how quickly symptomatic cases go for treatment.", [["treatment", "TREATMENT", 62, 71]]], ["We assume they immediately go for testing.", [["testing", "TEST", 34, 41]]], ["3 We also use Z(t) the total number of symptomatic cases, and W (t) the number of asymptomatic cases.", [["asymptomatic cases", "PROBLEM", 82, 100]]], ["At time t, the number of past infections is nP (t), so in time period [t \u2212 \u2206, t], the number of new symptomatics is (1 \u2212 r)nP (t)\u2206t \u2265 0, assuming P increasing.", [["infections", "DISEASE", 30, 40], ["past infections", "PROBLEM", 25, 40], ["new symptomatics", "TEST", 96, 112], ["P (t)", "TEST", 124, 129], ["\u2206t", "TEST", 129, 131], ["infections", "OBSERVATION", 30, 40]]], ["Thus,Derivation of Pandemic Rate EquationThere is also \u2206Y \u223c Y (t)\u2206t new tests, which counts those who sought help, and those asymptomatic cases caught up in essentially random sampling.", [["Pandemic Rate Equation", "TEST", 19, 41], ["new tests", "TEST", 68, 77]]], ["The proportion of these testing positive isDerivation of Pandemic Rate EquationIn [1] we considered the plausible idea that there was delay \u223c \u03c4 .", [["these testing", "TEST", 18, 31], ["Pandemic Rate EquationIn", "TREATMENT", 57, 81]]], ["No reuse allowed without permission.Derivation of Pandemic Rate Equation(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Derivation of Pandemic Rate EquationThe copyright holder for this preprint this version posted August 21, 2020. . https://doi.org/10.1101/2020.08.17.20176602 doi: medRxiv preprint Thus, the new asymptomatics isDerivation of Pandemic Rate EquationWith \u2206t \u2192 0, and x = X/n, y = Y /n gives the delay-differential equationDerivation of Pandemic Rate EquationThe nonlinear dde cannot be solved explicity in general, but is well suited for numerical solutions such as NDSolve in Mathematica, which has routines for delay-differential equations.", [["Pandemic Rate Equation", "PROBLEM", 50, 72], ["Pandemic Rate Equation", "TEST", 221, 243], ["medRxiv", "TREATMENT", 370, 377], ["Pandemic Rate", "TEST", 431, 444], ["the delay", "PROBLEM", 494, 503], ["Pandemic Rate Equation", "TREATMENT", 539, 561], ["numerical solutions", "TREATMENT", 641, 660], ["med", "ANATOMY", 151, 154]]], ["First case: \u03c4 = 0 \u21d2 P (t) \u2212 P (t \u2212 \u03c4 ) = 0, and the dde becomesProof of THEOREMSecondly: once infected always infected, i.e. \u03c4 = \u221e \u21d2 P (t \u2212 \u03c4 ) = 0 , dde isProof of THEOREMWe are assuming x, y, are both are increasing with x \u2264 y .", [["P", "TEST", 28, 29], ["the dde", "TEST", 48, 55], ["THEOREMSecondly", "TEST", 72, 87], ["both", "ANATOMY_MODIFIER", 198, 202], ["increasing", "OBSERVATION_MODIFIER", 207, 217]]], ["Writing y = x+u we have u > 0 and t 0 u ds = y(t) \u2212 x(t) viewed as constraints on u.", [["u", "TEST", 24, 25]]], ["Hence,Proof of THEOREMNow 0 < P (s) < 1 is increasing soProof of THEOREMAll rights reserved.", [["increasing soProof of THEOREMAll rights", "TREATMENT", 43, 82]]], ["No reuse allowed without permission.Proof of THEOREM(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Proof of THEOREMThe copyright holder for this preprint this version posted August 21, 2020. . https://doi.org/10.1101/2020.08.17.20176602 doi: medRxiv preprint is maximized at s = t.", [["medRxiv", "TREATMENT", 330, 337], ["med", "ANATOMY", 131, 134]]], ["It follows that P has lower boundProof of THEOREMSolving for P (t) givesProof of THEOREMwhich proves the lower bound.", [["P", "DNA", 16, 17], ["Proof of THEOREMwhich", "TREATMENT", 72, 93]]], ["Observe that for smooth x, y, this lower bound is not achieved, even in the limit as \u03c4 \u2192 \u221e.", [["this lower bound", "PROBLEM", 30, 46]]], ["Indeed, numerical solution of (4) for given x and y provides a somewhat better lower bound than P 2 .Proof of THEOREMFinally, we prove P (t) is sandwiched between P 1 and P 2 by showing the solution is monotone decreasing in \u03c4 .", [["P 2", "PROTEIN", 96, 99], ["P (t)", "DNA", 135, 140], ["P 1 and P 2", "DNA", 163, 174]]], ["ConsiderProof of THEOREMNow, as 0 < r < 1 and x < y we see that H \u2265 0 as 0 < P (t) \u2212 P (t \u2212 \u03c4 ) < 1.Proof of THEOREMAs \u03c4 varies from 0 to \u221e, we observe P (t) \u2212 P (t \u2212 \u03c4 ) increases from 0 to P (t).", [["THEOREMNow", "TEST", 17, 27], ["H", "TEST", 64, 65]]], ["Define functionProof of THEOREMwhich is decreasing asProof of THEOREMThus P = H is monotone decreasing in \u03c4 .", [["P = H", "CHEMICAL", 74, 79], ["decreasing", "OBSERVATION_MODIFIER", 40, 50], ["decreasing", "OBSERVATION_MODIFIER", 92, 102]]], ["Hence, P decreases as \u03c4 increases.Proof of THEOREMAll rights reserved.", [["P", "DNA", 7, 8], ["THEOREMAll rights", "TREATMENT", 43, 60], ["decreases", "OBSERVATION_MODIFIER", 9, 18]]], ["No reuse allowed without permission.Proof of THEOREM(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Estimating \u03c1 and \u03c4The estimate of \u03c1 (or r) is from a variety of sources, collected in [12] .", [["\u03c1", "GENE_OR_GENE_PRODUCT", 221, 222], ["\u03c1", "PROTEIN", 198, 199], ["\u03c1", "PROTEIN", 221, 222], ["Estimating \u03c1", "TEST", 187, 199], ["med", "ANATOMY", 131, 134]]], ["In China, for children r \u223c .95; at a NYC hospital where all pregnant women were tested r \u223c .9; while r \u223c .5 for passengers on cruise ships.", [["children", "ORGANISM", 14, 22], ["women", "ORGANISM", 69, 74], ["children", "SPECIES", 14, 22], ["women", "SPECIES", 69, 74]]], ["WHO currently has r \u223c .8 which is consistent with results from Iceland, where it is estimated r > 0.8 (where many \"symptomatics\" really had the flu which reduced the ratio).Estimating \u03c1 and \u03c4We expect r to be different for different populations, indeed, be age dependent.", [["the flu", "PROBLEM", 140, 147], ["consistent with", "UNCERTAINTY", 34, 49]]], ["Now, on March 29, for NYC, the CDC [9] , [8] used anti-bodies to estimate P \u223c .07, while x \u223c .004, giving r \u223c .943.", [["anti-bodies", "TEST", 50, 61]]], ["Similar results were found in different regions of the US giving the CDC average estimate r = 0.9.", [["the US", "TEST", 51, 57], ["the CDC", "TEST", 65, 72]]], ["[2] estimates at least 25% more infections from their study of T-cell immunity.", [["T-cell", "ANATOMY", 63, 69], ["infections", "DISEASE", 32, 42], ["T-cell", "CELL", 63, 69], ["their study", "TEST", 48, 59]]], ["This underestimate will grow as x and y become larger.Estimating \u03c1 and \u03c4All rights reserved.", [["larger", "OBSERVATION_MODIFIER", 47, 53]]], ["No reuse allowed without permission.Estimating \u03c1 and \u03c4(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Estimating \u03c1 and \u03c4The copyright holder for this preprint this version posted August 21, 2020. . https://doi.org/10.1101/2020.08.17.20176602 doi: medRxiv preprintResultsOur method was first tested on a hypothetical case.", [["medRxiv preprintResultsOur method", "TREATMENT", 334, 367], ["med", "ANATOMY", 133, 136]]], ["Then we use USA data.Test casesAs nobody knows the true level of infection, we test by using a hypothetical infection which has proportion P 0 in the population governed by:Test casesThis assumes about 50% of the population can be infected (exactly once) and the period of contagion is \u03c4 0 .", [["infection", "DISEASE", 65, 74], ["infection", "DISEASE", 108, 117], ["USA data", "TEST", 12, 20], ["Test cases", "TEST", 21, 31], ["infection", "PROBLEM", 65, 74], ["a hypothetical infection", "PROBLEM", 93, 117], ["infection", "OBSERVATION", 65, 74], ["infection", "OBSERVATION", 108, 117], ["infected", "OBSERVATION", 231, 239]]], ["R is the rate of infection.", [["infection", "DISEASE", 17, 26], ["R", "GENE_OR_GENE_PRODUCT", 0, 1], ["infection", "PROBLEM", 17, 26], ["infection", "OBSERVATION", 17, 26]]], ["Also some small initial value P 0 (t) = \u03c6(t), t < 0 is required.", [["some small initial value", "PROBLEM", 5, 29], ["small", "OBSERVATION_MODIFIER", 10, 15]]], ["For R = 5 and \u03c4 = 0.25, this was solved numerically:test function P (t) 0We need some testing function y (t), choose y = 0.1 constant.", [["some testing function", "TEST", 81, 102]]], ["No reuse allowed without permission.test function P (t) 0(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.test function P (t) 0The copyright holder for this preprint this version posted August 21, 2020.", [["The copyright holder", "TREATMENT", 213, 233], ["med", "ANATOMY", 136, 139]]], ["Then, obtain the predicted proportion P (t) using PRE:test function P (t) 0Now, of course, we have no apriori way of choosing the right \u03c1 and \u03c4 .", [["P", "DNA", 38, 39], ["PRE", "DNA", 50, 53], ["\u03c4", "PROTEIN", 142, 143], ["right", "ANATOMY_MODIFIER", 130, 135]]], ["However, if we choose the right ones, in this case \u03c4 = 0.25, \u03c1 = 9 We find if r, \u03c4 , are close to the true r 0 , \u03c4 0 , then the predicted proportion P is close to the true proportion P 0 .", [["P", "DNA", 149, 150], ["right", "ANATOMY_MODIFIER", 26, 31]]], ["However, if say r is twice r 0 , then P is approximately twice the value of P 0 .", [["P", "DNA", 38, 39]]], ["On the other hand, the solution P is relatively less sensitive to variations in the period of infection \u03c4 .test function P (t) 0All rights reserved.", [["infection", "DISEASE", 94, 103], ["infection", "PROBLEM", 94, 103], ["infection", "OBSERVATION", 94, 103]]], ["No reuse allowed without permission.test function P (t) 0(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.test function P (t) 0The copyright holder for this preprint this version posted August 21, 2020. .", [["The copyright holder", "TREATMENT", 213, 233], ["med", "ANATOMY", 136, 139]]], ["What this means is that the PRE is well posed, indeed, it is linear in x , y and roughly linear in \u03c1.USA dataFor the US over time, 0 \u2264 t \u2264 4.6 months, the data is approximated by y(t) = (0.01539t 2 \u2212 0.00422t 3 + 0.000661t 4 )U (t) , and by the function x(t) = (0.00473t 2 \u2212 0.0030094t 3 + 0.0007488t 4 \u2212 0.00006139t 5 )U (t) , using the Heaviside Step Function U (t) to emphasize x, y = 0 for t \u2264 0.", [["PRE", "DNA", 28, 31], ["the data", "TEST", 151, 159], ["U (t)", "TEST", 226, 231], ["linear", "OBSERVATION_MODIFIER", 61, 67], ["linear", "OBSERVATION_MODIFIER", 89, 95]]], ["This is simply a smooth interpolation and not meant to be any prediction, although the 3-4 term polynomials are a good fit for data at 11 points.", [["smooth", "OBSERVATION_MODIFIER", 17, 23]]], ["No reuse allowed without permission.USA data(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.ConclusionsOur theory shows that it is possible to estimate the proportion of all who have been infected by methods easy enough to perform on any computer with Mathematica.", [["USA data", "TEST", 36, 44], ["med", "ANATOMY", 123, 126], ["infected", "OBSERVATION", 275, 283]]], ["The estimate is as accurate as sampling, and stable.", [["stable", "OBSERVATION_MODIFIER", 45, 51]]], ["Thus, it is not necessary to sample the whole population.ConclusionsUsing this method, one can make predictions on the saturation point, i.e. the proportion \u03c3 of susceptibles in the population.", [["this method", "TREATMENT", 74, 85]]], ["Of course, this depends also on the population profile, in particular the amount of older, sick people.", [["people", "ORGANISM", 96, 102], ["people", "SPECIES", 96, 102], ["amount", "OBSERVATION_MODIFIER", 74, 80]]], ["Applying our formula to data from the states NY and NJ one sees that P > 30%, which suggests that \u03c3 lies in the range 35\u221245%, which is consistent with their x curves.ConclusionsThe formula shows proportion presently infected isConclusionsVarious authorities have tried to estimate P P : they use the proportion of infected among those daily tested , analytically this is the function x (t)/y (t).ConclusionsAll rights reserved.", [["P P", "DNA", 281, 284], ["infected", "OBSERVATION", 216, 224], ["infected", "OBSERVATION", 314, 322]]], ["No reuse allowed without permission.Conclusions(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.ConclusionsThe copyright holder for this preprint this version posted August 21, 2020. . https://doi.org/10.1101/2020.08.17.20176602 doi: medRxiv preprint Comparing x (t)/y (t) with P (t)\u03c4 for USA data: USA data : r =0.93, \u03c4 = 0.5 PP = P' \u03c4Conclusionsx'/y' At the present time, the x (t)/y (t) estimate is out by about a factor two, but nonetheless, in the right ballpark (and erring on the safe side).ConclusionsThe CDC has used x/P to estimate \u03c1.", [["The copyright holder", "TREATMENT", 193, 213], ["USA data", "TEST", 385, 393], ["r", "TEST", 396, 397], ["\u03c4", "TEST", 405, 406], ["PP", "TEST", 413, 415], ["med", "ANATOMY", 126, 129], ["right", "ANATOMY_MODIFIER", 539, 544]]], ["This is accurate enough for small t, but for current time, our theory shows, with \u03c4 \u223c 0.5, that the CDC method underestimates \u03c1 by at least 20%, with the discrepancy growing with time.ConclusionsOne could also make quick estimates of P for various nations.", [["the CDC method", "TEST", 96, 110]]], ["Our main example is the USA, which at P \u223c 18%, has not too far to go before reaching saturation.", [["main", "OBSERVATION_MODIFIER", 4, 8]]], ["On the other hand, my native Australia, which had a severe lockdown, seems to have P \u223c 1%, i.e. it has a long, long way to go.Data and computationsThere is considerable data available from CDC, Oxford University [4], and Los Alamos [6] .", [["a severe lockdown", "PROBLEM", 50, 67], ["severe", "OBSERVATION_MODIFIER", 52, 58]]], ["All computations done on an iMac using Mathematica.Data and computationsAll rights reserved.", [["All computations", "TEST", 0, 16], ["an iMac", "TREATMENT", 25, 32]]], ["No reuse allowed without permission.Data and computations(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Data and computationsThe copyright holder for this preprint this version posted August 21, 2020. . https://doi.org/10.1101/2020.08.17.20176602 doi: medRxiv preprint", [["medRxiv", "TREATMENT", 340, 347], ["med", "ANATOMY", 136, 139]]]], "PMC7499480": [["Incorporating Clinical Laboratory COVID-19 Pandemic Responses in Course-Based Learning ::: Materials and MethodsSARS-CoV-2 remained a key topic of discussion throughout the course.", [["MethodsSARS", "TEST", 105, 116]]], ["Specific questions from or interests expressed by students prompted additional discussions and supplemental reading/journal articles related to both the new pathogen and vaccine development in other outbreak situations (ie, Ebola, severe acute respiratory syndrome virus, Zika virus).", [["Ebola", "DISEASE", 224, 229], ["acute respiratory syndrome virus", "DISEASE", 238, 270], ["Ebola", "ORGANISM", 224, 229], ["severe acute respiratory syndrome virus", "ORGANISM", 231, 270], ["Zika virus", "ORGANISM", 272, 282], ["Zika virus", "SPECIES", 272, 282], ["Ebola, severe acute respiratory syndrome virus", "SPECIES", 224, 270], ["Zika virus", "SPECIES", 272, 282], ["the new pathogen", "PROBLEM", 149, 165], ["vaccine", "TREATMENT", 170, 177], ["Ebola", "PROBLEM", 224, 229], ["severe acute respiratory syndrome virus", "PROBLEM", 231, 270], ["Zika virus", "PROBLEM", 272, 282], ["severe", "OBSERVATION_MODIFIER", 231, 237], ["acute", "OBSERVATION_MODIFIER", 238, 243], ["respiratory syndrome", "OBSERVATION", 244, 264]]], ["Impromptu and extemporaneous discussions or modifications were made to existing scheduled lectures to incorporate SARS-CoV-2 biology, epidemiology, and laboratory responses.", [["SARS", "DISEASE", 114, 118]]], ["The professional version of the teleconferencing application was made available for university students, faculty, and staff on March 4, 2020, including a Health Insurance Portability and Accountability Act (HIPAA)\u2013compliant version for Protected Health Information (PHI).", [["the teleconferencing application", "TREATMENT", 28, 60]]], ["The new online-only course, Medical Science 585C: \u201cClinical Laboratory Testing Distance Learning\u2014Methods and Interpretation\u201d (MedSci 585C), relied on the cloud-based Canvas Learning Management System (Canvas GFX) for distribution of course materials and submission of assignments.", [["the cloud", "TREATMENT", 150, 159]]], ["The Zoom \u201cbreakout room\u201d feature was used for small-group discussions in MedSci 585C.Changes to Educational Structure ::: Materials and MethodsChanges to course structures made due to COVID-19 are summarized in Table 1.", [["MedSci 585C", "CELL_LINE", 73, 84], ["COVID-19", "DNA", 184, 192], ["COVID", "TEST", 184, 189]]], ["Briefly, the second week of LabM 685 was conducted online.", [["LabM 685", "CHEMICAL", 28, 36]]], ["Scheduled sessions of LabM 680 (March to June 2020) were canceled by the UW SOM along with all in-person medical student rotations.", [["LabM", "TREATMENT", 22, 26]]], ["LabM 680 was replaced with MedSci 585C, which provided most regularly scheduled LabM 680 curricula in an online format.", [["LabM 680", "CHEMICAL", 0, 8], ["LabM", "TEST", 0, 4], ["MedSci", "TREATMENT", 27, 33]]], ["In addition, we identified previously recorded and upcoming lectures that could be recorded, as well as the clinical services with remote-access capabilities for trainees, and created supplemental activities not typically part of LabM 680, such as guided discussions, self-study resources, and reflective writing assignments.", [["LabM 680", "PROTEIN", 230, 238]]], ["To maintain low trainee/faculty ratios, we also planned twice-weekly small-group discussions facilitated by at least one faculty plus a second faculty or senior fellow.", [["low", "OBSERVATION_MODIFIER", 12, 15]]], ["For MedSci 585C, student feedback was gathered through (1) a final wrap-up session with the whole class, (2) an assigned reflection piece, and (3) a course survey.", [["a final wrap", "TREATMENT", 59, 71], ["an assigned reflection piece", "TREATMENT", 109, 137]]], ["The anonymous course survey contained quantitative and free-text elements for students to give feedback on small groups, lectures, and the overall course (Supplemental Table 1; all supplemental materials can be found at American Journal of Clinical Pathology online).", [["feedback on small groups", "TREATMENT", 95, 119], ["Supplemental Table 1", "TREATMENT", 155, 175], ["all supplemental materials", "TREATMENT", 177, 203]]], ["Students graded the course on a scale of 1 to 5, with 5 indicating the strongest level of agreement or most positive assessment.Real-Time Modifications to Course-Based Learning ::: ResultsWhen the Centers for Disease Control and Prevention began issuing guidance to curb the spread of COVID-19, 11 students were enrolled in course-based learning via LabM 685 Table 2.", [["Disease Control", "TREATMENT", 209, 224], ["COVID", "TEST", 285, 290], ["course", "OBSERVATION_MODIFIER", 20, 26]]], ["Adjustments to LabM 685 (Table 1) were implemented in both week 1 and week 2, with significant structural changes in week 2 Table 3.", [["LabM 685", "CHEMICAL", 15, 23], ["LabM 685", "CHEMICAL", 15, 23]]], ["The most significant alteration implemented in week 1 was the real-time incorporation of the COVID-19 pandemic as an overarching theme or case study to highlight the role of laboratory medicine.", [["the COVID", "TEST", 89, 98], ["case study", "TEST", 138, 148], ["laboratory medicine", "TREATMENT", 174, 193], ["most", "OBSERVATION_MODIFIER", 4, 8], ["significant", "OBSERVATION_MODIFIER", 9, 20], ["alteration", "OBSERVATION", 21, 31]]], ["These covered a diverse array of topics, including clinical features of COVID-19, understanding outbreak dynamics through representative graphs, specific infection control precautions in clinical laboratories, molecular epidemiology from viral genome sequence data, and sharing emerging data and reports.", [["infection", "DISEASE", 154, 163], ["viral genome sequence", "DNA", 238, 259], ["COVID", "TEST", 72, 77], ["specific infection control precautions", "TREATMENT", 145, 183], ["viral genome sequence data", "TEST", 238, 264], ["infection", "OBSERVATION", 154, 163]]], ["Other discussions covered SARS-CoV-2 test development and regulatory requirements for clinical laboratories.", [["CoV", "TEST", 31, 34], ["clinical laboratories", "TEST", 86, 107]]], ["These discussions were facilitated by the start of clinical testing for SARS-CoV-2 by the clinical virology laboratory11 on the first day of LabM 685.", [["SARS", "DISEASE", 72, 76], ["LabM 685", "CHEMICAL", 141, 149], ["SARS-CoV", "SPECIES", 72, 80], ["clinical testing", "TEST", 51, 67], ["SARS", "TEST", 72, 76], ["CoV", "TEST", 77, 80]]], ["In-person instruction was suspended at the midpoint of the course in concordance with university official policy.12Real-Time Modifications to Course-Based Learning ::: ResultsWeek 2 of LabM 685 was conducted entirely online.", [["LabM 685", "CHEMICAL", 185, 193]]], ["In addition, one grand rounds presentation was canceled by the invited speaker, an expert in tropical medicine, who declined to travel given the risks of SARS-CoV-2 transmission.", [["SARS", "DISEASE", 154, 158], ["SARS-CoV-2", "ORGANISM", 154, 164], ["SARS-CoV", "SPECIES", 154, 162], ["SARS", "PROBLEM", 154, 158]]], ["These included clinical microbiology\u2013infectious diseases plate rounds, resident didactics, call rounds, and coagulation/hemoglobinopathy testing sign-out.", [["hemoglobinopathy", "DISEASE", 120, 136], ["coagulation/hemoglobinopathy testing sign", "TEST", 108, 149]]], ["Small-group sessions and flipped classroom teaching sessions were incorporated.", [["flipped classroom teaching sessions", "TREATMENT", 25, 60], ["-group", "OBSERVATION_MODIFIER", 5, 11]]], ["The new course, MedSci 585C, provided third- and fourth-year medical students an opportunity to develop their diagnostic and patient management skills through directed distance learning in the hospital-based clinical laboratory.Student Evaluations ::: ResultsFourteen students completed each session of the new course, MedSci 585C.", [["patient", "ORGANISM", 125, 132], ["patient", "SPECIES", 125, 132], ["new", "OBSERVATION_MODIFIER", 4, 7]]], ["As a required assignment, all students completed the reflection piece.", [["the reflection piece", "TREATMENT", 49, 69]]], ["Students most frequently commented on phases of testing (n = 10), test utilization (n = 10), regulatory agencies (n = 8), and the experience of teaching reverse lectures (n = 3).", [["testing", "TEST", 48, 55], ["test utilization", "TEST", 66, 82]]], ["All students completed the course evaluation survey in the first session, and 11 of 14 students completed the course evaluation in the second session.", [["the course evaluation survey", "TEST", 23, 51], ["the course evaluation", "TEST", 106, 127]]], ["Critical remarks about the course most frequently included teleconferencing fatigue (n = 4) and the density of complex subject matter in sign-out and conferences (n = 7), with the majority of these comments directed toward the first session.", [["fatigue", "DISEASE", 76, 83], ["teleconferencing fatigue", "PROBLEM", 59, 83]]], ["Only free text or verbal feedback on the adaptation to LabM 685 was available.DiscussionDuring the COVID-19 pandemic, the clinical laboratory response has been dynamic.", [["LabM 685", "CHEMICAL", 55, 63], ["LabM 685", "CHEMICAL", 55, 63], ["LabM", "TEST", 55, 59], ["the COVID", "TEST", 95, 104]]], ["As new developments have arisen on a global and national scale, these disruptions to the community at large have greatly affected academic practice.6,13,14 Other groups in dermatology,15 surgery,16,17 nursing,18 and anatomic pathology19,20 have reported on rapid and drastic changes in medical education and ways to proceed.", [["anatomic pathology", "TEST", 216, 234]]], ["In laboratory medicine, most divisions\u2014except for therapeutic apheresis\u2014conduct clinical service work without direct patient contact.", [["patient", "ORGANISM", 117, 124], ["patient", "SPECIES", 117, 124]]], ["In compliance with COVID-19 distancing measures, laboratory medicine service work, sign-out, and didactics have shifted to a predominately remote-access paradigm for trainees and faculty alike.", [["COVID", "TREATMENT", 19, 24]]], ["Therefore, the course structure involved elements of direct sign-out observation, in addition to both guided and independent study.", [["direct sign", "TEST", 53, 64], ["independent study", "TEST", 113, 130]]], ["Additional activities involve small-group sessions, journal article reading, and live or prerecorded didactics.DiscussionThe lack of a vaccine against SARS-CoV-2 has placed diagnostic tests for the virus at the leading edge of the pandemic response.", [["SARS", "DISEASE", 151, 155], ["SARS-CoV-2", "ORGANISM", 151, 161], ["SARS-CoV", "SPECIES", 151, 159], ["a vaccine", "TREATMENT", 133, 142], ["SARS", "PROBLEM", 151, 155], ["diagnostic tests", "TEST", 173, 189], ["the virus", "PROBLEM", 194, 203], ["pandemic response", "OBSERVATION", 231, 248]]], ["The result has been enormous medical and popular interest in laboratory diagnostics with the recognition that issues pertaining to the laboratory have vital repercussions for society.", [["laboratory diagnostics", "TEST", 61, 83], ["enormous", "OBSERVATION_MODIFIER", 20, 28]]], ["This was apparent from the student response during LabM 685.", [["LabM 685", "CHEMICAL", 51, 59], ["LabM 685", "CHEMICAL", 51, 59], ["LabM", "TEST", 51, 55]]], ["As in the pre-COVID rotation, the goal was to provide exposure to multiple laboratories and the breadth of testing performed at our institution.", [["multiple laboratories", "TEST", 66, 87], ["the breadth of testing", "TEST", 92, 114]]], ["Special focus included how the clinical laboratories have mobilized in response to an urgent pandemic and whether this response is generalizable or unique to this institution.", [["the clinical laboratories", "TEST", 27, 52], ["an urgent pandemic", "PROBLEM", 83, 101]]], ["More quotidian goals included introducing students to common activities of the laboratory; exploring concepts of preclinical variables, including labeling/patient identification and patient safety in the clinical laboratory; and encouraging consultation with laboratorian/pathologist colleagues in future clinical practice.DiscussionThe change of the course from a two- to four-student rotation conducted in person to a potentially 40-student rotation conducted entirely online necessitated changes in structure to preserve interactivity, engagement, and participation in sign-out.", [["patient", "ORGANISM", 155, 162], ["patient", "ORGANISM", 182, 189], ["patient", "SPECIES", 155, 162], ["patient", "SPECIES", 182, 189], ["person", "SPECIES", 408, 414], ["labeling/patient identification", "TEST", 146, 177]]], ["To facilitate discussions, we structured portions of the clerkship as small groups of up to 10 students co-led by laboratory medicine faculty and fellows who meet twice a week for an hour.", [["small", "OBSERVATION_MODIFIER", 70, 75]]], ["The first two sessions consisted of guided discussion and question-and-answer sessions, while the last two sessions consist of flipped classroom teaching sessions moderated by small-group instructors (Table 4).", [["small", "OBSERVATION_MODIFIER", 176, 181]]], ["The benefits of small-group and reverse teaching methods in the classroom in promoting interaction and collaboration have been reported on previously,21-23 and students commented positively on their experience in evaluations.", [["reverse teaching methods", "TREATMENT", 32, 56], ["evaluations", "TEST", 213, 224], ["small", "OBSERVATION_MODIFIER", 16, 21]]], ["Together with the distance learning clerkship offered by our anatomic pathology colleagues, pathology accounted for two of 13 courses offered to third- and fourth-year medical students at this institution during COVID-19.DiscussionThe changes in the clerkship increased the visibility of and access to laboratory medicine education, including nine (32%) medical students who were out of state.", [["COVID", "TEST", 212, 217], ["laboratory medicine education", "TREATMENT", 302, 331]]], ["Additional trade-offs between traditional and online format are presented in Table 1.DiscussionTechnology such as teleconferencing, didactic recording, and learning management software was already partially used in the SOM, but the global pandemic quickly forced universal adoption of these tools to facilitate education in this period of social distancing.6,18,24 An unprecedented amount of online resources, media, and readings have been made available through both online commercial modules purchased by the university and free online learning materials.19,20,25,26 Stored content has the main advantage of flexibility\u2014students and trainees can access high-quality content at any time\u2014but lacks the immersion of a real case and an experienced mentor to navigate the clinical thinking around each case.", [["6,18,24", "CHEMICAL", 357, 364], ["didactic recording", "TEST", 132, 150], ["learning management", "TREATMENT", 156, 175], ["unprecedented", "OBSERVATION_MODIFIER", 368, 381], ["amount", "OBSERVATION_MODIFIER", 382, 388]]], ["Hence, a curriculum that would bring students into the environment of clinical pathology, combined with small-group activities to navigate cases and increase learning engagement, was used.DiscussionWe identified two additional challenges unique to the remote format: teleconferencing fatigue and HIPAA compliance.", [["fatigue", "DISEASE", 284, 291], ["clinical pathology", "TEST", 70, 88], ["learning engagement", "TREATMENT", 158, 177], ["teleconferencing fatigue", "PROBLEM", 267, 291], ["HIPAA compliance", "TREATMENT", 296, 312]]], ["Students in the first session reported teleconferencing fatigue on days with back-to-back conferences.", [["fatigue", "DISEASE", 56, 63], ["teleconferencing fatigue", "PROBLEM", 39, 63], ["back", "ANATOMY", 85, 89]]], ["Concerns over the security of teleconferencing applications are not unique to this setting,27 but because teleconferencing was used extensively for didactics and sign-out of clinical cases that could involve sensitive PHI, HIPAA compliance was critical.", [["didactics", "TEST", 148, 157]]], ["This required that teleconferencing applications could (1) ensure the confidentiality of electronic PHI, (2) protect against reasonably anticipated threats to such information, (3) protect against reasonably anticipated nonpermitted uses or disclosures of such information, and (4) ensure compliance by its workforce.28,29 We relied on the HIPAA-compliant accounts made available by our institution, required students include their role in their screen name (eg, \u201cmedical student,\u201d \u201cMS-4\u201d), and encouraged teleconference hosts of PHI-sensitive meetings to require a passcode for access as recommended.28DiscussionOur efforts reflect one of several ways in which medical educators have adapted to COVID-19.", [["COVID-19", "DNA", 696, 704], ["teleconferencing applications", "TREATMENT", 19, 48], ["a passcode for access", "TREATMENT", 564, 585]]], ["Even though our SOM is returning to in-person clerkships with some limitations in the summer and fall of 2020, this remote learning approach has the benefits of providing in-depth instruction in laboratory medicine, exposing students to the critical role of the clinical laboratory in response to emerging infections, and affords flexibility for educators to respond to the continuing pandemic.", [["infections", "DISEASE", 306, 316], ["emerging infections", "PROBLEM", 297, 316], ["infections", "OBSERVATION", 306, 316]]], ["These have ranged from graduating senior medical students early30,31 to training medical students to perform critical public health activities, particularly contact tracing, conducting telehealth visits, and staffing COVID-19 call centers.32-34 We encourage such innovative solutions and believe that our approach to rapidly adapt to distance learning dovetails with engaging medical students in a variety of alternative learning activities.", [["such innovative solutions", "TREATMENT", 258, 283]]], ["The changes in medical education afford a new opportunity for medical student exposure to pathology and laboratory medicine.", [["laboratory medicine", "TREATMENT", 104, 123]]], ["As the United States faces a prolonged first wave of COVID-19 infections, such changes in medical education appear to reflect a new normal and may require further evolution.", [["infections", "DISEASE", 62, 72], ["COVID-19 infections", "PROBLEM", 53, 72], ["medical education", "TREATMENT", 90, 107], ["infections", "OBSERVATION", 62, 72], ["new", "OBSERVATION_MODIFIER", 128, 131], ["normal", "OBSERVATION", 132, 138]]]], "b94c4fb90d59de2d9e9e63f8b8db367da9a0225c": [["Non-invasive positive-pressure ventilation (NIPPV) is the preferred method of ventilatory support in patients with acute respiratory failure secondary to an acute exacerbation of COPD (AECOPD).", [["respiratory", "ANATOMY", 121, 132], ["acute respiratory failure", "DISEASE", 115, 140], ["COPD", "DISEASE", 179, 183], ["AECOPD", "DISEASE", 185, 191], ["patients", "ORGANISM", 101, 109], ["patients", "SPECIES", 101, 109], ["Non-invasive positive-pressure ventilation", "TREATMENT", 0, 42], ["NIPPV", "TREATMENT", 44, 49], ["ventilatory support", "TREATMENT", 78, 97], ["acute respiratory failure", "PROBLEM", 115, 140], ["an acute exacerbation", "PROBLEM", 154, 175], ["COPD", "PROBLEM", 179, 183], ["AECOPD", "PROBLEM", 185, 191], ["positive", "OBSERVATION", 13, 21], ["pressure ventilation", "OBSERVATION", 22, 42], ["acute", "OBSERVATION_MODIFIER", 115, 120], ["respiratory failure", "OBSERVATION", 121, 140], ["acute", "OBSERVATION_MODIFIER", 157, 162], ["exacerbation", "OBSERVATION", 163, 175], ["COPD", "OBSERVATION", 179, 183]]], ["This patient was placed on bilevel NIPPV with an inspiratory pressure of 12 cm of water and an expiratory pressure of 5 cm of water with an inspired fraction of oxygen of 0.5 via an oronasal mask interface.", [["oronasal", "ANATOMY", 182, 190], ["oxygen", "CHEMICAL", 161, 167], ["oxygen", "CHEMICAL", 161, 167], ["patient", "ORGANISM", 5, 12], ["oxygen", "SIMPLE_CHEMICAL", 161, 167], ["patient", "SPECIES", 5, 12], ["bilevel NIPPV", "TREATMENT", 27, 40], ["an inspiratory pressure", "TEST", 46, 69], ["an expiratory pressure", "TEST", 92, 114], ["an inspired fraction of oxygen", "TREATMENT", 137, 167], ["an oronasal mask interface", "TREATMENT", 179, 205], ["oronasal mask", "OBSERVATION", 182, 195]]], ["His oxygen saturation was maintained between 88 and 92%.", [["oxygen", "CHEMICAL", 4, 10], ["oxygen", "CHEMICAL", 4, 10], ["oxygen", "SIMPLE_CHEMICAL", 4, 10], ["His oxygen saturation", "TEST", 0, 21]]], ["He was given 500 mg of intravenous azithromycin and 60 mg of intravenous methylprednisolone.", [["intravenous", "ANATOMY", 23, 34], ["intravenous", "ANATOMY", 61, 72], ["azithromycin", "CHEMICAL", 35, 47], ["methylprednisolone", "CHEMICAL", 73, 91], ["azithromycin", "CHEMICAL", 35, 47], ["methylprednisolone", "CHEMICAL", 73, 91], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 23, 34], ["azithromycin", "SIMPLE_CHEMICAL", 35, 47], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 61, 72], ["methylprednisolone", "SIMPLE_CHEMICAL", 73, 91], ["intravenous azithromycin", "TREATMENT", 23, 47], ["intravenous methylprednisolone", "TREATMENT", 61, 91]]], ["Within hours, his respiratory rate had decreased to 22 and he appeared comfortable with improvement in his arterial blood gas.Diagnosis and Impact of COPD ExacerbationsThe natural history of COPD is punctuated by periods of acute exacerbation, during which patients experience increased symptoms and utilize more healthcare resources.", [["respiratory", "ANATOMY", 18, 29], ["arterial blood", "ANATOMY", 107, 121], ["COPD", "DISEASE", 191, 195], ["arterial", "MULTI-TISSUE_STRUCTURE", 107, 115], ["blood", "ORGANISM_SUBSTANCE", 116, 121], ["patients", "ORGANISM", 257, 265], ["patients", "SPECIES", 257, 265], ["his respiratory rate", "TEST", 14, 34], ["his arterial blood gas", "TEST", 103, 125], ["COPD Exacerbations", "PROBLEM", 150, 168], ["COPD", "PROBLEM", 191, 195], ["acute exacerbation", "PROBLEM", 224, 242], ["increased symptoms", "PROBLEM", 277, 295], ["arterial", "ANATOMY", 107, 115], ["COPD", "OBSERVATION", 150, 154], ["COPD", "OBSERVATION", 191, 195], ["acute", "OBSERVATION_MODIFIER", 224, 229], ["exacerbation", "OBSERVATION", 230, 242]]], ["Common symptoms of AECOPD include increased sputum production, cough and dyspnea as a result of increased airway inflammation, mucous plugging and gas trapping [1, 2] .", [["sputum", "ANATOMY", 44, 50], ["airway", "ANATOMY", 106, 112], ["mucous", "ANATOMY", 127, 133], ["AECOPD", "DISEASE", 19, 25], ["cough", "DISEASE", 63, 68], ["dyspnea", "DISEASE", 73, 80], ["inflammation", "DISEASE", 113, 125], ["sputum", "ORGANISM_SUBSTANCE", 44, 50], ["airway", "MULTI-TISSUE_STRUCTURE", 106, 112], ["mucous", "MULTI-TISSUE_STRUCTURE", 127, 133], ["Common symptoms", "PROBLEM", 0, 15], ["AECOPD", "PROBLEM", 19, 25], ["increased sputum production", "PROBLEM", 34, 61], ["cough", "PROBLEM", 63, 68], ["dyspnea", "PROBLEM", 73, 80], ["increased airway inflammation", "PROBLEM", 96, 125], ["mucous plugging", "PROBLEM", 127, 142], ["gas trapping", "PROBLEM", 147, 159], ["AECOPD", "OBSERVATION", 19, 25], ["increased", "OBSERVATION_MODIFIER", 34, 43], ["sputum", "OBSERVATION", 44, 50], ["increased", "OBSERVATION_MODIFIER", 96, 105], ["airway", "ANATOMY", 106, 112], ["inflammation", "OBSERVATION", 113, 125], ["mucous plugging", "OBSERVATION", 127, 142], ["gas trapping", "OBSERVATION", 147, 159]]], ["Exacerbations of COPD are associated with a mortality of 10% in the hospital, 43% at 1 year and 50% in the subsequent 5 years [3] [4] [5] .", [["COPD", "DISEASE", 17, 21], ["Exacerbations", "PROBLEM", 0, 13], ["COPD", "PROBLEM", 17, 21], ["COPD", "OBSERVATION", 17, 21]]], ["Exacerbations themselves are associated with a step-wise decline in lung function and deteriorating quality of life [6] .", [["lung", "ANATOMY", 68, 72], ["lung", "ORGAN", 68, 72], ["Exacerbations themselves", "PROBLEM", 0, 24], ["a step-wise decline in lung function", "PROBLEM", 45, 81], ["lung", "ANATOMY", 68, 72]]], ["The most commonly identified triggers for AECOPD are respiratory viruses, particularly rhinovirus, as well as bacterial pathogens and environmental exposures. many of the risks of invasive ventilation (via an endotracheal tube), including the risk of aspiration, hypotension or trauma during laryngoscopy and placement of the endotracheal tube.", [["endotracheal tube", "ANATOMY", 209, 226], ["endotracheal tube", "ANATOMY", 326, 343], ["AECOPD", "DISEASE", 42, 48], ["respiratory viruses", "DISEASE", 53, 72], ["rhinovirus", "DISEASE", 87, 97], ["hypotension", "DISEASE", 263, 274], ["trauma", "DISEASE", 278, 284], ["rhinovirus", "ORGANISM", 87, 97], ["endotracheal tube", "MULTI-TISSUE_STRUCTURE", 209, 226], ["endotracheal tube", "MULTI-TISSUE_STRUCTURE", 326, 343], ["AECOPD", "PROBLEM", 42, 48], ["respiratory viruses", "PROBLEM", 53, 72], ["rhinovirus", "PROBLEM", 87, 97], ["bacterial pathogens", "PROBLEM", 110, 129], ["invasive ventilation", "TREATMENT", 180, 200], ["an endotracheal tube", "TREATMENT", 206, 226], ["aspiration", "PROBLEM", 251, 261], ["hypotension", "PROBLEM", 263, 274], ["trauma", "PROBLEM", 278, 284], ["laryngoscopy", "TEST", 292, 304], ["placement", "TREATMENT", 309, 318], ["the endotracheal tube", "TREATMENT", 322, 343], ["respiratory viruses", "OBSERVATION", 53, 72], ["rhinovirus", "OBSERVATION", 87, 97], ["bacterial", "OBSERVATION_MODIFIER", 110, 119], ["pathogens", "OBSERVATION", 120, 129], ["invasive ventilation", "OBSERVATION", 180, 200], ["endotracheal tube", "OBSERVATION", 209, 226], ["aspiration", "OBSERVATION", 251, 261], ["hypotension", "OBSERVATION", 263, 274], ["endotracheal tube", "OBSERVATION", 326, 343]]], ["In addition, NIPPV preserves airway defenses, which may reduce the risk of ventilator-associated pneumonia and usually does not require sedation or physical restraints.", [["airway", "ANATOMY", 29, 35], ["pneumonia", "DISEASE", 97, 106], ["airway", "MULTI-TISSUE_STRUCTURE", 29, 35], ["NIPPV", "TREATMENT", 13, 18], ["ventilator-associated pneumonia", "PROBLEM", 75, 106], ["sedation", "TREATMENT", 136, 144], ["physical restraints", "TREATMENT", 148, 167], ["airway defenses", "OBSERVATION", 29, 44], ["pneumonia", "OBSERVATION", 97, 106]]], ["The target oxygen saturation in the setting of a COPD exacerbation is 88-92%, which has been associated with lower mortality compared to non-titrated supplemental oxygen [9] .Diagnosis and Impact of COPD ExacerbationsNIPPV reduces in-hospital mortality in COPD exacerbations in addition to reducing the need for intubation, and hospital length of stay [8, 10] .", [["oxygen", "CHEMICAL", 11, 17], ["COPD", "DISEASE", 49, 53], ["oxygen", "CHEMICAL", 163, 169], ["COPD", "DISEASE", 256, 260], ["oxygen", "CHEMICAL", 11, 17], ["oxygen", "CHEMICAL", 163, 169], ["oxygen", "SIMPLE_CHEMICAL", 11, 17], ["oxygen", "SIMPLE_CHEMICAL", 163, 169], ["The target oxygen saturation", "TEST", 0, 28], ["a COPD exacerbation", "PROBLEM", 47, 66], ["supplemental oxygen", "TREATMENT", 150, 169], ["COPD Exacerbations", "PROBLEM", 199, 217], ["NIPPV", "TREATMENT", 217, 222], ["COPD exacerbations", "PROBLEM", 256, 274], ["intubation", "TREATMENT", 312, 322], ["target", "OBSERVATION_MODIFIER", 4, 10], ["oxygen saturation", "OBSERVATION", 11, 28], ["COPD", "OBSERVATION", 49, 53], ["COPD", "OBSERVATION", 199, 203], ["COPD", "OBSERVATION", 256, 260]]], ["It has also been shown to reduce respiratory rate and improve respiratory acidosis [11] .Diagnosis and Impact of COPD ExacerbationsTypical settings for NIPPV in COPD exacerbation are bilevel positive pressure support, with an inspiratory pressure set at 8-12 cm H 2 O and an expiratory pressure set at 3-5 cm H 2 O. Oronasal mask (covering the mouth and nose) interface is generally used due to known benefits in physiologic parameters and wide availability.", [["respiratory", "ANATOMY", 33, 44], ["respiratory", "ANATOMY", 62, 73], ["mouth", "ANATOMY", 344, 349], ["nose", "ANATOMY", 354, 358], ["respiratory acidosis", "DISEASE", 62, 82], ["COPD", "DISEASE", 161, 165], ["mouth", "ORGANISM_SUBDIVISION", 344, 349], ["nose", "ORGANISM_SUBDIVISION", 354, 358], ["respiratory rate", "TEST", 33, 49], ["respiratory acidosis", "PROBLEM", 62, 82], ["COPD Exacerbations", "PROBLEM", 113, 131], ["NIPPV", "TREATMENT", 152, 157], ["COPD exacerbation", "PROBLEM", 161, 178], ["bilevel positive pressure support", "TREATMENT", 183, 216], ["an inspiratory pressure", "TEST", 223, 246], ["an expiratory pressure", "TEST", 272, 294], ["Oronasal mask", "TREATMENT", 316, 329], ["known benefits in physiologic parameters", "PROBLEM", 395, 435], ["respiratory rate", "OBSERVATION", 33, 49], ["respiratory acidosis", "OBSERVATION", 62, 82], ["COPD", "OBSERVATION", 113, 117], ["COPD", "OBSERVATION", 161, 165], ["pressure support", "OBSERVATION", 200, 216], ["inspiratory pressure", "OBSERVATION", 226, 246], ["mouth", "ANATOMY", 344, 349], ["nose", "ANATOMY", 354, 358]]], ["If not tolerated, a nasal mask or nasal cushions may be more comfortable, with the caveat that they generally have larger air leaks [12, 13] .", [["nasal", "ANATOMY", 20, 25], ["nasal", "ANATOMY", 34, 39], ["nasal", "ORGAN", 20, 25], ["a nasal mask", "TREATMENT", 18, 30], ["nasal cushions", "TREATMENT", 34, 48], ["larger air leaks", "PROBLEM", 115, 131], ["larger", "OBSERVATION_MODIFIER", 115, 121], ["air leaks", "OBSERVATION", 122, 131]]], ["Newer interfaces including helmet devices may have added benefit, including patient comfort and the ability to drink while receiving positive pressure ventilation, but are not widely used at this time [14] .Diagnosis and Impact of COPD ExacerbationsIndications and absolute contraindications to NIPPV are listed below.", [["patient", "ORGANISM", 76, 83], ["patient", "SPECIES", 76, 83], ["helmet devices", "TREATMENT", 27, 41], ["positive pressure ventilation", "TREATMENT", 133, 162], ["COPD Exacerbations", "PROBLEM", 231, 249], ["absolute contraindications", "TREATMENT", 265, 291], ["NIPPV", "TREATMENT", 295, 300], ["COPD", "OBSERVATION", 231, 235]]], ["Encephalopathy due to hypercapnic respiratory failure is not a contraindication, but requires the frequent monitoring and follow up of the patient to ensure improvement in mental status and respiratory acidosis in the first hours [15] .Diagnosis and Impact of COPD Exacerbations\"NIPPV failure\" is better described as the progression or lack of improvement of respiratory failure despite NIPPV, often leading to invasive mechanical ventilation (IMV) [16] .", [["respiratory", "ANATOMY", 34, 45], ["respiratory", "ANATOMY", 190, 201], ["respiratory", "ANATOMY", 359, 370], ["Encephalopathy", "DISEASE", 0, 14], ["hypercapnic respiratory failure", "DISEASE", 22, 53], ["respiratory acidosis", "DISEASE", 190, 210], ["NIPPV failure", "DISEASE", 279, 292], ["respiratory failure", "DISEASE", 359, 378], ["patient", "ORGANISM", 139, 146], ["patient", "SPECIES", 139, 146], ["Encephalopathy", "PROBLEM", 0, 14], ["hypercapnic respiratory failure", "PROBLEM", 22, 53], ["the frequent monitoring", "TEST", 94, 117], ["respiratory acidosis", "PROBLEM", 190, 210], ["COPD Exacerbations", "PROBLEM", 260, 278], ["NIPPV failure", "PROBLEM", 279, 292], ["respiratory failure", "PROBLEM", 359, 378], ["NIPPV", "TREATMENT", 387, 392], ["invasive mechanical ventilation", "TREATMENT", 411, 442], ["hypercapnic", "OBSERVATION_MODIFIER", 22, 33], ["respiratory failure", "OBSERVATION", 34, 53], ["respiratory acidosis", "OBSERVATION", 190, 210], ["COPD", "OBSERVATION", 260, 264], ["NIPPV failure", "OBSERVATION", 279, 292], ["respiratory failure", "OBSERVATION", 359, 378]]], ["Approximately 30% of patients with AECOPD treated with NIPPV fall into this category [17] .", [["AECOPD", "DISEASE", 35, 41], ["patients", "ORGANISM", 21, 29], ["patients", "SPECIES", 21, 29], ["AECOPD", "PROBLEM", 35, 41], ["NIPPV", "TREATMENT", 55, 60], ["AECOPD", "OBSERVATION", 35, 41]]], ["NIPPV failure is associated with a high mortality.", [["NIPPV failure", "DISEASE", 0, 13], ["NIPPV failure", "PROBLEM", 0, 13], ["a high mortality", "PROBLEM", 33, 49], ["failure", "OBSERVATION", 6, 13], ["high", "OBSERVATION_MODIFIER", 35, 39], ["mortality", "OBSERVATION", 40, 49]]], ["Reported mortality ranges from 13.5% in the ICU to 60.2% and is higher than the mortality of those initially placed on IMV [17, 18] .BronchodilatorsInhaled bronchodilators are the mainstay of treatment for COPD exacerbations.", [["COPD", "DISEASE", 206, 210], ["IMV", "TREATMENT", 119, 122], ["BronchodilatorsInhaled bronchodilators", "TREATMENT", 133, 171], ["treatment", "TREATMENT", 192, 201], ["COPD exacerbations", "PROBLEM", 206, 224], ["higher", "OBSERVATION_MODIFIER", 64, 70]]], ["Short acting beta-agonists (e.g., albuterol) have proven reliable and quick-acting bronchodilators.", [["albuterol", "CHEMICAL", 34, 43], ["albuterol", "CHEMICAL", 34, 43], ["albuterol", "SIMPLE_CHEMICAL", 34, 43], ["Short acting beta-agonists", "TREATMENT", 0, 26], ["albuterol", "TREATMENT", 34, 43], ["quick-acting bronchodilators", "TREATMENT", 70, 98]]], ["No difference has been found in efficacy between short-acting beta-agonists and anticholinergics delivered via nebulizer or metered-dose inhaler (MDI) [19] , although nebulizer may be preferred if the patient is in respiratory failure and unable to generate the negative inspiratory force required for optimal MDI medication delivery.", [["respiratory", "ANATOMY", 215, 226], ["respiratory failure", "DISEASE", 215, 234], ["anticholinergics", "SIMPLE_CHEMICAL", 80, 96], ["patient", "ORGANISM", 201, 208], ["patient", "SPECIES", 201, 208], ["short-acting beta-agonists", "TREATMENT", 49, 75], ["anticholinergics", "TREATMENT", 80, 96], ["nebulizer", "TREATMENT", 111, 120], ["metered-dose inhaler (MDI)", "TREATMENT", 124, 150], ["nebulizer", "TREATMENT", 167, 176], ["respiratory failure", "PROBLEM", 215, 234], ["optimal MDI medication delivery", "TREATMENT", 302, 333], ["difference", "OBSERVATION", 3, 13], ["respiratory failure", "OBSERVATION", 215, 234]]], ["Nair et al. found no difference in maximal bronchodilatory response between 2.5 mg/3 mL and 5 mg/3 mL of nebulized albuterol in COPD exacerbations [20] .BronchodilatorsShort-acting inhaled anticholinergics (e.g., ipratropium bromide) are often used alongside inhaled beta-agonist therapy [7] .", [["albuterol", "CHEMICAL", 115, 124], ["COPD", "DISEASE", 128, 132], ["ipratropium bromide", "CHEMICAL", 213, 232], ["albuterol", "CHEMICAL", 115, 124], ["ipratropium bromide", "CHEMICAL", 213, 232], ["albuterol", "SIMPLE_CHEMICAL", 115, 124], ["ipratropium bromide", "SIMPLE_CHEMICAL", 213, 232], ["beta-agonist", "SIMPLE_CHEMICAL", 267, 279], ["maximal bronchodilatory response", "TREATMENT", 35, 67], ["nebulized albuterol", "TREATMENT", 105, 124], ["COPD exacerbations", "PROBLEM", 128, 146], ["BronchodilatorsShort-acting inhaled anticholinergics", "TREATMENT", 153, 205], ["ipratropium bromide", "TREATMENT", 213, 232], ["inhaled beta-agonist therapy", "TREATMENT", 259, 287], ["no", "UNCERTAINTY", 18, 20]]], ["Data are mixed whether the combination of anticholinergic and beta-agonists produce bronchodilation in excess of either alone [21, 22] .BronchodilatorsNeither intravenous methylxanthines nor beta-agonists are recommended for the treatment of COPD exacerbation.GlucocorticoidsSystemic glucocorticoids should be given to all patients admitted to the hospital for AECOPD.", [["intravenous", "ANATOMY", 159, 170], ["beta-agonists", "CHEMICAL", 62, 75], ["methylxanthines", "CHEMICAL", 171, 186], ["COPD", "DISEASE", 242, 246], ["glucocorticoids", "CHEMICAL", 284, 299], ["AECOPD", "DISEASE", 361, 367], ["methylxanthines", "CHEMICAL", 171, 186], ["beta-agonists", "SIMPLE_CHEMICAL", 62, 75], ["intravenous methylxanthines", "SIMPLE_CHEMICAL", 159, 186], ["patients", "ORGANISM", 323, 331], ["patients", "SPECIES", 323, 331], ["anticholinergic and beta-agonists", "TREATMENT", 42, 75], ["bronchodilation", "TREATMENT", 84, 99], ["Bronchodilators", "TREATMENT", 136, 151], ["intravenous methylxanthines", "TREATMENT", 159, 186], ["beta-agonists", "TREATMENT", 191, 204], ["COPD exacerbation", "PROBLEM", 242, 259], ["GlucocorticoidsSystemic glucocorticoids", "TREATMENT", 260, 299], ["AECOPD", "PROBLEM", 361, 367], ["COPD", "OBSERVATION", 242, 246], ["AECOPD", "OBSERVATION", 361, 367]]], ["This therapy improves lung function, reduces rates of treatment failure, improves symptoms and decreases length of stay [23, 24] .", [["lung", "ANATOMY", 22, 26], ["lung", "ORGAN", 22, 26], ["This therapy", "TREATMENT", 0, 12], ["treatment failure", "PROBLEM", 54, 71], ["improves symptoms", "PROBLEM", 73, 90], ["lung", "ANATOMY", 22, 26], ["decreases", "OBSERVATION_MODIFIER", 95, 104], ["length", "OBSERVATION_MODIFIER", 105, 111]]], ["One systematic review established that ten patients would need to be treated with systemic corticosteroids to prevent one treatment failure [25] .", [["patients", "ORGANISM", 43, 51], ["patients", "SPECIES", 43, 51], ["systemic corticosteroids", "TREATMENT", 82, 106], ["one treatment failure", "PROBLEM", 118, 139]]], ["Intravenous corticosteroids offer no advantage over oral therapy, unless the patient cannot tolerate oral medication [26, 27] .", [["oral", "ANATOMY", 52, 56], ["oral", "ANATOMY", 101, 105], ["oral", "ORGANISM_SUBDIVISION", 52, 56], ["patient", "ORGANISM", 77, 84], ["oral", "ORGANISM_SUBDIVISION", 101, 105], ["patient", "SPECIES", 77, 84], ["Intravenous corticosteroids", "TREATMENT", 0, 27], ["oral therapy", "TREATMENT", 52, 64], ["oral medication", "TREATMENT", 101, 116]]], ["Oral steroids should be stopped after 5 days if the patient has improved clinically.", [["Oral", "ANATOMY", 0, 4], ["steroids", "CHEMICAL", 5, 13], ["steroids", "CHEMICAL", 5, 13], ["patient", "ORGANISM", 52, 59], ["patient", "SPECIES", 52, 59], ["Oral steroids", "TREATMENT", 0, 13]]], ["In a single randomized-controlled trial, a five-day course of oral prednisone in AECOPD was shown to be non-inferior to a 14-day course [28] .GlucocorticoidsThe ideal dose of corticosteroids in COPD exacerbations is unknown.", [["oral", "ANATOMY", 62, 66], ["prednisone", "CHEMICAL", 67, 77], ["AECOPD", "DISEASE", 81, 87], ["corticosteroids", "CHEMICAL", 175, 190], ["COPD", "DISEASE", 194, 198], ["prednisone", "CHEMICAL", 67, 77], ["corticosteroids", "CHEMICAL", 175, 190], ["oral", "ORGANISM_SUBDIVISION", 62, 66], ["prednisone", "SIMPLE_CHEMICAL", 67, 77], ["oral prednisone", "TREATMENT", 62, 77], ["AECOPD", "PROBLEM", 81, 87], ["Glucocorticoids", "TREATMENT", 142, 157], ["corticosteroids", "TREATMENT", 175, 190], ["COPD exacerbations", "PROBLEM", 194, 212], ["COPD", "OBSERVATION", 194, 198]]], ["The GOLD guidelines recommend the dose equivalent of 40 mg of prednisone once daily [7] .", [["prednisone", "CHEMICAL", 62, 72], ["prednisone", "CHEMICAL", 62, 72], ["prednisone", "SIMPLE_CHEMICAL", 62, 72], ["prednisone", "TREATMENT", 62, 72]]], ["Published dosing regimens range from 40 mg of prednisone once daily to 125 mg of methylprednisolone up to four times a day [7, 27, 29] .", [["prednisone", "CHEMICAL", 46, 56], ["methylprednisolone", "CHEMICAL", 81, 99], ["prednisone", "CHEMICAL", 46, 56], ["methylprednisolone", "CHEMICAL", 81, 99], ["prednisone", "SIMPLE_CHEMICAL", 46, 56], ["methylprednisolone", "SIMPLE_CHEMICAL", 81, 99], ["Published dosing regimens", "TREATMENT", 0, 25], ["prednisone", "TREATMENT", 46, 56], ["methylprednisolone", "TREATMENT", 81, 99]]], ["Systemic steroids, especially at higher doses, have been associated with hyperglycemia [30] .AntibioticsAlthough not all COPD exacerbations are due to bacterial pathogens, antibiotics are recommended for all patients with moderate to severe exacerbations, including all patients requiring hospitalization [7] .", [["steroids", "CHEMICAL", 9, 17], ["hyperglycemia", "DISEASE", 73, 86], ["COPD", "DISEASE", 121, 125], ["exacerbations", "DISEASE", 241, 254], ["steroids", "CHEMICAL", 9, 17], ["patients", "ORGANISM", 208, 216], ["patients", "ORGANISM", 270, 278], ["patients", "SPECIES", 208, 216], ["patients", "SPECIES", 270, 278], ["Systemic steroids", "TREATMENT", 0, 17], ["hyperglycemia", "PROBLEM", 73, 86], ["Antibiotics", "TREATMENT", 93, 104], ["all COPD exacerbations", "PROBLEM", 117, 139], ["bacterial pathogens", "PROBLEM", 151, 170], ["antibiotics", "TREATMENT", 172, 183], ["moderate to severe exacerbations", "PROBLEM", 222, 254], ["steroids", "OBSERVATION", 9, 17], ["moderate", "OBSERVATION_MODIFIER", 222, 230], ["severe", "OBSERVATION_MODIFIER", 234, 240], ["exacerbations", "OBSERVATION", 241, 254]]], ["Antibiotics have been shown to reduce treatment failure in severe exacerbations [31] .AntibioticsSeveral attempts have been made to define subgroups who may benefit from antibiotics: for example, those with purulent sputum, elevated c-reactive protein (CRP) or procalcitonin.", [["purulent sputum", "ANATOMY", 207, 222], ["c-reactive protein", "GENE_OR_GENE_PRODUCT", 233, 251], ["CRP", "GENE_OR_GENE_PRODUCT", 253, 256], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 261, 274], ["c-reactive protein", "PROTEIN", 233, 251], ["CRP", "PROTEIN", 253, 256], ["procalcitonin", "PROTEIN", 261, 274], ["Antibiotics", "TREATMENT", 0, 11], ["treatment failure", "PROBLEM", 38, 55], ["severe exacerbations", "PROBLEM", 59, 79], ["Antibiotics", "TREATMENT", 86, 97], ["antibiotics", "TREATMENT", 170, 181], ["purulent sputum", "PROBLEM", 207, 222], ["elevated c-reactive protein", "PROBLEM", 224, 251], ["CRP", "TEST", 253, 256], ["procalcitonin", "TEST", 261, 274], ["severe", "OBSERVATION_MODIFIER", 59, 65], ["exacerbations", "OBSERVATION", 66, 79]]], ["Sputum purulence may be related to bacterial infection, but a clinical benefit from antibiotics has not been established prospectively in this group [32, 33] .", [["Sputum", "ANATOMY", 0, 6], ["bacterial infection", "DISEASE", 35, 54], ["Sputum purulence", "PROBLEM", 0, 16], ["bacterial infection", "PROBLEM", 35, 54], ["antibiotics", "TREATMENT", 84, 95], ["purulence", "OBSERVATION", 7, 16], ["may be related to", "UNCERTAINTY", 17, 34], ["bacterial", "OBSERVATION_MODIFIER", 35, 44], ["infection", "OBSERVATION", 45, 54]]], ["Clark et al. showed that an elevated CRP did not reliably distinguish between viral and bacterial infections so is unhelpful in guiding the decision to use antibiotics [34] .", [["viral and bacterial infections", "DISEASE", 78, 108], ["CRP", "GENE_OR_GENE_PRODUCT", 37, 40], ["CRP", "PROTEIN", 37, 40], ["an elevated CRP", "PROBLEM", 25, 40], ["viral and bacterial infections", "PROBLEM", 78, 108], ["antibiotics", "TREATMENT", 156, 167], ["elevated", "OBSERVATION", 28, 36], ["bacterial", "OBSERVATION_MODIFIER", 88, 97], ["infections", "OBSERVATION", 98, 108]]], ["Procalcitonin is a promising biomarker, which may help distinguish bacterial and viral infections [35] .", [["bacterial and viral infections", "DISEASE", 67, 97], ["Procalcitonin", "GENE_OR_GENE_PRODUCT", 0, 13], ["Procalcitonin", "TREATMENT", 0, 13], ["bacterial and viral infections", "PROBLEM", 67, 97], ["viral", "OBSERVATION_MODIFIER", 81, 86], ["infections", "OBSERVATION", 87, 97]]], ["Procalcitonin-guided antibiotic use was associated with similar outcomes but less antibiotic exposure in AECOPD [35] .", [["AECOPD", "DISEASE", 105, 111], ["Procalcitonin", "TREATMENT", 0, 13], ["antibiotic use", "TREATMENT", 21, 35], ["AECOPD", "PROBLEM", 105, 111]]], ["However, more recent data including patients with either pneumonia or AECOPD failed to replicate this finding [36] .AntibioticsThe antibiotic choice for COPD exacerbations should reflect local antibiograms and resistance patterns.", [["pneumonia", "DISEASE", 57, 66], ["AECOPD", "DISEASE", 70, 76], ["COPD", "DISEASE", 153, 157], ["patients", "ORGANISM", 36, 44], ["patients", "SPECIES", 36, 44], ["pneumonia", "PROBLEM", 57, 66], ["AECOPD", "PROBLEM", 70, 76], ["Antibiotics", "TREATMENT", 116, 127], ["The antibiotic choice", "TREATMENT", 127, 148], ["COPD exacerbations", "PROBLEM", 153, 171], ["local antibiograms", "TEST", 187, 205], ["pneumonia", "OBSERVATION", 57, 66], ["AECOPD", "OBSERVATION", 70, 76]]], ["Typical duration is 5 days [7] , which has similar treatment success to 7 and 10 day courses [37] .Smoking CessationAlthough not a treatment for the acute exacerbation, smoking cessation should be addressed in patients who smoke cigarettes and present to a healthcare setting with acute symptoms.", [["smoking", "CHEMICAL", 169, 176], ["patients", "ORGANISM", 210, 218], ["patients", "SPECIES", 210, 218], ["a treatment", "TREATMENT", 129, 140], ["the acute exacerbation", "PROBLEM", 145, 167], ["acute symptoms", "PROBLEM", 281, 295], ["acute", "OBSERVATION_MODIFIER", 149, 154], ["exacerbation", "OBSERVATION", 155, 167]]], ["Smoking cessation can reduce the frequency of COPD exacerbations by one third [5] .", [["COPD", "DISEASE", 46, 50], ["COPD exacerbations", "PROBLEM", 46, 64], ["COPD", "OBSERVATION", 46, 50]]], ["Several effective therapies are available which may promote sustained abstinence from smoking, although a combination of pharmacotherapy with behavioral modifications have the most robust evidence [38] .Extracorporeal Carbon Dioxide RemovalExtracorporeal carbon dioxide removal (ECCO2R) refers to the removal of carbon dioxide (CO 2 ) from the blood via an extracorporeal gas exchanger.", [["blood", "ANATOMY", 344, 349], ["smoking", "CHEMICAL", 86, 93], ["Carbon Dioxide", "CHEMICAL", 218, 232], ["carbon dioxide", "CHEMICAL", 255, 269], ["carbon dioxide", "CHEMICAL", 312, 326], ["CO 2", "CHEMICAL", 328, 332], ["Carbon Dioxide", "CHEMICAL", 218, 232], ["carbon dioxide", "CHEMICAL", 255, 269], ["carbon dioxide", "CHEMICAL", 312, 326], ["CO 2", "CHEMICAL", 328, 332], ["Carbon Dioxide", "SIMPLE_CHEMICAL", 218, 232], ["Extracorporeal carbon dioxide", "SIMPLE_CHEMICAL", 240, 269], ["carbon dioxide", "SIMPLE_CHEMICAL", 312, 326], ["CO 2", "SIMPLE_CHEMICAL", 328, 332], ["blood", "ORGANISM_SUBSTANCE", 344, 349], ["Several effective therapies", "TREATMENT", 0, 27], ["pharmacotherapy", "TREATMENT", 121, 136], ["behavioral modifications", "TREATMENT", 142, 166], ["Extracorporeal Carbon Dioxide Removal", "TREATMENT", 203, 240], ["Extracorporeal carbon dioxide removal", "TREATMENT", 240, 277], ["the removal of carbon dioxide", "TREATMENT", 297, 326], ["the blood", "TEST", 340, 349], ["an extracorporeal gas exchanger", "TREATMENT", 354, 385], ["Carbon", "OBSERVATION", 218, 224], ["Dioxide Removal", "OBSERVATION", 225, 240], ["carbon dioxide", "OBSERVATION", 255, 269], ["blood", "ANATOMY", 344, 349], ["extracorporeal", "OBSERVATION", 357, 371], ["gas exchanger", "OBSERVATION", 372, 385]]], ["This process, initially explored for the acute respiratory distress syndrome (ARDS), can be part of conventional venovenous (VV) extracorporeal membrane oxygenation (ECMO) or arteriovenous (AV) ECMO [39] .", [["respiratory", "ANATOMY", 47, 58], ["extracorporeal membrane", "ANATOMY", 129, 152], ["arteriovenous", "ANATOMY", 175, 188], ["acute respiratory distress syndrome", "DISEASE", 41, 76], ["ARDS", "DISEASE", 78, 82], ["arteriovenous", "MULTI-TISSUE_STRUCTURE", 175, 188], ["VV", "SPECIES", 125, 127], ["the acute respiratory distress syndrome", "PROBLEM", 37, 76], ["ARDS", "PROBLEM", 78, 82], ["conventional venovenous (VV) extracorporeal membrane oxygenation", "TREATMENT", 100, 164], ["arteriovenous (AV) ECMO", "TREATMENT", 175, 198], ["acute", "OBSERVATION_MODIFIER", 41, 46], ["respiratory distress", "OBSERVATION", 47, 67], ["venovenous", "OBSERVATION", 113, 123]]], ["However, more recently, lower flow circuits of only 0.3-1 L/min have been proposed for the purposes of CO 2 removal, particularly in AECOPD to supplement NIPPV and prevent the need for endotracheal intubation [39, 40] .", [["endotracheal", "ANATOMY", 185, 197], ["AECOPD", "DISEASE", 133, 139], ["CO 2", "CHEMICAL", 103, 107], ["CO 2", "SIMPLE_CHEMICAL", 103, 107], ["lower flow circuits", "TREATMENT", 24, 43], ["CO 2 removal", "TREATMENT", 103, 115], ["AECOPD", "PROBLEM", 133, 139], ["NIPPV", "TREATMENT", 154, 159], ["endotracheal intubation", "TREATMENT", 185, 208], ["AECOPD", "OBSERVATION", 133, 139]]], ["One retrospective analysis compared 21 patients with AECOPD who did not improve on NIPPV and were subsequently intubated with 21 patients treated with a pumpless extracorporeal lung-assist device (PECLA).", [["lung", "ANATOMY", 177, 181], ["AECOPD", "DISEASE", 53, 59], ["patients", "ORGANISM", 39, 47], ["patients", "ORGANISM", 129, 137], ["lung", "ORGAN", 177, 181], ["patients", "SPECIES", 39, 47], ["patients", "SPECIES", 129, 137], ["One retrospective analysis", "TEST", 0, 26], ["AECOPD", "PROBLEM", 53, 59], ["NIPPV", "TREATMENT", 83, 88], ["a pumpless extracorporeal lung-assist device", "TREATMENT", 151, 195], ["lung", "ANATOMY", 177, 181]]], ["No difference was noted in ICU or hospital stay, though those treated with PECLA had reduction in PCO 2 , improvement in pH, and required no sedation, allowing them to eat, exercise and communicate [41] .Extracorporeal Carbon Dioxide RemovalOthers have evaluated ECCO2R as a tool to facilitate extubation in patients with AECOPD with some success, though in very small numbers: n = 5 and n = 20, respectively [42, 43] .", [["PECLA", "CHEMICAL", 75, 80], ["PCO", "DISEASE", 98, 101], ["Carbon Dioxide", "CHEMICAL", 219, 233], ["AECOPD", "DISEASE", 322, 328], ["Carbon Dioxide", "CHEMICAL", 219, 233], ["Carbon Dioxide RemovalOthers", "SIMPLE_CHEMICAL", 219, 247], ["ECCO2R", "SIMPLE_CHEMICAL", 263, 269], ["patients", "ORGANISM", 308, 316], ["patients", "SPECIES", 308, 316], ["PECLA", "TREATMENT", 75, 80], ["reduction in PCO", "TREATMENT", 85, 101], ["pH", "TEST", 121, 123], ["sedation", "TREATMENT", 141, 149], ["Extracorporeal Carbon Dioxide RemovalOthers", "TREATMENT", 204, 247], ["extubation", "TREATMENT", 294, 304], ["AECOPD", "PROBLEM", 322, 328], ["difference", "OBSERVATION_MODIFIER", 3, 13], ["Carbon Dioxide", "OBSERVATION", 219, 233]]], ["Other small studies have been published with similar benefits, but reported significant bleeding complications [44, 45] .", [["bleeding", "DISEASE", 88, 96], ["Other small studies", "TEST", 0, 19], ["significant bleeding complications", "PROBLEM", 76, 110], ["small", "OBSERVATION_MODIFIER", 6, 11], ["significant", "OBSERVATION_MODIFIER", 76, 87], ["bleeding", "OBSERVATION", 88, 96]]], ["A recent metaanlaysis concluded that ECCO2R for AECOPD is still experimental, noting both potential benefit, but also serious risk for complications [46] .", [["ECCO2R", "CHEMICAL", 37, 43], ["AECOPD", "DISEASE", 48, 54], ["ECCO2R", "SIMPLE_CHEMICAL", 37, 43], ["A recent metaanlaysis", "PROBLEM", 0, 21], ["AECOPD", "PROBLEM", 48, 54], ["complications", "PROBLEM", 135, 148]]], ["No prospective randomized trials on the subject have been published, though several are ongoing [40] .AECOPD and Thromboembolic DiseaseThere is a high prevalence of pulmonary embolism (PE) in the setting of unexplained AECOPD, ranging from 16-25% [47] [48] [49] .", [["pulmonary", "ANATOMY", 165, 174], ["AECOPD", "DISEASE", 102, 108], ["Thromboembolic DiseaseThere", "DISEASE", 113, 140], ["pulmonary embolism", "DISEASE", 165, 183], ["PE", "DISEASE", 185, 187], ["AECOPD", "DISEASE", 219, 225], ["pulmonary", "ORGAN", 165, 174], ["prospective randomized trials", "TREATMENT", 3, 32], ["AECOPD", "PROBLEM", 102, 108], ["Thromboembolic DiseaseThere", "PROBLEM", 113, 140], ["pulmonary embolism", "PROBLEM", 165, 183], ["PE", "PROBLEM", 185, 187], ["unexplained AECOPD", "PROBLEM", 207, 225], ["Thromboembolic", "OBSERVATION", 113, 127], ["high", "OBSERVATION_MODIFIER", 146, 150], ["pulmonary", "ANATOMY", 165, 174], ["embolism", "OBSERVATION", 175, 183], ["PE", "OBSERVATION", 185, 187], ["unexplained", "OBSERVATION_MODIFIER", 207, 218], ["AECOPD", "OBSERVATION", 219, 225]]], ["A recent systematic review including 880 patients demonstrated a prevalence of 16.1%, with the majority of the clots located in proximal rather than subsegmental arteries [49] .", [["clots", "ANATOMY", 111, 116], ["subsegmental arteries", "ANATOMY", 149, 170], ["patients", "ORGANISM", 41, 49], ["clots", "ORGANISM_SUBSTANCE", 111, 116], ["subsegmental arteries", "MULTI-TISSUE_STRUCTURE", 149, 170], ["patients", "SPECIES", 41, 49], ["the clots", "PROBLEM", 107, 116], ["majority", "OBSERVATION_MODIFIER", 95, 103], ["clots", "OBSERVATION", 111, 116], ["proximal", "ANATOMY_MODIFIER", 128, 136], ["subsegmental arteries", "ANATOMY", 149, 170]]], ["In this analysis, patients with PE and AECOPD had longer hospital stays and higher mortality.", [["PE", "DISEASE", 32, 34], ["AECOPD", "DISEASE", 39, 45], ["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26], ["this analysis", "TEST", 3, 16], ["PE", "PROBLEM", 32, 34], ["AECOPD", "PROBLEM", 39, 45], ["PE", "OBSERVATION", 32, 34], ["AECOPD", "OBSERVATION", 39, 45]]], ["The mechanistic connection between AECOPD and thromboembolic disease is not clear at this time, and there is no established causal link between PE and AECOPD.", [["AECOPD", "DISEASE", 35, 41], ["thromboembolic disease", "DISEASE", 46, 68], ["PE", "DISEASE", 144, 146], ["AECOPD", "DISEASE", 151, 157], ["AECOPD", "PROBLEM", 35, 41], ["thromboembolic disease", "PROBLEM", 46, 68], ["PE", "PROBLEM", 144, 146], ["AECOPD", "PROBLEM", 151, 157], ["AECOPD", "OBSERVATION", 35, 41], ["thromboembolic", "OBSERVATION", 46, 60], ["no established", "UNCERTAINTY", 109, 123], ["PE", "OBSERVATION", 144, 146], ["AECOPD", "OBSERVATION", 151, 157]]], ["Clinicians should maintain a high level of suspicion for thromboembolic disease when caring for patients with AECOPD given the known association and implications for management, specifically the need for anticoagulation.", [["thromboembolic disease", "DISEASE", 57, 79], ["AECOPD", "DISEASE", 110, 116], ["patients", "ORGANISM", 96, 104], ["patients", "SPECIES", 96, 104], ["thromboembolic disease", "PROBLEM", 57, 79], ["AECOPD", "PROBLEM", 110, 116], ["management", "TREATMENT", 166, 176], ["anticoagulation", "TREATMENT", 204, 219], ["suspicion for", "UNCERTAINTY", 43, 56], ["thromboembolic", "OBSERVATION", 57, 71]]]], "51a9f0de2c657fd582c5ff023027833d48e4876b": [["IntroductionDengue virus (DENV) is a flavivirus with four related but antigenically distinct serotypes (DENV1-4).", [["flavivirus", "DISEASE", 37, 47], ["IntroductionDengue virus", "ORGANISM", 0, 24], ["DENV", "ORGANISM", 26, 30], ["DENV1-4", "CELL", 104, 111], ["IntroductionDengue virus", "SPECIES", 0, 24], ["DENV", "SPECIES", 26, 30], ["IntroductionDengue virus (DENV", "PROBLEM", 0, 30], ["a flavivirus", "PROBLEM", 35, 47], ["antigenically distinct serotypes", "PROBLEM", 70, 102], ["distinct", "OBSERVATION_MODIFIER", 84, 92], ["serotypes", "OBSERVATION", 93, 102]]], ["It infects approximately 50-100 million people each year, of which 500,000 people exhibit the life-threatening form of severe dengue -dengue haemorrhagic fever (DHF) and dengue shock syndrome (DSS) [1] .", [["dengue -dengue haemorrhagic fever", "DISEASE", 126, 159], ["DHF", "DISEASE", 161, 164], ["dengue shock syndrome", "DISEASE", 170, 191], ["DSS", "DISEASE", 193, 196], ["people", "ORGANISM", 40, 46], ["people", "ORGANISM", 75, 81], ["people", "SPECIES", 40, 46], ["people", "SPECIES", 75, 81], ["dengue -dengue haemorrhagic fever", "SPECIES", 126, 159], ["severe dengue -dengue haemorrhagic fever", "PROBLEM", 119, 159], ["DHF", "PROBLEM", 161, 164], ["dengue shock syndrome", "PROBLEM", 170, 191], ["severe", "OBSERVATION_MODIFIER", 119, 125], ["dengue", "OBSERVATION", 126, 132], ["shock syndrome", "OBSERVATION", 177, 191]]], ["The current lack of treatment or licensed vaccine means dengue poses a serious public health threat [2] .", [["dengue", "DISEASE", 56, 62], ["dengue", "SPECIES", 56, 62], ["treatment", "TREATMENT", 20, 29], ["licensed vaccine", "TREATMENT", 33, 49]]], ["Infection by one serotype of DENV confers lifelong immunity against the homologous serotype, but only limited crossprotection to the remaining three serotypes [3, 4] .", [["DENV", "ORGANISM", 29, 33], ["DENV", "SPECIES", 29, 33], ["Infection", "PROBLEM", 0, 9], ["DENV", "PROBLEM", 29, 33], ["the homologous serotype", "PROBLEM", 68, 91]]], ["The presence of cross-reactive, non-neutralizing antibodies generated during a primary infection has been suggested to enhance the pathogenicity of subsequent infections via the process of antibody-dependent enhancement (ADE) [5] .", [["primary infection", "DISEASE", 79, 96], ["infections", "DISEASE", 159, 169], ["non-neutralizing antibodies", "PROTEIN", 32, 59], ["cross-reactive, non-neutralizing antibodies", "PROBLEM", 16, 59], ["a primary infection", "PROBLEM", 77, 96], ["subsequent infections", "PROBLEM", 148, 169], ["antibody-dependent enhancement", "PROBLEM", 189, 219], ["cross-reactive", "OBSERVATION_MODIFIER", 16, 30], ["non-neutralizing antibodies", "OBSERVATION", 32, 59], ["infection", "OBSERVATION", 87, 96], ["infections", "OBSERVATION", 159, 169], ["dependent", "OBSERVATION_MODIFIER", 198, 207], ["enhancement", "OBSERVATION_MODIFIER", 208, 219]]], ["A successful and safe vaccine candidate must therefore elicit a protective long-lasting immune response to all four serotypes [4, [6] [7] [8] .IntroductionRecent immunological studies have shown the human anti-DENV immune response to be dominated by prM-specific antibodies in both primary and secondary infections [9, 10] .", [["primary and secondary infections", "DISEASE", 282, 314], ["[6] [7", "SIMPLE_CHEMICAL", 130, 136], ["human", "ORGANISM", 199, 204], ["anti-DENV", "CANCER", 205, 214], ["prM-specific antibodies", "PROTEIN", 250, 273], ["human", "SPECIES", 199, 204], ["human", "SPECIES", 199, 204], ["A successful and safe vaccine", "TREATMENT", 0, 29], ["a protective long-lasting immune response", "TREATMENT", 62, 103], ["Recent immunological studies", "TEST", 155, 183], ["prM-specific antibodies", "PROBLEM", 250, 273], ["secondary infections", "PROBLEM", 294, 314], ["secondary", "OBSERVATION_MODIFIER", 294, 303], ["infections", "OBSERVATION", 304, 314]]], ["These prM-specific antibodies are highly cross-reactive and non-neutralizing.", [["prM-specific antibodies", "PROTEIN", 6, 29], ["These prM-specific antibodies", "TEST", 0, 29], ["highly", "OBSERVATION_MODIFIER", 34, 40], ["cross-reactive", "OBSERVATION", 41, 55]]], ["When complexed with immature DENV (imDENV), it has the ability to render normally non-infectious imDENV highly infectious [11, 12] .", [["DENV", "ORGANISM", 29, 33], ["imDENV", "GENE_OR_GENE_PRODUCT", 35, 41], ["imDENV", "PROTEIN", 35, 41], ["DENV", "SPECIES", 29, 33], ["imDENV", "SPECIES", 35, 41], ["immature DENV", "PROBLEM", 20, 33], ["immature", "OBSERVATION_MODIFIER", 20, 28], ["DENV", "OBSERVATION", 29, 33], ["non-infectious", "OBSERVATION", 82, 96], ["infectious", "OBSERVATION", 111, 121]]], ["This has caused concern over current vaccine candidates that contain native dengue prM [9] -which is a component of most current vaccine strategies whether naturally attenuated, recombinantly attenuated, yellow fever-dengue-virus chimeras, chemically inacti-vated virus, DNA vaccine or recombinant subunit protein vaccines [13, 14] .", [["dengue", "DISEASE", 76, 82], ["fever", "DISEASE", 211, 216], ["dengue", "DISEASE", 217, 223], ["dengue prM", "ORGANISM", 76, 86], ["yellow fever-dengue-virus chimeras", "ORGANISM", 204, 238], ["DNA", "CELLULAR_COMPONENT", 271, 274], ["recombinant subunit protein", "PROTEIN", 286, 313], ["yellow fever-dengue-virus", "SPECIES", 204, 229], ["yellow fever-dengue-virus", "SPECIES", 204, 229], ["current vaccine candidates", "TREATMENT", 29, 55], ["native dengue prM", "PROBLEM", 69, 86], ["most current vaccine strategies", "TREATMENT", 116, 147], ["yellow fever", "PROBLEM", 204, 216], ["dengue", "PROBLEM", 217, 223], ["virus chimeras", "PROBLEM", 224, 238], ["chemically inacti-vated virus", "PROBLEM", 240, 269], ["DNA vaccine", "TREATMENT", 271, 282], ["recombinant subunit protein vaccines", "TREATMENT", 286, 322]]], ["Vaccine candidates that do not contain prM proteins, such as soluble recombinant Envelope (E) protein or E domain subunit vaccines may thus become increasingly important.IntroductionTo gain a deeper understanding of the early DENV-specific immune response in humans, the four serotypes of DENV were sequentially screened with a non-immunized human Fab phage display library.", [["prM", "GENE_OR_GENE_PRODUCT", 39, 42], ["Envelope (E) protein", "GENE_OR_GENE_PRODUCT", 81, 101], ["humans", "ORGANISM", 259, 265], ["DENV", "ORGANISM", 289, 293], ["human", "ORGANISM", 342, 347], ["Fab", "GENE_OR_GENE_PRODUCT", 348, 351], ["prM proteins", "PROTEIN", 39, 51], ["soluble recombinant Envelope (E) protein", "PROTEIN", 61, 101], ["E domain subunit", "PROTEIN", 105, 121], ["non-immunized human Fab phage display library", "DNA", 328, 373], ["humans", "SPECIES", 259, 265], ["human", "SPECIES", 342, 347], ["DENV", "SPECIES", 226, 230], ["humans", "SPECIES", 259, 265], ["DENV", "SPECIES", 289, 293], ["human", "SPECIES", 342, 347], ["Vaccine candidates", "TREATMENT", 0, 18], ["prM proteins", "PROBLEM", 39, 51], ["soluble recombinant Envelope (E) protein or E domain subunit vaccines", "TREATMENT", 61, 130], ["the early DENV", "PROBLEM", 216, 230], ["DENV", "PROBLEM", 289, 293], ["a non-immunized human Fab phage", "TREATMENT", 326, 357]]], ["Broadly cross-reactive prM-specific antibodies dominated the screen and the Fab with highest affinity, D29 Fab-IgG, was converted into full-length human IgG1 format for thorough characterization.", [["Fab", "GENE_OR_GENE_PRODUCT", 76, 79], ["IgG", "GENE_OR_GENE_PRODUCT", 111, 114], ["human", "ORGANISM", 147, 152], ["IgG1", "GENE_OR_GENE_PRODUCT", 153, 157], ["cross-reactive prM-specific antibodies", "PROTEIN", 8, 46], ["Fab", "PROTEIN", 76, 79], ["D29 Fab", "PROTEIN", 103, 110], ["IgG", "PROTEIN", 111, 114], ["IgG1", "PROTEIN", 153, 157], ["human", "SPECIES", 147, 152], ["human", "SPECIES", 147, 152], ["Broadly cross-reactive prM-specific antibodies", "TEST", 0, 46], ["the screen", "TEST", 57, 67], ["the Fab", "TEST", 72, 79], ["highest affinity", "TEST", 85, 101], ["thorough characterization", "TEST", 169, 194]]], ["This antibody (D29 Fab-IgG) was found to have high affinity for a conformational epitope on prM and, like other prM antibodies [11, 12] , was capable of restoring the infectivity of virtually non-infectious immature DENV (imDENV) in FccR-bearing K562 cells.", [["FccR", "ANATOMY", 233, 237], ["K562 cells", "ANATOMY", 246, 256], ["D29 Fab-IgG", "GENE_OR_GENE_PRODUCT", 15, 26], ["prM", "GENE_OR_GENE_PRODUCT", 92, 95], ["DENV", "ORGANISM", 216, 220], ["FccR", "CELL", 233, 237], ["K562 cells", "CELL", 246, 256], ["D29 Fab", "PROTEIN", 15, 22], ["IgG", "PROTEIN", 23, 26], ["conformational epitope", "PROTEIN", 66, 88], ["prM", "PROTEIN", 92, 95], ["prM antibodies", "PROTEIN", 112, 126], ["FccR-bearing K562 cells", "CELL_LINE", 233, 256], ["DENV", "SPECIES", 216, 220], ["imDENV", "SPECIES", 222, 228], ["This antibody", "TEST", 0, 13], ["D29 Fab-IgG", "TEST", 15, 26], ["high affinity", "PROBLEM", 46, 59], ["a conformational epitope on prM", "PROBLEM", 64, 95], ["other prM antibodies", "TEST", 106, 126], ["virtually non-infectious immature DENV", "PROBLEM", 182, 220], ["non-infectious", "OBSERVATION_MODIFIER", 192, 206], ["DENV", "OBSERVATION", 216, 220], ["bearing K562 cells", "OBSERVATION", 238, 256]]], ["The antibody also cross-reacted with E protein -fine mapping and site-directed mutagenesis studies localized the epitope to the DI/ DII junction of E, which would be inaccessible in a native virus particle.", [["E", "GENE_OR_GENE_PRODUCT", 148, 149], ["E protein", "PROTEIN", 37, 46], ["The antibody", "TEST", 0, 12], ["E protein", "TEST", 37, 46], ["directed mutagenesis studies", "TEST", 70, 98], ["a native virus particle", "PROBLEM", 182, 205], ["native virus particle", "OBSERVATION", 184, 205]]], ["This suggests the possibility that immunization strategies employing E protein alone or subunits of E proteins may not be able to completely avoid generation of anti-prM antibodies that enhance DENV infection.CellsAedes albopictus C6/36 cells (ATCC) were maintained in Leibovitz L-15 media (GIBCO, Invitrogen) supplemented with 8% fetal bovine serum (FBS), at 28 o C, 5% CO 2 .", [["C6/36 cells", "ANATOMY", 231, 242], ["ATCC", "ANATOMY", 244, 248], ["fetal bovine serum", "ANATOMY", 331, 349], ["FBS", "ANATOMY", 351, 354], ["DENV infection", "DISEASE", 194, 208], ["CO", "CHEMICAL", 371, 373], ["E protein", "GENE_OR_GENE_PRODUCT", 69, 78], ["E", "GENE_OR_GENE_PRODUCT", 100, 101], ["anti-prM antibodies", "GENE_OR_GENE_PRODUCT", 161, 180], ["DENV", "ORGANISM", 194, 198], ["CellsAedes albopictus C6/36 cells", "CELL", 209, 242], ["ATCC", "CELL", 244, 248], ["bovine", "ORGANISM", 337, 343], ["serum", "ORGANISM_SUBSTANCE", 344, 349], ["FBS", "ORGANISM_SUBSTANCE", 351, 354], ["E protein", "PROTEIN", 69, 78], ["E proteins", "PROTEIN", 100, 110], ["anti-prM antibodies", "PROTEIN", 161, 180], ["C6/36 cells", "CELL_LINE", 231, 242], ["ATCC", "CELL_LINE", 244, 248], ["bovine", "SPECIES", 337, 343], ["DENV", "SPECIES", 194, 198], ["CellsAedes albopictus", "SPECIES", 209, 230], ["immunization strategies", "TREATMENT", 35, 58], ["E protein alone", "TREATMENT", 69, 84], ["subunits of E proteins", "TREATMENT", 88, 110], ["anti-prM antibodies", "PROBLEM", 161, 180], ["DENV infection", "PROBLEM", 194, 208], ["CellsAedes", "TEST", 209, 219], ["ATCC", "TEST", 244, 248], ["8% fetal bovine serum", "TEST", 328, 349], ["FBS", "TEST", 351, 354], ["suggests the possibility", "UNCERTAINTY", 5, 29], ["DENV", "OBSERVATION_MODIFIER", 194, 198], ["infection", "OBSERVATION", 199, 208]]], ["BHK-21 cells (ATCC) and human erythroleukemic K562 cells (ATCC) were maintained in RPMI 1640 GlutaMAX medium (RPMI) (GIBCO, Invitrogen) containing 10% FBS, and incubated at 37 o C, 5% CO 2 .", [["BHK-21 cells", "ANATOMY", 0, 12], ["ATCC", "ANATOMY", 14, 18], ["erythroleukemic K562 cells", "ANATOMY", 30, 56], ["ATCC", "ANATOMY", 58, 62], ["FBS", "ANATOMY", 151, 154], ["CO", "CHEMICAL", 184, 186], ["BHK-21 cells", "CELL", 0, 12], ["ATCC", "CELL", 14, 18], ["human", "ORGANISM", 24, 29], ["erythroleukemic K562 cells", "CELL", 30, 56], ["ATCC", "CELL", 58, 62], ["FBS", "ORGANISM_SUBSTANCE", 151, 154], ["BHK-21 cells", "CELL_LINE", 0, 12], ["ATCC", "CELL_LINE", 14, 18], ["human erythroleukemic K562 cells", "CELL_LINE", 24, 56], ["ATCC", "CELL_LINE", 58, 62], ["human", "SPECIES", 24, 29], ["human", "SPECIES", 24, 29], ["BHK", "TEST", 0, 3], ["ATCC", "TEST", 14, 18], ["human erythroleukemic K562 cells", "PROBLEM", 24, 56], ["ATCC", "TEST", 58, 62], ["GIBCO, Invitrogen)", "TREATMENT", 117, 135], ["21 cells", "OBSERVATION_MODIFIER", 4, 12], ["erythroleukemic K562 cells", "OBSERVATION", 30, 56]]], ["Vero cells (ATCC) were grown in 199 medium (M199) (GIBCO, Invitrogen) supplemented with 8% FBS, 1% sodium pyruvate and 1% NEAA.", [["Vero cells", "ANATOMY", 0, 10], ["ATCC", "ANATOMY", 12, 16], ["sodium pyruvate", "CHEMICAL", 99, 114], ["NEAA", "CHEMICAL", 122, 126], ["sodium pyruvate", "CHEMICAL", 99, 114], ["NEAA", "CHEMICAL", 122, 126], ["Vero cells", "CELL", 0, 10], ["ATCC", "CELL", 12, 16], ["FBS", "ORGANISM_SUBSTANCE", 91, 94], ["sodium", "SIMPLE_CHEMICAL", 99, 105], ["pyruvate", "SIMPLE_CHEMICAL", 106, 114], ["NEAA", "SIMPLE_CHEMICAL", 122, 126], ["Vero cells", "CELL_LINE", 0, 10], ["ATCC", "CELL_LINE", 12, 16], ["Vero cells (ATCC", "TEST", 0, 16], ["GIBCO", "TEST", 51, 56], ["Invitrogen", "TEST", 58, 68], ["FBS", "TEST", 91, 94], ["sodium pyruvate", "TEST", 99, 114]]], ["HEK293 T cells (ATCC) was cultured in Dulbecco's modified Eagle's medium (DMEM) (GIBCO, Invitrogen) supplemented with 10% FBS at 37 o C in 5% CO 2 .Antibodies and ProteinsMouse monoclonal antibodies 3H5 (m3H5), 4G2 (m4G2) and 2H2 (m2H2) are specific to EDIII of DENV2, EDII of flaviviruses and prM of DENV1-4 respectively.", [["HEK293 T cells", "ANATOMY", 0, 14], ["ATCC", "ANATOMY", 16, 20], ["CO 2", "CHEMICAL", 142, 146], ["HEK293 T cells", "CELL", 0, 14], ["ATCC", "CELL", 16, 20], ["FBS", "ORGANISM_SUBSTANCE", 122, 125], ["DENV2", "ORGANISM", 262, 267], ["HEK293 T cells", "CELL_LINE", 0, 14], ["ATCC", "CELL_LINE", 16, 20], ["ProteinsMouse monoclonal antibodies", "PROTEIN", 163, 198], ["3H5", "PROTEIN", 199, 202], ["m3H5", "PROTEIN", 204, 208], ["4G2", "PROTEIN", 211, 214], ["m4G2", "PROTEIN", 216, 220], ["2H2", "PROTEIN", 226, 229], ["m2H2", "PROTEIN", 231, 235], ["EDIII", "PROTEIN", 253, 258], ["DENV2", "PROTEIN", 262, 267], ["EDII", "PROTEIN", 269, 273], ["prM", "PROTEIN", 294, 297], ["DENV1", "PROTEIN", 301, 306], ["Mouse", "SPECIES", 171, 176], ["Mouse", "SPECIES", 171, 176], ["DENV2", "SPECIES", 262, 267], ["ATCC", "TEST", 16, 20], ["Dulbecco", "TEST", 38, 46], ["Antibodies", "TEST", 148, 158], ["ProteinsMouse monoclonal antibodies", "TEST", 163, 198], ["DENV2", "PROBLEM", 262, 267], ["flaviviruses", "PROBLEM", 277, 289], ["DENV1", "TEST", 301, 306]]], ["Chimeric humanized 3H5 (h3H5) and 4G2 (h4G2) were constructed by cloning the Fab portion (variable light and heavy chains) into an expression vector containing the human IgG1 framework for expression in HEK293 T cells [15] .", [["HEK293 T cells", "ANATOMY", 203, 217], ["3H5", "GENE_OR_GENE_PRODUCT", 19, 22], ["h3H5", "GENE_OR_GENE_PRODUCT", 24, 28], ["4G2", "GENE_OR_GENE_PRODUCT", 34, 37], ["Fab", "GENE_OR_GENE_PRODUCT", 77, 80], ["human", "ORGANISM", 164, 169], ["IgG1", "GENE_OR_GENE_PRODUCT", 170, 174], ["HEK293 T cells", "CELL", 203, 217], ["Chimeric humanized 3H5", "PROTEIN", 0, 22], ["h3H5", "PROTEIN", 24, 28], ["4G2", "CELL_LINE", 34, 37], ["h4G2", "CELL_LINE", 39, 43], ["Fab portion", "PROTEIN", 77, 88], ["variable light and heavy chains", "PROTEIN", 90, 121], ["human IgG1 framework", "PROTEIN", 164, 184], ["HEK293 T cells", "CELL_LINE", 203, 217], ["human", "SPECIES", 164, 169], ["human", "SPECIES", 164, 169], ["Chimeric humanized", "TREATMENT", 0, 18], ["variable light and heavy chains", "TREATMENT", 90, 121], ["an expression vector", "TREATMENT", 128, 148], ["the human IgG1 framework", "TREATMENT", 160, 184]]], ["Conjugation of HRP to antibodies-D29, -m3H5 and -m2H2, was performed using the Lightning-Link HRP Conjugation Kit (Innova Biosciences).Virus GrowthDengue 1 (DENV1) strain Hawaii, Dengue 2 (DENV2) strains New Guinea C (NGC) and ST, Dengue 3 (DENV3) strain H87 and Dengue 4 (DENV4) strain H241 were passaged in Vero cells for all assays unless otherwise stated.", [["Vero cells", "ANATOMY", 309, 319], ["HRP", "GENE_OR_GENE_PRODUCT", 15, 18], ["antibodies-D29", "GENE_OR_GENE_PRODUCT", 22, 36], ["-m3H5", "GENE_OR_GENE_PRODUCT", 38, 43], ["-m2H2", "GENE_OR_GENE_PRODUCT", 48, 53], ["Virus GrowthDengue 1", "ORGANISM", 135, 155], ["DENV1) strain Hawaii", "ORGANISM", 157, 177], ["Dengue 2", "ORGANISM", 179, 187], ["DENV2) strains New Guinea C", "ORGANISM", 189, 216], ["NGC", "ORGANISM", 218, 221], ["ST, Dengue 3", "ORGANISM", 227, 239], ["DENV3) strain H87", "ORGANISM", 241, 258], ["Dengue 4", "ORGANISM", 263, 271], ["DENV4", "ORGANISM", 273, 278], ["Vero cells", "CELL", 309, 319], ["HRP", "PROTEIN", 15, 18], ["antibodies", "PROTEIN", 22, 32], ["D29", "PROTEIN", 33, 36], ["-m3H5", "PROTEIN", 38, 43], ["-m2H2", "PROTEIN", 48, 53], ["Vero cells", "CELL_LINE", 309, 319], ["Virus GrowthDengue 1", "SPECIES", 135, 155], ["DENV2", "SPECIES", 189, 194], ["antibodies", "TEST", 22, 32], ["-m2H2", "TREATMENT", 48, 53], ["New Guinea C (NGC", "TEST", 204, 221], ["ST, Dengue 3 (DENV3) strain H87 and Dengue 4 (DENV4) strain H241", "PROBLEM", 227, 291], ["all assays", "TEST", 324, 334]]], ["Virus titers were determined by plaque assay on BHK cells.", [["plaque", "ANATOMY", 32, 38], ["BHK cells", "ANATOMY", 48, 57], ["Virus", "ORGANISM", 0, 5], ["BHK cells", "CELL", 48, 57], ["BHK cells", "CELL_LINE", 48, 57], ["BHK", "SPECIES", 48, 51], ["Virus titers", "TEST", 0, 12], ["plaque", "OBSERVATION", 32, 38], ["BHK cells", "OBSERVATION", 48, 57]]], ["Immature DENV (imDENV) was produced as described previously [16] .", [["Immature DENV", "ORGANISM", 0, 13], ["imDENV", "GENE_OR_GENE_PRODUCT", 15, 21], ["DENV", "SPECIES", 9, 13], ["imDENV", "SPECIES", 15, 21], ["Immature DENV (imDENV)", "PROBLEM", 0, 22], ["DENV", "OBSERVATION", 9, 13]]], ["Briefly, the media of infected Vero cells was replaced 2 dpi with M199 NH 4 Cl medium (M199 with 10% FBS, 1% sodium pyruvate, 1% non essential amino acids, 1% PS, 2.5 mM L-Glutathione and 20 mM NH 4 Cl).", [["Vero cells", "ANATOMY", 31, 41], ["FBS", "ANATOMY", 101, 104], ["NH 4 Cl", "CHEMICAL", 71, 78], ["sodium pyruvate", "CHEMICAL", 109, 124], ["amino acids", "CHEMICAL", 143, 154], ["Glutathione", "CHEMICAL", 172, 183], ["NH 4 Cl", "CHEMICAL", 194, 201], ["NH", "CHEMICAL", 71, 73], ["Cl", "CHEMICAL", 76, 78], ["sodium pyruvate", "CHEMICAL", 109, 124], ["amino acids", "CHEMICAL", 143, 154], ["L-Glutathione", "CHEMICAL", 170, 183], ["NH 4 Cl", "CHEMICAL", 194, 201], ["Vero cells", "CELL", 31, 41], ["FBS", "ORGANISM_SUBSTANCE", 101, 104], ["sodium", "SIMPLE_CHEMICAL", 109, 115], ["pyruvate", "SIMPLE_CHEMICAL", 116, 124], ["amino acids", "AMINO_ACID", 143, 154], ["Glutathione", "SIMPLE_CHEMICAL", 172, 183], ["NH 4 Cl", "SIMPLE_CHEMICAL", 194, 201], ["infected Vero cells", "CELL_LINE", 22, 41], ["infected Vero cells", "PROBLEM", 22, 41], ["M199", "TEST", 87, 91], ["FBS", "TEST", 101, 104], ["sodium pyruvate", "TEST", 109, 124], ["amino acids", "TEST", 143, 154], ["PS", "TEST", 159, 161], ["mM L-Glutathione", "TEST", 167, 183], ["infected", "OBSERVATION_MODIFIER", 22, 30], ["Vero cells", "OBSERVATION", 31, 41]]], ["Culture supernatants were harvested after 5 days and imDENV was purified by PEG precipitation.", [["supernatants", "ANATOMY", 8, 20], ["PEG", "CHEMICAL", 76, 79], ["PEG", "CHEMICAL", 76, 79], ["imDENV", "SIMPLE_CHEMICAL", 53, 59], ["PEG", "SIMPLE_CHEMICAL", 76, 79], ["imDENV", "SPECIES", 53, 59], ["Culture supernatants", "TEST", 0, 20], ["imDENV", "TREATMENT", 53, 59], ["PEG precipitation", "TREATMENT", 76, 93], ["PEG precipitation", "OBSERVATION", 76, 93]]], ["Virus titer was determined as genome containing particles (GCP)/ml by quantifying real-time PCR (qPCR) described previously [17] .Direct Binding ELISATo ascertain the binding specificity of D29 Fab-IgG, direct binding ELISA against dengue virus was performed using standard ELISA methods.", [["dengue", "DISEASE", 232, 238], ["Virus", "ORGANISM", 0, 5], ["D29 Fab", "GENE_OR_GENE_PRODUCT", 190, 197], ["IgG", "GENE_OR_GENE_PRODUCT", 198, 201], ["dengue virus", "ORGANISM", 232, 244], ["GCP", "PROTEIN", 59, 62], ["D29 Fab", "PROTEIN", 190, 197], ["IgG", "PROTEIN", 198, 201], ["dengue virus", "SPECIES", 232, 244], ["Virus titer", "TEST", 0, 11], ["D29 Fab", "TEST", 190, 197], ["IgG", "TEST", 198, 201], ["direct binding ELISA", "TEST", 203, 223], ["dengue virus", "PROBLEM", 232, 244], ["standard ELISA methods", "TREATMENT", 265, 287]]], ["Briefly, 2610 5 pfu/well purified DENV1-4 was coated on Maxisorb plate followed by blocking using 5% SM.", [["DENV1-4", "CHEMICAL", 34, 41], ["DENV1-4", "CELL", 34, 41], ["DENV1-4", "DNA", 34, 41], ["Maxisorb plate", "TREATMENT", 56, 70]]], ["Following incubation with 1 mg/ml dengue-specific antibodies, plates were probed with HRP-conjugated anti-human IgG-Fc secondary antibody or anti-mouse IgG-Fc secondary antibody (Pierce).", [["dengue", "DISEASE", 34, 40], ["HRP", "SIMPLE_CHEMICAL", 86, 89], ["HRP-conjugated anti-human IgG", "PROTEIN", 86, 115], ["Fc secondary antibody", "PROTEIN", 116, 137], ["anti-mouse IgG", "PROTEIN", 141, 155], ["Fc secondary antibody", "PROTEIN", 156, 177], ["Pierce", "PROTEIN", 179, 185], ["anti-mouse", "SPECIES", 141, 151], ["dengue", "SPECIES", 34, 40], ["incubation", "TREATMENT", 10, 20], ["specific antibodies", "TEST", 41, 60], ["HRP", "TEST", 86, 89], ["conjugated anti-human IgG", "TEST", 90, 115], ["Fc secondary antibody", "TEST", 116, 137], ["anti-mouse IgG", "TEST", 141, 155]]], ["Detection steps in subsequent ELISAs followed this method unless otherwise stated.", [["subsequent ELISAs", "TEST", 19, 36]]], ["To determine the binding affinity of D29 Fab-IgG direct binding ELISA was performed with serially diluted D29 Fab-IgG.", [["D29 Fab", "GENE_OR_GENE_PRODUCT", 37, 44], ["D29 Fab", "PROTEIN", 37, 44], ["IgG", "PROTEIN", 45, 48], ["D29 Fab", "PROTEIN", 106, 113], ["IgG", "PROTEIN", 114, 117], ["D29 Fab", "TREATMENT", 37, 44], ["IgG direct binding ELISA", "TEST", 45, 69]]], ["Results were fitted to a one-site binding hyperbola using Prism 5.03 (GraphPad, San Diego, USA).Direct Binding ELISAFor Peptide phage ELISA, 2 mg of D29 and non-related control antibodies were coated on Maxisorb plate and incubated with phage, followed by detection with HRP-conjugated anti-M13 secondary antibody.Indirect Immunofluorescent Assay (IFA)DENV-infected Vero cells or C6/36 cells were fixed and permeablilized with 80% acetone at 220 o C for 10 min.", [["Vero cells", "ANATOMY", 366, 376], ["C6/36 cells", "ANATOMY", 380, 391], ["acetone", "CHEMICAL", 431, 438], ["acetone", "CHEMICAL", 431, 438], ["D29", "SIMPLE_CHEMICAL", 149, 152], ["HRP", "SIMPLE_CHEMICAL", 271, 274], ["DENV", "ORGANISM", 352, 356], ["Vero cells", "CELL", 366, 376], ["C6/36 cells", "CELL", 380, 391], ["acetone", "SIMPLE_CHEMICAL", 431, 438], ["D29", "PROTEIN", 149, 152], ["non-related control antibodies", "PROTEIN", 157, 187], ["HRP", "PROTEIN", 271, 274], ["M13 secondary antibody", "PROTEIN", 291, 313], ["DENV-infected Vero cells", "CELL_LINE", 352, 376], ["C6/36 cells", "CELL_LINE", 380, 391], ["DENV", "SPECIES", 352, 356], ["Prism", "TEST", 58, 63], ["Direct Binding ELISAFor Peptide phage ELISA", "TREATMENT", 96, 139], ["D29", "TREATMENT", 149, 152], ["non-related control antibodies", "TREATMENT", 157, 187], ["Maxisorb plate", "TREATMENT", 203, 217], ["phage", "TREATMENT", 237, 242], ["HRP", "TEST", 271, 274], ["Indirect Immunofluorescent Assay", "TEST", 314, 346], ["IFA", "TEST", 348, 351], ["DENV", "PROBLEM", 352, 356], ["infected Vero cells", "PROBLEM", 357, 376], ["C6/36 cells", "PROBLEM", 380, 391], ["Vero cells", "OBSERVATION", 366, 376]]], ["The presence of virus was detected by D29 Fab-IgG, h3H5 and h4G2 at 1 mg/ml, followed by staining with FITC-conjugated antihuman IgG (ZyMax, Invitrogen).", [["FITC", "CHEMICAL", 103, 107], ["Fab", "GENE_OR_GENE_PRODUCT", 42, 45], ["IgG", "GENE_OR_GENE_PRODUCT", 46, 49], ["FITC", "SIMPLE_CHEMICAL", 103, 107], ["Invitrogen", "GENE_OR_GENE_PRODUCT", 141, 151], ["D29 Fab", "PROTEIN", 38, 45], ["IgG", "PROTEIN", 46, 49], ["h3H5", "PROTEIN", 51, 55], ["h4G2", "PROTEIN", 60, 64], ["FITC-conjugated antihuman IgG", "PROTEIN", 103, 132], ["ZyMax, Invitrogen", "PROTEIN", 134, 151], ["virus", "PROBLEM", 16, 21], ["Fab", "TEST", 42, 45], ["h3H5", "TREATMENT", 51, 55], ["h4G2", "TREATMENT", 60, 64], ["FITC", "TEST", 103, 107], ["conjugated antihuman IgG", "TREATMENT", 108, 132], ["virus", "OBSERVATION", 16, 21]]], ["Cells were mounted with MOWIOL (Sigma) and images were captured using a fluorescent microscope (Olympus).Preparation of Dengue lysate and Western BlotDENV-infected Vero cells were harvested 5 days post-infection and lysed with cold lysis buffer (1.5% Triton X-100, 0.2 mM Phenylmethylsulfonyl Fluoride (PMSF), 1 mg/ml pepstatin A and 75 mM KCl in PBS) for 40 min on ice.", [["Cells", "ANATOMY", 0, 5], ["lysate", "ANATOMY", 127, 133], ["Vero cells", "ANATOMY", 164, 174], ["Dengue", "DISEASE", 120, 126], ["Triton X-100", "CHEMICAL", 251, 263], ["Phenylmethylsulfonyl Fluoride", "CHEMICAL", 272, 301], ["PMSF", "CHEMICAL", 303, 307], ["pepstatin A", "CHEMICAL", 318, 329], ["KCl", "CHEMICAL", 340, 343], ["Phenylmethylsulfonyl Fluoride", "CHEMICAL", 272, 301], ["PMSF", "CHEMICAL", 303, 307], ["pepstatin A", "CHEMICAL", 318, 329], ["KCl", "CHEMICAL", 340, 343], ["Cells", "CELL", 0, 5], ["Dengue", "ORGANISM", 120, 126], ["lysate", "ORGANISM_SUBSTANCE", 127, 133], ["BlotDENV", "GENE_OR_GENE_PRODUCT", 146, 154], ["Vero cells", "CELL", 164, 174], ["Triton X-100", "SIMPLE_CHEMICAL", 251, 263], ["Phenylmethylsulfonyl Fluoride", "SIMPLE_CHEMICAL", 272, 301], ["PMSF", "SIMPLE_CHEMICAL", 303, 307], ["pepstatin A", "SIMPLE_CHEMICAL", 318, 329], ["Western BlotDENV-infected Vero cells", "CELL_LINE", 138, 174], ["images", "TEST", 43, 49], ["a fluorescent microscope", "TEST", 70, 94], ["Dengue lysate", "TREATMENT", 120, 133], ["infected Vero cells", "PROBLEM", 155, 174], ["cold lysis buffer", "TREATMENT", 227, 244], ["0.2 mM Phenylmethylsulfonyl Fluoride (PMSF", "TREATMENT", 265, 307], ["pepstatin A", "TREATMENT", 318, 329], ["75 mM KCl in PBS", "TREATMENT", 334, 350], ["infected", "OBSERVATION_MODIFIER", 155, 163], ["Vero cells", "OBSERVATION", 164, 174]]], ["An equal volume of 56 loading dye was added to the cell lysate before 12% SDS-PAGE and transferred onto nitrocellulose membranes.", [["cell lysate", "ANATOMY", 51, 62], ["membranes", "ANATOMY", 119, 128], ["nitrocellulose", "CHEMICAL", 104, 118], ["cell", "CELL", 51, 55], ["membranes", "CELLULAR_COMPONENT", 119, 128], ["56 loading dye", "TREATMENT", 19, 33], ["the cell lysate", "TREATMENT", 47, 62], ["nitrocellulose membranes", "TREATMENT", 104, 128], ["equal", "OBSERVATION_MODIFIER", 3, 8], ["volume", "OBSERVATION_MODIFIER", 9, 15]]], ["Blocked membranes were probed with dengue-specific antibodies at RT for 1 hr and detected with HRP-conjugated anti-human IgG-Fc or antimouse IgG-Fc secondary antibody and developed with chemiluminescence (Supersignal West Pico Chemiluminescent Substrate, Pierce).Competition ELISA and Western BlotTo establish the binding target of D29 Fab-IgG, competition ELISA against epitope-characterized monoclonal antibodies was carried out.", [["membranes", "ANATOMY", 8, 17], ["membranes", "CELLULAR_COMPONENT", 8, 17], ["HRP", "SIMPLE_CHEMICAL", 95, 98], ["IgG-Fc", "GENE_OR_GENE_PRODUCT", 121, 127], ["D29", "ORGANISM", 332, 335], ["Fab", "GENE_OR_GENE_PRODUCT", 336, 339], ["IgG", "GENE_OR_GENE_PRODUCT", 340, 343], ["dengue-specific antibodies", "PROTEIN", 35, 61], ["HRP-conjugated anti-human IgG", "PROTEIN", 95, 124], ["Fc", "PROTEIN", 125, 127], ["antimouse IgG", "PROTEIN", 131, 144], ["Fc secondary antibody", "PROTEIN", 145, 166], ["D29 Fab", "PROTEIN", 332, 339], ["IgG", "PROTEIN", 340, 343], ["epitope-characterized monoclonal antibodies", "PROTEIN", 371, 414], ["Blocked membranes", "PROBLEM", 0, 17], ["dengue-specific antibodies", "PROBLEM", 35, 61], ["HRP", "TEST", 95, 98], ["conjugated anti-human IgG", "TEST", 99, 124], ["antimouse IgG", "TEST", 131, 144], ["secondary antibody", "PROBLEM", 148, 166], ["chemiluminescence", "PROBLEM", 186, 203], ["D29 Fab", "TEST", 332, 339], ["IgG", "TEST", 340, 343], ["competition ELISA", "TEST", 345, 362], ["epitope", "TEST", 371, 378], ["monoclonal antibodies", "TEST", 393, 414]]], ["Plates were prepared as for direct binding ELISA.", [["direct binding ELISA", "TEST", 28, 48]]], ["After blocking, serially diluted m3H5, m4G2 or m2H2 was added to the plates and incubated for 1 hr at RT, followed by addition of D29 Fab-IgG at 2.5 mg/ml and incubation for 1 hr at RT.", [["m4G2", "CHEMICAL", 39, 43], ["m2H2", "CHEMICAL", 47, 51], ["m2H2", "CHEMICAL", 47, 51], ["m3H5", "SIMPLE_CHEMICAL", 33, 37], ["m4G2", "SIMPLE_CHEMICAL", 39, 43], ["m2H2", "SIMPLE_CHEMICAL", 47, 51], ["Fab-IgG", "GENE_OR_GENE_PRODUCT", 134, 141], ["m3H5", "PROTEIN", 33, 37], ["m4G2", "PROTEIN", 39, 43], ["m2H2", "PROTEIN", 47, 51], ["D29 Fab", "PROTEIN", 130, 137], ["IgG", "PROTEIN", 138, 141], ["m4G2", "TREATMENT", 39, 43], ["m2H2", "TREATMENT", 47, 51], ["D29 Fab", "TREATMENT", 130, 137], ["IgG", "TREATMENT", 138, 141]]], ["Bound antigen-antibody complexes were detected by HRP-conjugated anti-human IgG-Fc secondary antibody (Pierce), and developed as described above.Competition ELISA and Western BlotFor competition Western, Fab-IgG D29 was incubated with m3H5, m4G2 or m2H2 for 1 hr at RT before applying to blocked membranes for 30 min at RT.", [["membranes", "ANATOMY", 296, 305], ["HRP", "SIMPLE_CHEMICAL", 50, 53], ["Fab", "GENE_OR_GENE_PRODUCT", 204, 207], ["m3H5", "SIMPLE_CHEMICAL", 235, 239], ["m4G2", "SIMPLE_CHEMICAL", 241, 245], ["m2H2", "SIMPLE_CHEMICAL", 249, 253], ["membranes", "CELLULAR_COMPONENT", 296, 305], ["Bound antigen-antibody complexes", "PROTEIN", 0, 32], ["HRP-conjugated anti-human IgG", "PROTEIN", 50, 79], ["Fc secondary antibody", "PROTEIN", 80, 101], ["Pierce", "PROTEIN", 103, 109], ["Fab", "PROTEIN", 204, 207], ["IgG D29", "PROTEIN", 208, 215], ["Bound antigen", "TEST", 0, 13], ["antibody complexes", "TEST", 14, 32], ["HRP", "TEST", 50, 53], ["conjugated anti-human IgG", "TEST", 54, 79], ["m2H2", "TREATMENT", 249, 253]]], ["HRP-conjugated anti-Human IgG-Fc secondary antibody was applied to detect bound D29 for 45 min at RT after 4 washes with PBST.ImmunoprecipitationFor radioactive immunoprecipitation, DENV2-infected BHK-21 cells were harvested 48 hr later and prepared as described previously [18] .", [["BHK-21 cells", "ANATOMY", 197, 209], ["HRP", "SIMPLE_CHEMICAL", 0, 3], ["DENV2", "ORGANISM", 182, 187], ["BHK-21 cells", "CELL", 197, 209], ["HRP-conjugated anti-Human IgG", "PROTEIN", 0, 29], ["Fc secondary antibody", "PROTEIN", 30, 51], ["D29", "PROTEIN", 80, 83], ["DENV2-infected BHK-21 cells", "CELL_LINE", 182, 209], ["DENV2", "SPECIES", 182, 187], ["BHK-21", "SPECIES", 197, 203], ["HRP", "TEST", 0, 3], ["conjugated anti-Human IgG", "TREATMENT", 4, 29], ["Fc secondary antibody", "TREATMENT", 30, 51], ["PBST", "TREATMENT", 121, 125], ["Immunoprecipitation", "TEST", 126, 145], ["radioactive immunoprecipitation", "TEST", 149, 180], ["DENV2", "PROBLEM", 182, 187], ["infected BHK", "PROBLEM", 188, 200]]], ["For immunoprecipitation with SDS to disrupt protein complexes, lysate from infected cells was incubated with 1.25% SDS for 30 min at 4 o C. The SDS concentration was diluted to 0.2% before immunoprecipitation and precipitated proteins were analysed by silver stained SDS-PAGE (Silver stain Plus Kit, Bio-Rad) and Western blot.Phage-displayed Random Peptide LibraryThe phage-displayed-12 random dodecapeptide (Ph.D-12) library (New England Biolabs) was panned against D29-Fab-IgG to identify the antibody epitope as per instruction manual.", [["lysate", "ANATOMY", 63, 69], ["cells", "ANATOMY", 84, 89], ["silver", "CHEMICAL", 252, 258], ["silver", "CHEMICAL", 252, 258], ["SDS", "CHEMICAL", 267, 270], ["lysate", "ORGANISM_SUBSTANCE", 63, 69], ["cells", "CELL", 84, 89], ["silver", "SIMPLE_CHEMICAL", 252, 258], ["dodecapeptide", "SIMPLE_CHEMICAL", 394, 407], ["Biolabs", "GENE_OR_GENE_PRODUCT", 439, 446], ["D29", "ORGANISM", 467, 470], ["IgG", "GENE_OR_GENE_PRODUCT", 475, 478], ["protein complexes", "PROTEIN", 44, 61], ["infected cells", "CELL_TYPE", 75, 89], ["precipitated proteins", "PROTEIN", 213, 234], ["phage-displayed-12 random dodecapeptide (Ph.D-12) library", "DNA", 368, 425], ["D29", "PROTEIN", 467, 470], ["Fab", "PROTEIN", 471, 474], ["IgG", "PROTEIN", 475, 478], ["antibody epitope", "PROTEIN", 495, 511], ["immunoprecipitation", "PROBLEM", 4, 23], ["SDS", "PROBLEM", 29, 32], ["disrupt protein complexes", "PROBLEM", 36, 61], ["infected cells", "PROBLEM", 75, 89], ["The SDS concentration", "TEST", 140, 161], ["immunoprecipitation", "TEST", 189, 208], ["proteins", "TEST", 226, 234], ["Silver stain", "TEST", 277, 289], ["Kit", "TEST", 295, 298], ["Phage", "TEST", 326, 331], ["The phage", "TEST", 364, 373], ["random dodecapeptide (Ph.D", "TREATMENT", 387, 413], ["New England Biolabs)", "TREATMENT", 427, 447], ["IgG", "TREATMENT", 475, 478], ["the antibody epitope", "TREATMENT", 491, 511], ["infected cells", "OBSERVATION", 75, 89]]], ["The first round of panning was carried out with 100 mg/ml D29 Fab-IgG immobilized on Maxisorb Immunotube (Nunc).", [["D29 Fab", "PROTEIN", 58, 65], ["IgG", "PROTEIN", 66, 69], ["Maxisorb Immunotube", "PROTEIN", 85, 104], ["Fab", "TEST", 62, 65], ["Maxisorb Immunotube", "TREATMENT", 85, 104]]], ["The amplified phage was enriched by three further rounds of panning in solution using Protein A or G sepharose in alternate rounds of panning.", [["G sepharose", "GENE_OR_GENE_PRODUCT", 99, 110], ["Protein A", "PROTEIN", 86, 95], ["G sepharose", "PROTEIN", 99, 110], ["The amplified phage", "TREATMENT", 0, 19], ["panning in solution", "TREATMENT", 60, 79], ["Protein A or G sepharose", "TREATMENT", 86, 110], ["phage", "OBSERVATION_MODIFIER", 14, 19]]], ["One round of negative selection with Protein A and G sepharose was carried out to minimize non-specific binders.", [["Protein A", "SIMPLE_CHEMICAL", 37, 46], ["G sepharose", "SIMPLE_CHEMICAL", 51, 62], ["Protein A", "PROTEIN", 37, 46], ["G sepharose", "PROTEIN", 51, 62], ["Protein A and G sepharose", "TREATMENT", 37, 62], ["non-specific binders", "PROBLEM", 91, 111], ["round", "OBSERVATION_MODIFIER", 4, 9], ["negative", "OBSERVATION", 13, 21]]], ["The isolated peptide phage sequences were mapped against 3D protein structure using the Peptiope server with crystal structures of prM-E heterodimer at neutral pH (Protein Data Bank (PDB) accession code 3C6E).", [["prM-E heterodimer", "GENE_OR_GENE_PRODUCT", 131, 148], ["3D protein structure", "PROTEIN", 57, 77], ["prM", "PROTEIN", 131, 134], ["E heterodimer", "PROTEIN", 135, 148], ["Protein Data Bank (PDB) accession code 3C6E", "PROTEIN", 164, 207], ["The isolated peptide phage sequences", "PROBLEM", 0, 36], ["prM-E heterodimer", "TREATMENT", 131, 148]]], ["Graphic visualization was carried out using MSI WebLab ViewLite (Accelrys).Phage-displayed Random Peptide LibraryTo test whether isolated peptide phage inhibits binding of D29 to its natural epitope, inhibition ELISA was carried out.", [["D29", "GENE_OR_GENE_PRODUCT", 172, 175], ["D29", "PROTEIN", 172, 175], ["Graphic visualization", "TEST", 0, 21], ["Phage", "TEST", 75, 80], ["isolated peptide phage", "PROBLEM", 129, 151], ["inhibition ELISA", "TEST", 200, 216]]], ["10-fold serially diluted peptide phage (starting at 10 12 pfu/ml) or 2610 5 pfu DENV2 was incubated with D29 Fab-IgG for 1 hr before applying to DENV2-coated plate for 5 min at RT.", [["DENV2", "ORGANISM", 80, 85], ["DENV2", "ORGANISM", 145, 150], ["D29 Fab", "PROTEIN", 105, 112], ["IgG", "PROTEIN", 113, 116], ["DENV2", "SPECIES", 80, 85], ["D29", "SPECIES", 105, 108], ["DENV2", "SPECIES", 145, 150], ["fold serially diluted peptide phage", "TREATMENT", 3, 38], ["D29 Fab", "TREATMENT", 105, 112], ["DENV2-coated plate", "TREATMENT", 145, 163]]], ["Bound antibody was detected with HRP-conjugated anti-human IgG-Fc secondary antibody for 1 hr at RT.Phage-displayed Random Peptide LibraryTo test the inhibition capacity of peptide phage by Western blot, pre-incubation of 0.1 mg/ml of D29 Fab-IgG with 4610 11 pfu peptide phage; 8610 6 pfu DENV2 or 5%SM for 1 hr was carried out before applying to membrane transblotted with DENV2 lysate for 30 min.", [["membrane", "ANATOMY", 348, 356], ["lysate", "ANATOMY", 381, 387], ["HRP", "SIMPLE_CHEMICAL", 33, 36], ["D29", "ORGANISM", 235, 238], ["Fab", "GENE_OR_GENE_PRODUCT", 239, 242], ["IgG", "GENE_OR_GENE_PRODUCT", 243, 246], ["DENV2", "ORGANISM", 290, 295], ["membrane", "CELLULAR_COMPONENT", 348, 356], ["DENV2", "ORGANISM", 375, 380], ["Bound antibody", "PROTEIN", 0, 14], ["HRP-conjugated anti-human IgG", "PROTEIN", 33, 62], ["Fc secondary antibody", "PROTEIN", 63, 84], ["D29 Fab", "PROTEIN", 235, 242], ["IgG", "PROTEIN", 243, 246], ["DENV2", "SPECIES", 290, 295], ["DENV2", "SPECIES", 375, 380], ["Bound antibody", "TEST", 0, 14], ["HRP", "TEST", 33, 36], ["conjugated anti-human IgG", "TEST", 37, 62], ["Phage", "TEST", 100, 105], ["peptide phage", "TREATMENT", 173, 186], ["D29 Fab", "TREATMENT", 235, 242], ["pfu peptide phage", "TREATMENT", 260, 277], ["DENV2 lysate", "TREATMENT", 375, 387]]], ["HRP-conjugated anti-Human IgG-Fc secondary antibody was applied to detect bound D29 Fab-IgG for 45 min at RT and the membrane was processed as described previously to visualize the reactive bands.Site-directed MutagenesisThe gene portion containing prM-E, as described in Puttikhunt, et al [24] , was amplified from DENV2 (NGC) cDNA using the primers D2-FW (59-AATTAATACGACCGTCTCCCATGAA-TAGAAGACGCAGATCTGCAGGC-39) and D2-RV (59-CGC-CCGTTTGATCTCGAGCTACTAGGCCTGCACCATGACT-CCC-39) and cloned into pCMV-myc-ER vector via the restriction sites Nco I and Xho I to create plasmid construct pCMV-prM-E.", [["membrane", "ANATOMY", 117, 125], ["HRP", "SIMPLE_CHEMICAL", 0, 3], ["IgG", "GENE_OR_GENE_PRODUCT", 88, 91], ["membrane", "CELLULAR_COMPONENT", 117, 125], ["prM-E", "GENE_OR_GENE_PRODUCT", 249, 254], ["DENV2", "ORGANISM", 316, 321], ["pCMV-myc", "GENE_OR_GENE_PRODUCT", 494, 502], ["ER", "GENE_OR_GENE_PRODUCT", 503, 505], ["Nco I", "GENE_OR_GENE_PRODUCT", 539, 544], ["Xho I", "GENE_OR_GENE_PRODUCT", 549, 554], ["HRP-conjugated anti-Human IgG", "PROTEIN", 0, 29], ["Fc secondary antibody", "PROTEIN", 30, 51], ["D29 Fab", "PROTEIN", 80, 87], ["IgG", "PROTEIN", 88, 91], ["gene portion", "DNA", 225, 237], ["prM", "PROTEIN", 249, 252], ["E", "DNA", 253, 254], ["DENV2 (NGC) cDNA", "DNA", 316, 332], ["primers D2-FW", "DNA", 343, 356], ["D2-RV", "DNA", 418, 423], ["CCC-39", "DNA", 470, 476], ["pCMV-myc-ER vector", "DNA", 494, 512], ["restriction sites", "DNA", 521, 538], ["Nco I", "DNA", 539, 544], ["Xho I", "DNA", 549, 554], ["pCMV", "DNA", 583, 587], ["prM", "PROTEIN", 588, 591], ["HRP", "TEST", 0, 3], ["conjugated anti-Human IgG", "TREATMENT", 4, 29], ["Fc secondary antibody", "TREATMENT", 30, 51], ["Fab", "TEST", 84, 87], ["IgG", "TEST", 88, 91], ["Site-directed Mutagenesis", "TREATMENT", 196, 221], ["the primers", "TEST", 339, 350], ["FW", "TEST", 354, 356], ["TAGAAGACGCAGATCTGCAGGC", "TEST", 387, 409], ["D2-RV", "TEST", 418, 423], ["myc-ER vector", "TREATMENT", 499, 512], ["the restriction sites", "TREATMENT", 517, 538], ["plasmid construct pCMV", "TREATMENT", 565, 587], ["reactive bands", "OBSERVATION", 181, 195]]], ["Using this as template, selected amino acids residues of the predicted epitopes, P3 and P9, were mutated by site-directed mutagenesis using Quikchange Multi Site-directed Mutagenesis kit (Stratagene, Agilent Technologies).", [["amino acids", "CHEMICAL", 33, 44], ["amino acids", "CHEMICAL", 33, 44], ["amino acids", "AMINO_ACID", 33, 44], ["epitopes", "PROTEIN", 71, 79], ["P3", "PROTEIN", 81, 83], ["P9", "PROTEIN", 88, 90], ["this as template", "TREATMENT", 6, 22], ["selected amino acids residues", "TREATMENT", 24, 53], ["Quikchange Multi Site-directed Mutagenesis kit (Stratagene, Agilent Technologies", "TREATMENT", 140, 220]]], ["PCR reactions and subsequent cloning steps were carried out according to manufacturer's instructions.", [["PCR reactions", "TEST", 0, 13], ["subsequent cloning steps", "TREATMENT", 18, 42]]], ["Substitution of amino acids in all mutant constructs was confirmed by sequencing.", [["amino acids", "CHEMICAL", 16, 27], ["amino acids", "CHEMICAL", 16, 27], ["amino acids", "AMINO_ACID", 16, 27], ["mutant constructs", "DNA", 35, 52], ["Substitution of amino acids", "TREATMENT", 0, 27], ["all mutant constructs", "TREATMENT", 31, 52], ["amino acids", "OBSERVATION", 16, 27]]], ["Mutants were expressed in HEK293-T cells and harvested 48 hr posttransfection for immunoblot analysis and immunoprecipitation experiments.Plaque Reduction Neutralization Test (PRNT) and ADE AssayTo determine the ability of D29 Fab-IgG to neutralize Dengue infection in vitro, PRNT was carried out on BHK cells as described previously [19] .Plaque Reduction Neutralization Test (PRNT) and ADE AssayThe ADE assay was performed as described previously [20] .", [["HEK293-T cells", "ANATOMY", 26, 40], ["Plaque", "ANATOMY", 138, 144], ["BHK cells", "ANATOMY", 300, 309], ["Plaque", "ANATOMY", 340, 346], ["Dengue infection", "DISEASE", 249, 265], ["HEK293-T cells", "CELL", 26, 40], ["D29", "ORGANISM", 223, 226], ["Fab", "GENE_OR_GENE_PRODUCT", 227, 230], ["IgG", "GENE_OR_GENE_PRODUCT", 231, 234], ["Dengue", "ORGANISM", 249, 255], ["BHK cells", "CELL", 300, 309], ["HEK293-T cells", "CELL_LINE", 26, 40], ["D29 Fab", "PROTEIN", 223, 230], ["IgG", "PROTEIN", 231, 234], ["BHK cells", "CELL_LINE", 300, 309], ["immunoblot analysis", "TEST", 82, 101], ["immunoprecipitation experiments", "TEST", 106, 137], ["Plaque Reduction", "TREATMENT", 138, 154], ["ADE AssayTo", "TREATMENT", 186, 197], ["D29 Fab", "TREATMENT", 223, 230], ["IgG", "TREATMENT", 231, 234], ["Dengue infection", "PROBLEM", 249, 265], ["PRNT", "TEST", 276, 280], ["BHK cells", "TREATMENT", 300, 309], ["Plaque Reduction", "TREATMENT", 340, 356], ["ADE Assay", "TEST", 388, 397], ["The ADE assay", "TEST", 397, 410]]], ["Briefly, pre-formed immune complexes were prepared by incubating serially diluted antibody with DENV2 or imDENV2 at a multiplicity of 25 GCP per cell (MOG 25) in RPMI MM at 37 o C for 1 hr before applying to 2610 4 K562 cells in 96-well U-bottom plate (Nunc).", [["cell", "ANATOMY", 145, 149], ["MM", "ANATOMY", 167, 169], ["2610 4 K562 cells", "ANATOMY", 208, 225], ["imDENV2", "CHEMICAL", 105, 112], ["DENV2", "ORGANISM", 96, 101], ["imDENV2", "SIMPLE_CHEMICAL", 105, 112], ["cell", "CELL", 145, 149], ["K562 cells", "CELL", 215, 225], ["pre-formed immune complexes", "PROTEIN", 9, 36], ["DENV2", "PROTEIN", 96, 101], ["imDENV2", "PROTEIN", 105, 112], ["MOG 25", "PROTEIN", 151, 157], ["K562 cells", "CELL_LINE", 215, 225], ["DENV2", "SPECIES", 96, 101], ["DENV2", "PROBLEM", 96, 101], ["K562 cells", "TEST", 215, 225]]], ["Supernatant was harvested 48 hr postinfection and virus titer was quantified by plaque assay.Binding Specificity and Affinity of D29 Fab-IgGFollowing isolation from the human non-immune Fab-phage library by panning against the 4 serotypes of DENV sequentially (Fig. S1 ), D29 Fab-IgG was converted into full length human IgG1 (Materials and Methods S1).", [["Supernatant", "ANATOMY", 0, 11], ["plaque", "ANATOMY", 80, 86], ["Supernatant", "ORGANISM_SUBSTANCE", 0, 11], ["human", "ORGANISM", 169, 174], ["Fab", "GENE_OR_GENE_PRODUCT", 186, 189], ["DENV", "ORGANISM", 242, 246], ["Fab", "GENE_OR_GENE_PRODUCT", 276, 279], ["IgG", "GENE_OR_GENE_PRODUCT", 280, 283], ["human", "ORGANISM", 315, 320], ["IgG1", "GENE_OR_GENE_PRODUCT", 321, 325], ["D29 Fab", "PROTEIN", 129, 136], ["human non-immune Fab-phage library", "DNA", 169, 203], ["D29 Fab", "PROTEIN", 272, 279], ["IgG", "PROTEIN", 280, 283], ["full length human IgG1", "PROTEIN", 303, 325], ["S1", "PROTEIN", 349, 351], ["human", "SPECIES", 169, 174], ["human", "SPECIES", 315, 320], ["human", "SPECIES", 169, 174], ["DENV", "SPECIES", 242, 246], ["human", "SPECIES", 315, 320], ["virus titer", "PROBLEM", 50, 61], ["Binding Specificity", "TEST", 93, 112], ["D29 Fab", "TREATMENT", 129, 136], ["IgGFollowing isolation", "TREATMENT", 137, 159], ["the human non-immune Fab-phage library", "TREATMENT", 165, 203], ["DENV", "PROBLEM", 242, 246], ["D29 Fab-IgG", "TREATMENT", 272, 283], ["plaque", "OBSERVATION", 80, 86]]], ["To ensure the antibody was specific for DENV viral proteins, ELISA and IFA were performed with all 4 serotypes of DENV grown in C6/36 and Vero cell lines.", [["C6/36", "ANATOMY", 128, 133], ["Vero cell lines", "ANATOMY", 138, 153], ["DENV", "ORGANISM", 114, 118], ["C6/36", "CELL", 128, 133], ["Vero cell lines", "CELL", 138, 153], ["DENV viral proteins", "PROTEIN", 40, 59], ["C6/36", "CELL_LINE", 128, 133], ["Vero cell lines", "CELL_LINE", 138, 153], ["DENV", "SPECIES", 40, 44], ["DENV", "SPECIES", 114, 118], ["the antibody", "TEST", 10, 22], ["DENV viral proteins", "PROBLEM", 40, 59], ["ELISA", "TEST", 61, 66], ["IFA", "TEST", 71, 74], ["DENV", "PROBLEM", 114, 118], ["Vero cell lines", "TREATMENT", 138, 153], ["DENV", "OBSERVATION", 114, 118], ["Vero cell lines", "OBSERVATION", 138, 153]]], ["D29 Fab-IgG reacted with infected cells from DENV1-4 without crossreaction to the non-infected cell controls, indicating that the determinant for D29 Fab binding is indeed viral and not host (Fig. 1A , B, C).Binding Specificity and Affinity of D29 Fab-IgGUsing direct ELISA, D29 Fab-IgG was found to have high affinity for all 4 serotypes of DENV ( Fig. 1D hypermutation.", [["cells", "ANATOMY", 34, 39], ["DENV1-4", "ANATOMY", 45, 52], ["cell", "ANATOMY", 95, 99], ["1A , B, C", "CHEMICAL", 197, 206], ["Fab", "GENE_OR_GENE_PRODUCT", 4, 7], ["cells", "CELL", 34, 39], ["DENV1-4", "CELL", 45, 52], ["cell", "CELL", 95, 99], ["D29 Fab", "GENE_OR_GENE_PRODUCT", 146, 153], ["B, C", "GENE_OR_GENE_PRODUCT", 202, 206], ["D29 Fab-IgG", "GENE_OR_GENE_PRODUCT", 275, 286], ["DENV", "ORGANISM", 342, 346], ["D29 Fab", "PROTEIN", 0, 7], ["IgG", "PROTEIN", 8, 11], ["D29 Fab", "PROTEIN", 146, 153], ["D29 Fab", "PROTEIN", 244, 251], ["IgGUsing", "PROTEIN", 252, 260], ["D29 Fab", "PROTEIN", 275, 282], ["IgG", "PROTEIN", 283, 286], ["D29", "SPECIES", 146, 149], ["DENV", "SPECIES", 342, 346], ["Fab", "TEST", 4, 7], ["IgG", "TEST", 8, 11], ["infected cells", "PROBLEM", 25, 39], ["DENV1", "TEST", 45, 50], ["crossreaction", "PROBLEM", 61, 74], ["D29 Fab binding", "PROBLEM", 146, 161], ["Binding Specificity", "TEST", 208, 227], ["Fab", "TEST", 248, 251], ["Fab", "TEST", 279, 282], ["high affinity", "PROBLEM", 305, 318], ["DENV", "PROBLEM", 342, 346], ["1D hypermutation", "PROBLEM", 354, 370], ["infected cells", "OBSERVATION", 25, 39], ["non-infected cell controls", "OBSERVATION", 82, 108], ["DENV", "OBSERVATION", 342, 346], ["hypermutation", "OBSERVATION", 357, 370]]], ["This suggests that antibodies like D29 can be generated in the early immune response against DENV.Identification of the Binding Target of D29-Fab IgGTo broadly characterize the epitope of D29 Fab-IgG on DENV, we used competition ELISA with well characterized DENV antibodies including mouse-derived 3H5 (m3H5) which is specific to DENV2 EDIII; m4G2, a cross-reactive antibody that recognizes EDII of all flaviviruses and m2H2, a cross-DENV reactive anti-prM antibody [21, 22] .", [["D29", "GENE_OR_GENE_PRODUCT", 35, 38], ["DENV", "ORGANISM", 93, 97], ["D29", "GENE_OR_GENE_PRODUCT", 138, 141], ["D29 Fab", "GENE_OR_GENE_PRODUCT", 188, 195], ["IgG", "GENE_OR_GENE_PRODUCT", 196, 199], ["DENV", "ORGANISM", 259, 263], ["mouse", "ORGANISM", 285, 290], ["3H5", "GENE_OR_GENE_PRODUCT", 299, 302], ["m3H5", "GENE_OR_GENE_PRODUCT", 304, 308], ["DENV2", "ORGANISM", 331, 336], ["m4G2", "GENE_OR_GENE_PRODUCT", 344, 348], ["EDII", "GENE_OR_GENE_PRODUCT", 392, 396], ["m2H2", "GENE_OR_GENE_PRODUCT", 421, 425], ["antibodies", "PROTEIN", 19, 29], ["D29", "PROTEIN", 35, 38], ["D29", "PROTEIN", 138, 141], ["Fab IgGTo", "PROTEIN", 142, 151], ["D29 Fab", "PROTEIN", 188, 195], ["IgG", "PROTEIN", 196, 199], ["DENV antibodies", "PROTEIN", 259, 274], ["3H5", "PROTEIN", 299, 302], ["m3H5", "PROTEIN", 304, 308], ["DENV2 EDIII", "PROTEIN", 331, 342], ["m4G2", "PROTEIN", 344, 348], ["cross-reactive antibody", "PROTEIN", 352, 375], ["EDII", "PROTEIN", 392, 396], ["m2H2", "PROTEIN", 421, 425], ["cross-DENV reactive anti-prM antibody", "PROTEIN", 429, 466], ["mouse", "SPECIES", 285, 290], ["DENV", "SPECIES", 93, 97], ["DENV", "SPECIES", 203, 207], ["DENV", "SPECIES", 259, 263], ["mouse", "SPECIES", 285, 290], ["DENV2", "SPECIES", 331, 336], ["antibodies like D29", "PROBLEM", 19, 38], ["DENV", "PROBLEM", 93, 97], ["D29-Fab IgGTo", "TREATMENT", 138, 151], ["the epitope of D29 Fab", "TEST", 173, 195], ["DENV", "PROBLEM", 203, 207], ["competition ELISA", "TEST", 217, 234], ["DENV antibodies", "TEST", 259, 274], ["a cross-reactive antibody", "TEST", 350, 375], ["all flaviviruses", "PROBLEM", 400, 416], ["a cross-DENV reactive anti-prM antibody", "TEST", 427, 466]]], ["Making use of humanized versus parental murine antibodies for 3H5 and 4G2, and HRPconjugated m2H2 versus non-conjugated for m2H2, each of the reference antibodies was shown to self-compete ( Fig. 2A) .", [["murine", "ORGANISM", 40, 46], ["m2H2", "GENE_OR_GENE_PRODUCT", 124, 128], ["murine antibodies", "PROTEIN", 40, 57], ["3H5", "PROTEIN", 62, 65], ["4G2", "PROTEIN", 70, 73], ["HRPconjugated m2H2", "PROTEIN", 79, 97], ["m2H2", "PROTEIN", 124, 128], ["reference antibodies", "PROTEIN", 142, 162], ["murine", "SPECIES", 40, 46], ["parental murine antibodies", "TREATMENT", 31, 57]]], ["No significant competition was observed between D29 Fab-IgG and m3H5, m4G2 or non-DENV specific control antibody.", [["D29 Fab-IgG", "GENE_OR_GENE_PRODUCT", 48, 59], ["m3H5", "GENE_OR_GENE_PRODUCT", 64, 68], ["m4G2", "GENE_OR_GENE_PRODUCT", 70, 74], ["D29 Fab", "PROTEIN", 48, 55], ["IgG", "PROTEIN", 56, 59], ["m3H5", "PROTEIN", 64, 68], ["m4G2", "PROTEIN", 70, 74], ["non-DENV specific control antibody", "PROTEIN", 78, 112], ["significant competition", "PROBLEM", 3, 26], ["Fab", "TEST", 52, 55], ["IgG", "TEST", 56, 59], ["m4G2", "TREATMENT", 70, 74], ["significant", "OBSERVATION_MODIFIER", 3, 14], ["competition", "OBSERVATION", 15, 26]]], ["However, binding of D29 Fab-IgG to DENV2 decreased significantly in the presence of m2H2 in a dose-dependent manner, indicating that D29 Fab-IgG recognized an epitope on prM similar to that of m2H2 ( Fig. 2A) .Identification of the Binding Target of D29-Fab IgGTo confirm the target protein of D29 Fab-IgG, Western blot analysis was carried out with DENV-infected Vero cell lysates and the recombinant ectodomain of DENV2 E protein (rE) under reducing and non-reducing conditions.", [["Vero cell lysates", "ANATOMY", 364, 381], ["m2H2", "CHEMICAL", 84, 88], ["m2H2", "CHEMICAL", 84, 88], ["D29 Fab", "GENE_OR_GENE_PRODUCT", 20, 27], ["IgG", "GENE_OR_GENE_PRODUCT", 28, 31], ["DENV2", "ORGANISM", 35, 40], ["m2H2", "SIMPLE_CHEMICAL", 84, 88], ["D29 Fab", "GENE_OR_GENE_PRODUCT", 133, 140], ["D29-Fab IgGTo", "GENE_OR_GENE_PRODUCT", 250, 263], ["D29 Fab-IgG", "GENE_OR_GENE_PRODUCT", 294, 305], ["DENV", "ORGANISM", 350, 354], ["Vero cell lysates", "CELL", 364, 381], ["DENV2 E protein", "GENE_OR_GENE_PRODUCT", 416, 431], ["D29 Fab", "PROTEIN", 20, 27], ["IgG", "PROTEIN", 28, 31], ["DENV2", "PROTEIN", 35, 40], ["m2H2", "PROTEIN", 84, 88], ["D29 Fab", "PROTEIN", 133, 140], ["IgG", "PROTEIN", 141, 144], ["prM", "PROTEIN", 170, 173], ["m2H2", "PROTEIN", 193, 197], ["Fig. 2A", "PROTEIN", 200, 207], ["D29", "PROTEIN", 250, 253], ["Fab IgGTo", "PROTEIN", 254, 263], ["D29 Fab", "PROTEIN", 294, 301], ["IgG", "PROTEIN", 302, 305], ["recombinant ectodomain", "PROTEIN", 390, 412], ["DENV2 E protein", "PROTEIN", 416, 431], ["rE", "PROTEIN", 433, 435], ["DENV", "SPECIES", 350, 354], ["DENV2", "SPECIES", 416, 421], ["D29 Fab", "TEST", 20, 27], ["DENV2", "PROBLEM", 35, 40], ["D29 Fab", "TEST", 133, 140], ["an epitope", "PROBLEM", 156, 166], ["D29", "TEST", 250, 253], ["Fab", "TEST", 298, 301], ["Western blot analysis", "TEST", 307, 328], ["DENV", "PROBLEM", 350, 354], ["infected Vero cell lysates", "TREATMENT", 355, 381], ["DENV2 E protein", "TREATMENT", 416, 431], ["Vero cell lysates", "OBSERVATION", 364, 381], ["non-reducing conditions", "OBSERVATION", 456, 479]]], ["Under non-reducing conditions, the control antibodies recognized their respective target proteins from the cell lysates: h4G2 detected the ,55 kDa E protein of all 4 serotypes and the ,50 kDa rE protein, and m2H2 detected the ,20 kDa prM of all 4 serotypes (Fig. 2B) .", [["cell lysates", "ANATOMY", 107, 119], ["cell lysates", "ORGANISM_SUBSTANCE", 107, 119], ["h4G2", "GENE_OR_GENE_PRODUCT", 121, 125], ["E", "GENE_OR_GENE_PRODUCT", 147, 148], ["rE", "GENE_OR_GENE_PRODUCT", 192, 194], ["m2H2", "GENE_OR_GENE_PRODUCT", 208, 212], ["control antibodies", "PROTEIN", 35, 53], ["target proteins", "PROTEIN", 82, 97], ["h4G2", "PROTEIN", 121, 125], ["55 kDa E protein", "PROTEIN", 140, 156], ["50 kDa rE protein", "PROTEIN", 185, 202], ["m2H2", "PROTEIN", 208, 212], ["prM", "PROTEIN", 234, 237], ["non-reducing conditions", "TREATMENT", 6, 29], ["the control antibodies", "TEST", 31, 53], ["the cell lysates", "TEST", 103, 119], ["kDa E protein", "TEST", 143, 156], ["serotypes", "TEST", 166, 175], ["kDa rE protein", "TEST", 188, 202], ["m2H2", "TEST", 208, 212]]], ["Remarkably, D29 Fab-IgG detected both E and prM of all 4 serotypes; however, the binding was abolished in the presence of reducing agent, indicating that the D29 epitope is conformational.", [["D29 Fab", "GENE_OR_GENE_PRODUCT", 12, 19], ["D29 Fab", "PROTEIN", 12, 19], ["IgG", "PROTEIN", 20, 23], ["E", "PROTEIN", 38, 39], ["prM", "PROTEIN", 44, 47], ["D29 epitope", "PROTEIN", 158, 169], ["D29 Fab", "TEST", 12, 19], ["IgG", "TEST", 20, 23], ["all 4 serotypes", "PROBLEM", 51, 66], ["reducing agent", "TREATMENT", 122, 136], ["the D29 epitope", "TREATMENT", 154, 169]]], ["All control antibodies except h3H5 lost binding to their target proteins under reducing condition (Fig. 2C) , which is expected since h3H5 recognizes a linear epitope on EDIII [22, 23] , whereas both h4G2 and m2H2 are conformationally sensitive [10, 24] .", [["h3H5", "CHEMICAL", 30, 34], ["h3H5", "SIMPLE_CHEMICAL", 30, 34], ["m2H2", "SIMPLE_CHEMICAL", 209, 213], ["control antibodies", "PROTEIN", 4, 22], ["h3H5", "PROTEIN", 30, 34], ["target proteins", "PROTEIN", 57, 72], ["h3H5", "PROTEIN", 134, 138], ["All control antibodies", "TREATMENT", 0, 22], ["h3H5 lost binding", "PROBLEM", 30, 47]]], ["In agreement with the competition ELISA data, h3H5 and h4G2 did not compete with D29 Fab-IgG for epitopes in the Western blot format, whereas incubation with m2H2 abolished D29 binding to prM but not to E protein (Fig. 2D) .Identification of the Binding Target of D29-Fab IgGGiven the ability of D29 Fab-IgG to bind both prM and E on western blots, immunoprecipitation was carried out with DENV2infected BHK cell lysate to elucidate if D29 Fab-IgG binds both proteins in solution.", [["BHK cell lysate", "ANATOMY", 404, 419], ["m2H2", "CHEMICAL", 158, 162], ["h3H5", "SIMPLE_CHEMICAL", 46, 50], ["m2H2", "SIMPLE_CHEMICAL", 158, 162], ["D29", "SIMPLE_CHEMICAL", 173, 176], ["prM", "GENE_OR_GENE_PRODUCT", 188, 191], ["E protein", "GENE_OR_GENE_PRODUCT", 203, 212], ["D29", "GENE_OR_GENE_PRODUCT", 264, 267], ["D29 Fab-IgG", "GENE_OR_GENE_PRODUCT", 296, 307], ["prM", "GENE_OR_GENE_PRODUCT", 321, 324], ["BHK cell", "CELL", 404, 412], ["D29 Fab", "GENE_OR_GENE_PRODUCT", 436, 443], ["IgG", "GENE_OR_GENE_PRODUCT", 444, 447], ["h4G2", "PROTEIN", 55, 59], ["D29 Fab", "PROTEIN", 81, 88], ["IgG", "PROTEIN", 89, 92], ["epitopes", "PROTEIN", 97, 105], ["m2H2", "PROTEIN", 158, 162], ["D29", "PROTEIN", 173, 176], ["prM", "PROTEIN", 188, 191], ["E protein", "PROTEIN", 203, 212], ["D29", "PROTEIN", 264, 267], ["Fab IgGGiven", "PROTEIN", 268, 280], ["D29 Fab", "PROTEIN", 296, 303], ["IgG", "PROTEIN", 304, 307], ["prM", "PROTEIN", 321, 324], ["E", "PROTEIN", 329, 330], ["D29 Fab", "PROTEIN", 436, 443], ["IgG", "PROTEIN", 444, 447], ["BHK", "SPECIES", 404, 407], ["the competition ELISA data", "TEST", 18, 44], ["D29 Fab", "TREATMENT", 81, 88], ["IgG", "TREATMENT", 89, 92], ["epitopes", "PROBLEM", 97, 105], ["m2H2", "TREATMENT", 158, 162], ["D29", "TEST", 264, 267], ["D29 Fab", "TREATMENT", 296, 303], ["IgG", "TREATMENT", 304, 307], ["immunoprecipitation", "TEST", 349, 368], ["DENV2infected BHK cell lysate", "TREATMENT", 390, 419], ["D29", "TEST", 436, 439], ["Fab", "TEST", 440, 443]]], ["An initial radioactive immunoprecipitation showed D29 Fab-IgG binding to both E (,55 kDa) and prM (,20 kDa), as both proteins are precipitated whereas h4G2 only precipitated E protein (Fig. 3A) .", [["prM", "GENE_OR_GENE_PRODUCT", 94, 97], ["D29 Fab", "PROTEIN", 50, 57], ["IgG", "PROTEIN", 58, 61], ["prM", "PROTEIN", 94, 97], ["h4G2", "PROTEIN", 151, 155], ["E protein", "PROTEIN", 174, 183], ["Fig. 3A", "PROTEIN", 185, 192], ["An initial radioactive immunoprecipitation", "TEST", 0, 42], ["D29 Fab", "TEST", 50, 57], ["IgG binding", "PROBLEM", 58, 69], ["prM", "TEST", 94, 97]]], ["However, as prM intrinsically interacts with E to form heterodimers, it is possible that antibody binding to one of the components in the heterodimer would pull down the other.", [["prM", "GENE_OR_GENE_PRODUCT", 12, 15], ["E", "GENE_OR_GENE_PRODUCT", 45, 46], ["prM", "PROTEIN", 12, 15], ["E", "PROTEIN", 45, 46], ["heterodimers", "PROTEIN", 55, 67], ["heterodimer", "PROTEIN", 138, 149], ["antibody binding", "PROBLEM", 89, 105]]], ["To address this, dissociation of the heterodimer with 1.25% SDS was performed prior to the assay.", [["heterodimer", "PROTEIN", 37, 48], ["the heterodimer", "TREATMENT", 33, 48], ["1.25% SDS", "TREATMENT", 54, 63], ["the assay", "TEST", 87, 96]]], ["Immunoprecipitated proteins were resolved by reducing SDS-PAGE and visualized by silver staining.", [["silver", "CHEMICAL", 81, 87], ["silver", "CHEMICAL", 81, 87], ["silver", "SIMPLE_CHEMICAL", 81, 87], ["Immunoprecipitated proteins", "PROBLEM", 0, 27], ["silver staining", "OBSERVATION", 81, 96]]], ["Identity of the precipitated proteins was verified by non-reducing Western blot analysis with h3H5 and m2H2, respectively (Fig. 3B ).", [["h3H5", "SIMPLE_CHEMICAL", 94, 98], ["precipitated proteins", "PROTEIN", 16, 37], ["the precipitated proteins", "PROBLEM", 12, 37], ["blot analysis", "TEST", 75, 88]]], ["The control antibodies were able to precipitate their corresponding binding partners.", [["control antibodies", "PROTEIN", 4, 22]]], ["Despite the ability to recognize both prM and E on western blots, D29 Fab-IgG only precipitated prM.", [["prM", "GENE_OR_GENE_PRODUCT", 38, 41], ["D29 Fab", "GENE_OR_GENE_PRODUCT", 66, 73], ["IgG", "GENE_OR_GENE_PRODUCT", 74, 77], ["prM", "PROTEIN", 38, 41], ["E", "PROTEIN", 46, 47], ["D29 Fab", "PROTEIN", 66, 73], ["IgG", "PROTEIN", 74, 77], ["western blots", "TEST", 51, 64], ["Fab", "TEST", 70, 73]]], ["Taken collectively, our data indicate that D29 binds both prM and E but the epitope on E is not accessible on the native protein.Fine Epitope Mapping by Phage-displayed Random Peptide Library ScreeningAs the DTT-sensitive m2H2 had previously been mapped to its epitope using linear peptides [21] , we attempted a similar approach to locate the binding epitope of D29 Fab-IgG.", [["D29", "CHEMICAL", 43, 46], ["DTT", "CHEMICAL", 208, 211], ["m2H2", "CHEMICAL", 222, 226], ["DTT", "CHEMICAL", 208, 211], ["D29", "SIMPLE_CHEMICAL", 43, 46], ["prM", "GENE_OR_GENE_PRODUCT", 58, 61], ["E", "GENE_OR_GENE_PRODUCT", 66, 67], ["DTT", "SIMPLE_CHEMICAL", 208, 211], ["m2H2", "SIMPLE_CHEMICAL", 222, 226], ["D29 Fab-IgG", "GENE_OR_GENE_PRODUCT", 363, 374], ["D29", "PROTEIN", 43, 46], ["prM", "PROTEIN", 58, 61], ["E", "PROTEIN", 66, 67], ["E", "PROTEIN", 87, 88], ["native protein", "PROTEIN", 114, 128], ["m2H2", "PROTEIN", 222, 226], ["binding epitope", "PROTEIN", 344, 359], ["D29 Fab", "PROTEIN", 363, 370], ["IgG", "PROTEIN", 371, 374], ["our data", "TEST", 20, 28], ["D29 binds", "TREATMENT", 43, 52], ["the DTT", "TEST", 204, 211], ["a similar approach", "TREATMENT", 311, 329], ["Fab", "TEST", 367, 370]]], ["An inhibition ELISA was carried out using synthetic ,20 mer linear peptides covering DENV2 prM [25] as well as a library of short 15-mer overlapping linear peptides (Mimotope) corresponding to aa1-166 of prM and aa1-495 of E (Materials and Methods S1).", [["DENV2", "ORGANISM", 85, 90], ["prM", "GENE_OR_GENE_PRODUCT", 204, 207], ["DENV2 prM", "PROTEIN", 85, 94], ["aa1", "PROTEIN", 193, 196], ["prM", "PROTEIN", 204, 207], ["aa1", "PROTEIN", 212, 215], ["S1", "PROTEIN", 248, 250], ["An inhibition ELISA", "TEST", 0, 19], ["synthetic ,20 mer linear peptides", "TREATMENT", 42, 75], ["aa1", "TEST", 193, 196], ["prM", "TEST", 204, 207], ["aa1", "TEST", 212, 215]]], ["However, none of the linear peptides were able to significantly inhibit the binding of D29 Fab-IgG to DENV2 (Fig. S3) , suggesting that the epitope of D29 Fab-IgG1 is discontinuous.", [["D29 Fab", "GENE_OR_GENE_PRODUCT", 87, 94], ["IgG", "GENE_OR_GENE_PRODUCT", 95, 98], ["DENV2", "ORGANISM", 102, 107], ["D29 Fab", "GENE_OR_GENE_PRODUCT", 151, 158], ["IgG1", "GENE_OR_GENE_PRODUCT", 159, 163], ["D29 Fab", "PROTEIN", 87, 94], ["IgG", "PROTEIN", 95, 98], ["DENV2", "PROTEIN", 102, 107], ["S3", "PROTEIN", 114, 116], ["D29 Fab", "PROTEIN", 151, 158], ["IgG1", "PROTEIN", 159, 163], ["the linear peptides", "PROBLEM", 17, 36], ["D29 Fab", "TEST", 87, 94], ["the epitope of D29 Fab", "TREATMENT", 136, 158]]], ["Next, D29 Fab-IgG was screened using a random dodecapeptide (Ph.D-12)-phage library as this approach has previously been used to map antibody-binding motifs [26, 27] .", [["Ph.D-12", "CHEMICAL", 61, 68], ["D29 Fab", "GENE_OR_GENE_PRODUCT", 6, 13], ["IgG", "GENE_OR_GENE_PRODUCT", 14, 17], ["D29 Fab", "PROTEIN", 6, 13], ["IgG", "PROTEIN", 14, 17], ["random dodecapeptide (Ph.D-12)-phage library", "DNA", 39, 83], ["a random dodecapeptide (Ph.D", "TREATMENT", 37, 65], ["phage library", "TREATMENT", 70, 83], ["map antibody", "TEST", 129, 141], ["binding motifs", "TEST", 142, 156]]], ["Peptide-phage clones were randomly selected from the second, third and fourth round of panning, and their binding specificity was confirmed by direct binding ELISA against D29 Fab-IgG.", [["D29 Fab-IgG", "GENE_OR_GENE_PRODUCT", 172, 183], ["phage clones", "CELL_LINE", 8, 20], ["D29 Fab", "PROTEIN", 172, 179], ["IgG", "PROTEIN", 180, 183], ["Peptide-phage clones", "TREATMENT", 0, 20], ["direct binding ELISA", "TEST", 143, 163], ["Fab", "TEST", 176, 179], ["phage clones", "OBSERVATION", 8, 20]]], ["Reactive clones were sequenced and checked against a list of common target-unrelated peptides (TUPs) [28] to eliminate peptides that react with constant regions of antibodies, protein A/G sepharose or plastic surfaces.", [["clones", "ANATOMY", 9, 15], ["clones", "CELL", 9, 15], ["protein A/G sepharose", "GENE_OR_GENE_PRODUCT", 176, 197], ["antibodies", "PROTEIN", 164, 174], ["protein A", "PROTEIN", 176, 185], ["G sepharose", "PROTEIN", 186, 197], ["Reactive clones", "PROBLEM", 0, 15], ["peptides", "TEST", 119, 127], ["constant regions of antibodies", "PROBLEM", 144, 174], ["A/G sepharose", "TREATMENT", 184, 197], ["plastic surfaces", "OBSERVATION", 201, 217]]], ["No TUPs were detected and the resulting 20 unique clones fall into three main consensus groups: 26% contained the motif W(TL/SV)K(L/X)PXW; 14% contained the motif AKTMP and 33% contained the motif KXPXW ( Table 1) .Fine Epitope Mapping by Phage-displayed Random Peptide Library ScreeningMapping of peptide sequences using the Peptiope server against the 3D crystal structure of the prM-E heterodimer at neutral pH (PDB 3C6E) identified three main clusters of predicted epitope location.", [["TUPs", "GENE_OR_GENE_PRODUCT", 3, 7], ["clones", "CELL", 50, 56], ["prM-E", "GENE_OR_GENE_PRODUCT", 382, 387], ["TUPs", "DNA", 3, 7], ["motif AKTMP", "DNA", 157, 168], ["motif KXPXW", "DNA", 191, 202], ["prM", "PROTEIN", 382, 385], ["E heterodimer", "PROTEIN", 386, 399], ["PDB 3C6E", "PROTEIN", 415, 423], ["TUPs", "PROBLEM", 3, 7], ["the motif W", "TEST", 110, 121], ["K", "TEST", 128, 129], ["(L/X)", "TREATMENT", 129, 134], ["PXW", "TEST", 134, 137], ["the motif AKTMP", "TREATMENT", 153, 168], ["Mapping of peptide sequences", "TEST", 287, 315], ["epitope location", "OBSERVATION", 469, 485]]], ["Since Pepitope assumes all input peptides mimic surface residues; all buried residues are eliminated from the search.", [["surface", "ANATOMY", 48, 55], ["Pepitope", "PROTEIN", 6, 14], ["Pepitope", "TREATMENT", 6, 14], ["surface residues", "PROBLEM", 48, 64], ["all buried residues", "PROBLEM", 66, 85], ["surface residues", "OBSERVATION", 48, 64], ["buried residues", "OBSERVATION", 70, 85]]], ["Localization of D29 Fab-IgG predicted epitopes in 3D crystal structures of DENV2 prM-E heterodimer (PDB 3C6E) and the binding specificity of peptide-phages.", [["D29 Fab-IgG", "GENE_OR_GENE_PRODUCT", 16, 27], ["DENV2", "ORGANISM", 75, 80], ["prM-E heterodimer", "GENE_OR_GENE_PRODUCT", 81, 98], ["D29 Fab", "PROTEIN", 16, 23], ["IgG predicted epitopes", "PROTEIN", 24, 46], ["DENV2 prM-E heterodimer", "PROTEIN", 75, 98], ["PDB 3C6E", "PROTEIN", 100, 108], ["Localization of D29 Fab", "TEST", 0, 23], ["DENV2 prM-E heterodimer", "TREATMENT", 75, 98], ["DENV2 prM", "OBSERVATION", 75, 84]]], ["(A) Clusters of conformational epitopes predicted by Pepitope server are displayed on the prM-E heterodimer crystal structure at neutral pH with their solvent-accessible surfaces highlighted.", [["conformational epitopes", "PROTEIN", 16, 39], ["prM", "PROTEIN", 90, 93], ["conformational epitopes", "PROBLEM", 16, 39], ["surfaces", "OBSERVATION_MODIFIER", 170, 178]]], ["The prM is pink, EDI is red, EDII is yellow, EDIII is blue, FP is cyan.", [["prM", "GENE_OR_GENE_PRODUCT", 4, 7], ["prM", "PROTEIN", 4, 7], ["pink", "OBSERVATION_MODIFIER", 11, 15], ["red", "OBSERVATION", 24, 27], ["yellow", "OBSERVATION", 37, 43], ["cyan", "OBSERVATION", 66, 70]]], ["(B) The binding specificity of peptide-phages (P1-P9) to D29 Fab-IgG was tested in a direct ELISA format with 10 mg/ml of D29 Fab-IgG, h3H5, m2H2 and non-DENV specific human antibody (Hu) immobilized on a Maxisorb plate.", [["D29", "ORGANISM", 57, 60], ["Fab", "GENE_OR_GENE_PRODUCT", 61, 64], ["IgG", "GENE_OR_GENE_PRODUCT", 65, 68], ["Fab", "GENE_OR_GENE_PRODUCT", 126, 129], ["IgG", "GENE_OR_GENE_PRODUCT", 130, 133], ["h3H5", "GENE_OR_GENE_PRODUCT", 135, 139], ["m2H2", "GENE_OR_GENE_PRODUCT", 141, 145], ["human", "ORGANISM", 168, 173], ["D29 Fab", "PROTEIN", 57, 64], ["IgG", "PROTEIN", 65, 68], ["D29 Fab", "PROTEIN", 122, 129], ["IgG", "PROTEIN", 130, 133], ["h3H5", "PROTEIN", 135, 139], ["m2H2", "PROTEIN", 141, 145], ["non-DENV specific human antibody", "PROTEIN", 150, 182], ["Hu", "PROTEIN", 184, 186], ["human", "SPECIES", 168, 173], ["human", "SPECIES", 168, 173], ["peptide-phages", "TREATMENT", 31, 45], ["D29 Fab", "TEST", 57, 64], ["IgG", "TEST", 65, 68], ["Fab", "TEST", 126, 129], ["IgG", "TEST", 130, 133], ["a Maxisorb plate", "TREATMENT", 203, 219]]], ["Ability of peptide-phages to inhibit D29 Fab-IgG binding to DENV2 was investigated by (C) ELISA and (D) Western blot analysis.", [["D29 Fab", "GENE_OR_GENE_PRODUCT", 37, 44], ["IgG", "GENE_OR_GENE_PRODUCT", 45, 48], ["DENV2", "ORGANISM", 60, 65], ["D29 Fab", "PROTEIN", 37, 44], ["IgG", "PROTEIN", 45, 48], ["DENV2", "SPECIES", 60, 65], ["peptide-phages", "TREATMENT", 11, 25], ["Fab", "TEST", 41, 44], ["IgG binding", "PROBLEM", 45, 56], ["DENV2", "PROBLEM", 60, 65], ["blot analysis", "TEST", 112, 125]]], ["For ELISA, peptide-phages (10 12 pfu/ml) were incubated with D29 Fab-IgG for 1 hr at RT before application to immobilized DENV2 for 5 min at RT.", [["Fab-IgG", "GENE_OR_GENE_PRODUCT", 65, 72], ["DENV2", "ORGANISM", 122, 127], ["D29 Fab", "PROTEIN", 61, 68], ["IgG", "PROTEIN", 69, 72], ["DENV2", "SPECIES", 122, 127], ["ELISA", "TEST", 4, 9], ["peptide-phages", "TREATMENT", 11, 25], ["D29 Fab-IgG", "TREATMENT", 61, 72]]], ["Bound D29 Fab-IgG was detected with HRP-conjugated anti-Human IgG-Fc.", [["D29", "GENE_OR_GENE_PRODUCT", 6, 9], ["IgG", "GENE_OR_GENE_PRODUCT", 14, 17], ["HRP", "SIMPLE_CHEMICAL", 36, 39], ["D29 Fab", "PROTEIN", 6, 13], ["IgG", "PROTEIN", 14, 17], ["HRP", "PROTEIN", 36, 39], ["anti-Human IgG", "PROTEIN", 51, 65], ["Bound D29 Fab", "TEST", 0, 13], ["IgG", "TEST", 14, 17], ["HRP", "TEST", 36, 39]]], ["The percentage of inhibition of D29 Fab-IgG binding by the peptide-phages shown is the average of three experiments.", [["D29 Fab", "GENE_OR_GENE_PRODUCT", 32, 39], ["IgG", "GENE_OR_GENE_PRODUCT", 40, 43], ["D29 Fab", "PROTEIN", 32, 39], ["IgG", "PROTEIN", 40, 43], ["D29 Fab", "TREATMENT", 32, 39], ["IgG binding", "PROBLEM", 40, 51]]]]}